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ABSTRACT 
 
 
The misfolding and aggregation of amyloid proteins has been associated with incurable 
diseases such as Alzheimer's or Parkinson's disease. In the specific case of Alzheimer's 
disease, insoluble mature fibrils formed of amyloid-beta (Aβ) peptide aggregates are one of 
the gross features detectable in brain of Alzheimer-disease-affected patients. Insoluble mature 
fibrils were for long time believed to be the main culprit of the pathology. Recent studies 
have shown that cell toxicity is caused by soluble oligomeric forms appearing in the early 
stages of aggregation, rather than by insoluble mature fibrils. Soluble Aβ oligomers are of 
difficult identification and study, since the classical amyloid detection techniques are not 
sensitive enough to reveal their formation. Research on new strategies to investigate Aβ 
oligomerization is imperative for the better understanding of the causes underlying the 
Alzheimer’s disease, and to set the basis for the diagnosis of the disease prior to the onset of 
clinical symptoms. 
In this work, we exploit the unique properties of an optical label-free refractometric 
sensing platform to propose a novel approach for investigating the initial and silent–lag–phase 
of Aβ42 oligomerization. Our sensing approach allows the real-time optical detection of local 
refraction index changes occurring as aggregation takes place. The method is based on the 
optical interrogation of a dielectric multilayer (one-dimensional photonic crystal) sustaining 
an electromagnetic surface wave, called Bloch Surface Wave (BSW). BSWs generated on 
dielectric multilayers are sensitive to external perturbations of the refractive index close to 
the surface of the photonic multilayer. In this work, we report on a proof of principle of the 
BSW-based detection technique for sensing protein aggregation by monitoring in real time 
the refractive index variation of an aqueous solution containing the Aβ42 peptide during early 
aggregation and fibril formation. The multilayer surface is directly contacted with the probed 
aqueous medium and the sensing chamber is positioned vertically. Hence, we exploit BSWs 
to locally probe the refractive index variations of a solution wherein the Aβ42 peptide is 
initially injected in a monomeric form and is progressively aggregating to form fibrils. During 
this process, the Aβ42 peptide tends to precipitate away from the multilayered surface, 
therefore, the measurements using BSWs monitor a local variation of the refractive index of 
the solution, which is directly related to the depletion of the concentration of the Aβ42 
monomeric form during aggregation. 
We demonstrate the efficacy of the BSW approach by monitoring in real-time the first 
crucial steps of Aβ42 oligomerization. To address a selective sensing of the analyte, we devise 
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a surface chemical functionalization strategy. Furthermore, we provide new insights into the 
complex mechanism of aggregation of this protein system in the presence of small molecular 
probes able to interfere with the dynamics of amyloid formation. As a control method, 
spectroscopic methods, Transmission Electron Microscopy, Thioflavin T binding assay, and 
NMR-based measurements are used to morphologically characterize the sample during 
aggregation. Finally, we present a potential improvement of the setup to perform a 
simultaneous light scattering measurement, with the purpose of real-time monitoring the size 
change of the Aβ aggregates, throughout fibrillization. 
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1. INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
1.1 Amyloidosis and conformational diseases 
 
When talking about conformational diseases, one implies the illnesses arising from 
aggregate deposits of specific peptides or proteins in different human tissues(1). They 
originate when peptides or proteins fail to adopt, or to maintain, their native functional 
conformation, and are generally referred to as protein misfolding diseases. Conformational 
diseases include pathological states in which lack of the folding efficiency of a given protein 
results in a reduction in the quantity of the protein that is available to play its physiological 
function(2). Nowadays, more than 40 human diseases are known to be associated with such 
an impairment(3). Generally, these peptidic or proteic deposits can be of two different 
natures: amorphous (disordered) or fibrillar (ordered). Examples of amorphous protein 
aggregates are the “inclusion bodies”: they can be caused, for instance, by a viral infection 
and consist mostly in viral capsid proteins. On the contrary, fibrillar or ordered aggregates 
are mostly represented by “amyloid” fibrils. Amyloid fibrils, or their precursors, are 
polymeric assemblies characterized by high β-sheet secondary structure(4-6). By classical 
definition(7), amyloid aggregates possess three key-features: a characteristic green 
birefringence when stained with Congo Red, fibrous morphology observed by transmission 
electron microscopy (TEM), and a distinctive X-ray diffraction pattern consistent with a high 
β-sheet content and cross-β-sheet quaternary structure. In contrast to α-helix structure in 
which hydrogen bonding is formed between residues within the same strand, the hydrogen 
bonding in β-sheet structures is among strands(8). This structural feature of the β-sheet allows 
the formation of intermolecular β-pleated sheets, which are most likely stabilized by protein 
oligomerization and fibrillization(9).  
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Generally, these aggregated structures are referred to as amyloid fibrils, or plaques, when 
they accumulate extracellularly, whereas the term “intracellular inclusions” has been 
suggested as more appropriate when fibrils morphologically and structurally related to 
extracellular amyloid form inside the cell(10). The intracellular inclusions thus have amyloid-
like characteristics, and are not to be confused with the previously described inclusion bodies, 
which are amorphous.  
The formation and deposition of amyloid fibrils in specific organs or tissues are key 
events in the pathogenesis of many degenerative diseases, which are in general referred to as 
“amyloidoses”. In a further attempt to classify these diseases, one can group them into 
neurodegenerative conditions, in which aggregation occurs in the brain, non-neuropathic 
localized amyloidoses, in which aggregation occurs in a single type of tissue excluding the 
brain, and non-neuropathic systemic amyloidoses, in which aggregation occurs in multiple 
tissues(3). Accordingly, a selection of amyloidoses is presented in Tab.1.1.1. 
 
Disease Aggregating protein or peptide 
Neurodegenerative diseases 
Alzheimer’s Disease Amyloid β peptide 
Spongiform Encephalopathies Prion Protein or fragments of it 
Parkinson’s Disease α-Synuclein 
Dementia with Lewy bodies α-Synuclein 
Frontotemporal dementia with   Parkinsonism Tau protein 
Nonneuropathic Diseases (systemic and localized) 
Lysozyme Amyloidosis Mutants of Lysozyme 
Fibrinogen Amyloidosis Variants of Fibrinogen α-chain 
Type II Diabetes Amylin, also called Islet Amyloid Polypeptide 
Medullary Carcinoma of the Thyroid Calcitonin 
Atrial Amyloidosis Atrial Natriuretic Factor 
Hereditary Cerebral Haemorrhage with Amyloidosis Mutants of Amyloid β Peptide 
Inclusion-body Myositis Amyloid β Peptide 
Tab.1.1.1. Partial list of human amyloidoses. Diseases associated with formation of extracellular 
amyloid deposits or intracellular inclusions with amyloid-like characteristics are here presented. Table 
adapted from Chiti & Dobson, 2006(3), with the permission from Annual Reviews. 
 
1.1.1  Protein aggregation 
 
Prior to get into the details of the specific case of amyloid aggregation, it is imperative 
to provide with an overall view of protein aggregation mechanisms. It is well accepted that 
any—if not all—protein or peptide, under specific condition, can undergo aggregation 
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process(9). The general fundamental model for protein aggregation is shown in Fig.1.1.1, 
where the native forms, ordered aggregates (amyloid fibrils), and amorphous aggregates 
(inclusion bodies) are all formed from the unfolded protein through intermediates. Hence, the 
intermediate can be considered a building block or a subunit, both in pathologic and in non-
pathologic conditions(11). Commonly, aggregates are formed upon an intermolecular 
hydrophobic interaction between surfaces, and the spreading in three dimensions of these 
intermediates forms larger aggregates(12). The aggregates precipitate once the solubility limit 
is exceeded. On the contrary, in the final folding state, which is normally associated with the 
functional native conformation of the globular protein, the hydrophobic surfaces are relatively 
sealed within the three dimensional structure, thus becoming inaccessible to intermolecular 
interactions. Thus, the native conformation is soluble(13). 
 
  
Fig.1.1.1. The basic model for protein aggregation. The central circle represents the intermediate, 
which is normally un- or partially folded. It can have as origin either the unfolded state (originating from 
the protein translation process) or the native state. It can itself be the transition state in the normal process 
of protein folding. Nevertheless, the intermediate has a high propensity to aggregate, leading to either 
ordered or disordered (amorphous) aggregates according to its amino acid composition. Image reprinted 
from Fink, 1998(13), with the permission from Elsevier. 
 
1.1.2  Amyloid aggregation: mechanistic models  
 
In the specific case of amyloid aggregation, three prevalent mechanistic models have 
been proposed depending on a different nature of the intermediate. The first model is known 
as the “Templated Assembly” (TA), and was first introduced by Griffith in his 1967 Nature 
article(14). It states that the aggregation is triggered by the formation of a preassembled 
nucleus, which binds to a soluble state (S) monomeric peptide or protein in a random-coil 
conformation. The assembly of the fibril is then coincident with the structural change of the 
peptide, which assumes the conformation of the aggregate (the A state) (Fig.1.1.2, (a)). The 
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second model was first presented by Prusiner in 1982 and published in Science(15). This 
model is nowadays known as the “Monomer-Directed Conversion” (MDC) model and 
suggests that, contrary to the TA model, the transition of the monomeric peptide to the 
conformation called the A state, prone to aggregation, occurs prior to the formation of fibrils. 
This A-state monomer binds and converts an S state monomer into another A-state monomer 
prone to rapidly attach to the end of the growing fibril (Fig.1.1.2, (b)). The third model is 
probably the best known and most often cited: the nucleated polymerization (NP) mechanism, 
which was fully described by Jarrett & Lansbury in Cell in 1993(16). In the NP model the 
formation of a nucleus is the result of an equilibrium between monomers that are (A state) 
and are not (S state) in an aggregation-competent conformation. Thereafter, the aggregation 
proceeds by the addition of A-state monomers to the growing end of the fibril (Fig.1.1.2, (c)). 
In this thesis work, we mainly focused on the NP model and made advantage of it to interpret 
our results. 
 
 
Fig.1.1.2. Putative models for conversion of amyloidogenic polypeptides (monomers) into 
amyloid fibrils(17). Figure reprinted from Serio et al, 2000(17) with modification by Lindquist and Feder, 
2002(18), with the permission from Nature Publishing Group. 
 
(b) 
(a) 
(c) 
(d) 
INTRODUCTION 
5 
For the sake of completeness, we here describe a fourth model, which was notably 
introduced by Serio et al in 2000 and published in Science(17). This model was presented to 
particularly explain yeast prion amyloidogenicity. It is known as the “Nucleated 
Conformation Conversion” (NCC) model and one can perceive it as a modern and more 
complete adaptation of the NP model. This model introduces the role of molten oligomeric 
species as intermediates responsible for triggering the fibrillization. The authors propose that 
“nuclei form by conformational rearrangements within structurally dynamic oligomers 
lacking a defined quaternary structure. Once nuclei are formed, they interact with a 
structurally flexible oligomer with a distribution of subunits, adding a group of subunits to 
the fibril end simultaneously”(18) (Fig.1.1.2, (d)). The authors speculate that the oligomers 
have an initial micellar structure and that are in a continuous equilibrium with monomers and 
aggregates. 
 
1.1.3  Amyloid aggregation: kinetics  
 
As mentioned before, in this project we especially regarded the NP as the fundamental 
model to describe amyloid aggregation, for kinetic studies strongly support it, thus being the 
best accepted by many authors(7, 19, 20). The kinetics of amyloid fibril formation explained 
with the NP model can be represented with a sigmoidal curve, typical of cooperative 
reactions, related to the extent of formed fibrils(7), as represented in the graphs in 
Fig.1.1.3 (a). The amyloid aggregation process typically begins with a “lag phase”, in which 
no fibril formation is observed and no variation in the signal is observed. From a 
thermodynamic point of view, during the lag phase the entropically unfavorable process of 
nuclei formation occurs. The length of the lag phase, as represented in Fig.1.1.3 (a), strongly 
depends on the initial concentration of the amyloid monomer(21), in such a way that the 
higher the concentration, the shorter this silent phase is. Once the nuclei are formed, 
aggregation proceeds abruptly via fibrillization, and this corresponds to a sudden increase of 
the signal. A plateau is then reached when the amyloid fibrillization process has ended. This 
is due to the depletion of the soluble species that are converted into fibrils, thus resulting in a 
decreased fibrillization rate. The rate of the fibrillization process can be varied, and in general, 
increased, upon the “seeding” of the system, which corresponds to the introduction of pre-
formed nuclei. With this interference, very often a lack of a lag phase has been reported, 
typical of cooperative assembly(7). 
Recently, several authors have reported what is known as “secondary nucleation 
mechanism”(22, 23), for which the primary nucleation step can also be followed by secondary 
processes that lead to the spreading and multiplication of amyloid fibrils (see Fig.1.1.3 (b)). 
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Specifically, these secondary processes involve: the fragmentation of the amyloid fibril, to 
whose extremities the soluble amyloid proteins can attach; the monomer-dependent 
secondary nucleation, in which already existing aggregates catalyze the formation of new 
nuclei(9). The introduction of the monomer-dependent secondary nucleation has helped 
explaining the, albeit often stochastic(24), length of the lag phase of the NP mechanism. This 
theory has served more precise and modern mathematical models to fit experimental kinetics 
of amyloid aggregation, compared to those stemming from the original and classical NP 
model(25). 
 
 
Fig.1.1.3. Kinetics of the aggregation of a protein into amyloid fibrils. (a) Experimental kinetics 
of amyloid aggregations for different initial monomer concentrations. (b) Schematic representation of the 
processes of primary nucleation, fibril fragmentation, and secondary nucleation. The fits in (a) use 
mathematical models where the prevalent mechanisms are primary nucleation, fragmentation, and 
secondary nucleation, respectively. The agreement between experimental and numerical model for the 
secondary nucleation mechanism is highlighted. Figure adapted from Knowles et al, 2014(9), with the 
permission from Nature Publishing Group. 
  
(a)
(b)
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1.2 Alzheimer’s disease 
 
The Alzheimer’s disease (AD) is an aberrant fatal neurodegenerative disease that causes 
the loss of the neural tissues resulting in disorders regarding memory, ability to communicate, 
mobility and, finally, with the death of the patient(26). The name “Alzheimer” originates 
from the German neurologist, Dr. Alois Alzheimer, who, in 1907, first described the case of 
a 51-year-old female patient that showed severe cognitive disorders pertaining to memory, 
language, and social interactions. Alzheimer performed an autopsy of the patient and 
described a dramatic shrinkage of the brain, especially of the cortex, and what he believed to 
be fatty deposits in small blood vessels, dead and dying brain cells, and abnormal deposits in 
and around cells(27, 28). 
At present, AD has become the most common neurodegenerative disease in the world 
with more than 25 million patients worldwide, and it is among the ten leading causes of death 
in the developed countries. AD will become more and more common in the coming decades, 
especially because of the increased life expectancy and changing population demographics. 
According to the 2015 World Alzheimer Report, in the United States alone, 5.3 million people 
are affected by the disease(29). In a study carried out by Hebert et al in 2013(30), it has been 
estimated that, by 2025, the number of people aged 65 and older with AD will reach 7.1 
million in the United States. The number of patients is expected to increase to 13.2 million in 
the United States by 2050 (see Fig.1.2.1), and 114 million worldwide, if new preventive or 
neuroprotective therapies do not emerge(29). 
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Fig.1.2.1. Projected number of persons in US population with Alzheimer disease. Prospected data 
are reported by age groups, 65 to 74 years old, 75 to 84 years old, and 85 years and older, using the 2010 
US Census Bureau middle-series estimate of population growth. Image reprinted from Hebert et al, 
2013(30), with the permission from Wolters Kluwer Health, Inc. 
 
Despite a great effort is constantly put on research for preventing and curing AD, leading 
to the expense of $631 million per year in the USA only(31), AD is a complex disease and 
the cause for its onset is not yet fully understood. There is no definitive cure to AD(26). 
Commonly, AD pathology is characterized by two main abnormal histological features: 
structures formed by aggregated protein deposits called plaques and neurofibrillary tangles 
(NFT) are present in neural tissue of AD patients(10). Plaques are found in the extracellular 
brain matrix, and contain deposits of a protein fragment called beta-amyloid (Aβ), while 
NFTs are twisted fibers of a protein called Tau, forming intracellularly. Although plaques 
and NFTs might develop in healthy people as they age(32), AD patients tend to develop 
massive amounts of these protein deposits, which, notably, tend to form in a predictable 
pattern, beginning in brain areas involved in learning and memory, and then spreading to 
other brain regions. Although the gross histological features of AD in the brain are well 
characterized, a “century-old debate” on the correlation between protein aggregation and 
neurodegeneration has not been sufficient for researchers to unequivocally identify what role 
plaques and NFTs play in AD(10, 32, 33). Even the specific mechanisms of cell death 
occurring during AD is disputed, since it is not fully understood whether it is the result of the 
activation of apoptotic or necrotic mechanisms(34). 
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1.2.1  Main theories on Alzheimer’s disease etiology 
 
From the histological observations of brain tissues affected by AD, two major misfolding 
hypotheses have been advanced regarding the primary cause of AD: the “Tau Hypothesis” 
and the “Amyloid Hypothesis”. They suggest that either Tau protein or Aβ peptide misfolding 
and aggregation trigger the onset of the disease by disrupting the neural signaling or by 
interfering with normal cell activities(35). Another accepted hypothesis is also the oldest: The 
so-called “Cholinergic Hypothesis” suggests that deficits in cholinergic neurotransmission 
prompt the development of the disease(36). While researchers have not identified an 
unambiguous causative pathway originating from any of the three molecular hypotheses to 
explain the gross anatomical changes observed in advanced AD, variants of the amyloid 
hypothesis have become dominant among the three possibilities(2, 32, 37). In this work, we 
focused our research on the Aβ peptide investigation, thus considering the amyloid hypothesis 
as the prevailing. Before illustrating it in details, the other hypotheses are briefly presented in 
the following. 
 
  Cholinergic hypothesis  
 
The “cholinergic hypothesis of Alzheimer’s disease” was first postulated in the mid-
1970s when researchers remarked substantial deficits of the choline acetyltransferase 
enzyme, responsible for acetylcholine (ACh) synthesis, in subjects affected with AD(36). 
This observation, together with subsequent studies on another enzyme related to the 
degradation of ACh, the acetylcholinesterase (AChE), lead to the belief of a strong correlation 
between ACh signaling in neural tissue and the development of AD. Nowadays, this 
correlation is considered less as a cause, but mostly as a result or a secondary effect of other 
complex mechanisms underlying the disease(38). Nevertheless, current approved and 
administered pharmacological AD treatments are mostly effective on the replacement of 
presynaptic ACh, having been developed based on the cholinergic hypothesis(39). These are 
clearly all palliative treatments, used to improve life quality of AD patients and of their 
families, and consist mainly in AChE-inhibitor medicaments. The first drug of this class to 
be approved by the FDA for the treatment of mild to severe AD was galantamine (in 2001), 
followed by donezepil (in 2006), and rivastigmine (in 2006, and in 2007 the rivastigmine 
transdermal patch became the first patch treatment for dementia). Notably, memantine 
(approved by FDA in 2003) is the exclusive approved drug acting on the glutamatergic system 
by reversibly blocking NMDA-glutamate receptor, which is responsible for synaptic 
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plasticity, instead of directly inhibiting AChE, thus being the flagship of a novel class of AD 
medications(40-42). 
 
  Tau hypothesis  
 
Tau protein aggregation must play a more complex and compelling role in the 
development of AD. Tau protein is a microtubule-associated protein expressed in mainly 
normal mature neuron, promoting assembly and stability of microtubules in the neural 
cytoskeleton. This biological function is negatively regulated by the degree of 
phosphorylation of specific Ser or Thr amino acidic residues of the protein. Hence, 
pathogenic hyperphosphorylation of Tau is associated with the disintegration of 
microtubules, resulting in the degradation of the neural cytoskeleton, but also with the 
aggregation of Tau itself. In AD subjects, hyperphosphorylated Tau has been reported to 
accumulate as paired helical filaments (PHF) that in turn aggregate into NFT masses inside 
nerve cell bodies (see Fig.1.2.2) and as dystrophic neurites associated with amyloid 
plaques(43, 44).  
 
  
Fig.1.2.2. Schematics of the role of tau-protein as microtubule-associated protein and its 
aggregation into intracellular NFTs.  Image reprinted from Brunden et al, 2009(44), with the permission 
from Nature Publishing Group. 
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Many neurons in the brain regions typically affected in AD contain large, non-
membrane-bound bundles of abnormal NFTs that occupy much of the perinuclear cytoplasm. 
However, scientific unanimity has not been reached on whether Tau hyperphosphorylation is 
the cause or the consequence of the formation of the abnormal PHFs(45).  
 
1.2.2  The amyloid hypothesis and the amyloid-β peptide  
 
The well accepted “Amyloid Hypothesis” was first formulated more than 20 years ago 
by Hardy & Higgins(46), when the correlation between the abnormal deposition of Aβ 
peptide in amyloid plaques and the development of AD in patients was starting to emerge(37, 
47, 48). This unequivocal connection stemmed from the observation that patient with trisomy 
21, also known as Down syndrome, inevitably exhibited AD-like disorders. Studies led to the 
identification of a gene located on chromosome 21 encoding for the amyloid precursor protein 
(APP)(49). APP is a large type I transmembrane protein expressed, among other tissues, in 
the synapses of neurons, and subject to a proteolytic cleavage performed by enzymes called 
α-, β- and γ- secretases. For example, the specific cleavage of APP performed by β- and γ- 
secretases forms the N- and C- termini, respectively, of the Aβ peptides(50). Among a 
relatively large pool of products of the APP molecular processing(51), the Aβ peptides were 
identified as the main components of the senile neuritic plaque of AD patient brain tissue(47). 
The link between the overexpression of APP in patients with trisomy 21 and the presence of 
Aβ peptides in neuritic plaques characteristic of AD was then drawn: The amyloid hypothesis 
was postulated(37). This discovery opened a new and advanced field of research aimed at 
determining the actual origin and molecular mechanism underlying AD. Especially, this lead 
to the formulation of the “amyloid cascade” hypothesis, which postulates the role played by 
the Aβ42 peptide, one of the longest APP double-cleavage product, in dementia. Accordingly, 
an overproduction and ineffective clearance of Aβ42 peptide in the brain triggers neuronal 
degeneration and is the initiating event of the disease, as it results in the accumulation and 
aggregation of Aβ42 in amyloid plaques(37, 46). 
As presented in Fig.1.2.3, the amyloid cascade hypothesis has been recently revised in 
the light of the failure of several therapeutics designed based on it(52), which either targeted 
the production of Aβ42 by inhibiting γ-secretase(53), or bound soluble Aβ42 to prevent its 
aggregation into fibrils(54, 55). Moreover, accumulating evidences from human AD studies 
revealed that amyloid plaque extent poorly correlated with cognitive impairment and severity 
of dementia(32). Nowadays, a growing body of evidence ascribe the neural cytotoxicity to 
the first soluble oligomeric aggregated forms of the Aβ42 peptide, rather than to the insoluble 
amyloid plaques formed by advanced-aggregation-stage fibrils(32, 56-59). Aβ42 oligomers 
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formation, nature and plausible mechanism of toxicity are described in the following sections. 
For the sake of simplicity, the genetic aspects correlated to the onset of AD are not discussed 
in this dissertation. They are briefly summarized in Fig.1.2.3, where they are linked to the 
activation of Aβ42 production. They are specific of particular forms of AD, and have not yet 
been unequivocally correlated to sporadic AD(32, 50, 60). 
 
  
Fig.1.2.3. The sequence of pathogenic events leading to AD proposed by the amyloid cascade 
hypothesis. The amyloid cascade hypothesis now suggests that synaptotoxicity and neurotoxicity may be 
mediated by soluble forms of oligomeric amyloid-β peptide species. The dynamic nature of these species 
and the poorly defined mechanism (or mechanisms) of toxicity make this topic particularly controversial 
in the field. Given this uncertainty, we prefer to use the term ‘aggregate stress’ to describe the potential 
mechanisms that may lead to amyloid-β aggregation, the formation of paired helical filaments (PHFs) of 
Tau aggregates and, ultimately, result in neuronal loss. Image and caption adapted from Karran et al, 
2011(52), with permission from Nature Publishing Group. 
 
1.2.3  Aβ aggregation pathway and structure 
 
In the previous sections we described the general mechanism of amyloid aggregation. 
The NP model supports the explanation of the in vitro observed aggregation pathway of many 
amyloidogenic proteins, including the Aβ peptide. The Aβ peptide is approximately 4kDa 
and the length varies from 39 to 43 residues, with most of the heterogeneity at the C-terminus. 
The predominant species that are found in amyloid plaques in brain are the Aβ42 and Aβ40. 
Both peptides undergo in vitro fibrillization with similar mechanism, but different critical 
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concentration and aggregation rates(19, 61, 62). In most of the cases, the research on Aβ 
peptides encompasses the parallel investigation of both Aβ42 and 40, especially for the latter 
forms fibrils at lower kinetic rates(63), thus resulting less demanding in studies with “slow-
outcome” techniques(64). The sequences of the two peptides are shown in Fig.1.2.4. 
 
Fig.1.2.4. Sequence of human Aβ40 and Aβ42. Colors indicate residues with hydrophobic (green), polar 
(magenta), positively charged (blue), and negatively charged (red) side chains. 
 
Although Aβ40 is the predominant species produced during APP processing(65), Aβ42, 
which accounts for only about 10% of total secreted Aβ peptides, is more hydrophobic, more 
cytotoxic and much more prone to aggregate than Aβ40(23, 65), thus having been commonly 
accepted as the major culprit of AD(57). As depicted in Fig.1.2.4, the minor differences in 
the C-terminal cleavage at Val40 or Ala42 have profound consequence on the propensity of 
aggregation and fibril formation(61), which is schematically represented in Fig.1.2.7. 
The Aβ42 peptide is intrinsically disordered or natively unfolded at physiological 
conditions in its free soluble form, the monomer(66, 67). As the critical concentration of the 
monomer is exceeded (in vivo, in the order of few nM(68), despite dissensus exists among 
different authors, which have reported values that differ significantly(19)) the monomer 
undergoes structural transformations for, or driven by, the self-assembly(32). As described 
by the NP model, monomers assemble to form the first soluble oligomeric nuclei, around 
which the aggregation proceeds, as represented in Fig.1.2.7. Throughout the elongation 
phase, mature fibrils are produced(4). They are formed by a bundle of fibrous protofilaments 
and characterized by typical β-sheet secondary structure(5) (see Fig.1.2.7). As shown in 
Fig.1.2.5, results from solid state NMR of Aβ40 fibrils(64) have revealed an in-register 
parallel β-sheet alignment of peptide chains within the cross-β motif. A series of cross-β 
pleated sheets are oriented parallel to the main (long) axis of the fiber, while the direction of 
the β-strands constituting the β-sheet is perpendicular to the main axis of the fiber. The 
hydrogen bonds between strands are thus parallel to the fibril long axis(4, 5). 
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Fig.1.2.5. NMR-derived structural model for Aβ40 protofilaments within fibrils. Top: view of 
the protofilament through the long axis of the fibril. Parallel in-register β-sheet motifs between separate 
strands of the peptide (red and blue) form a double-layered cross-β pattern. Bottom: atomic representation 
of Aβ40 monomers within the fibril structure. Colors are consistent with those used in Fig.1.2.4 to represent 
hydrophobic (green), polar (magenta), positively charged (blue), and negatively charged (red) side-chains 
residues. Image reprinted from Tycko, 2003(69), with permission from the American Chemical Society.  
 
While the Aβ fibrils structure model has gained large consensus, interestingly, many 
types of prefibrillar assembly of Aβ have been isolated and described in the literature, 
including: Aβ dimers and trimers(70), doughnut-shaped oligomers(71), protofibrils (not to be 
confused with protofilaments, which are the fibril subunits, as explained before)(72), Aβ 
derived diffusible ligands (ADDLs), annular Aβ assemblies(58). Generally, they can be 
defined as high molecular weight (HMW) oligomers when they can be visualized by imaging 
techniques such as AFM and TEM, being formed by more than 8 monomers, or low molecular 
weight (LMW) oligomers, when composed of a smaller number of monomers. For example, 
protofibrils are a heterogeneous mixture of HMW oligomers, metastable, with β-sheet 
content, revealing curvilinear shape when observed at TEM, and nearly incapable to form 
fibrils when deprived of free monomers. A robust protocol for the preparation of protofibrils 
has recently been developed by Jan et al(73). Finally, LMW and HMW oligomers are all 
examples of “soluble oligomers”. The term “soluble Aβ oligomers” encompasses any form 
of Aβ aggregate that is soluble in aqueous buffer and remains in solution after high-speed 
centrifugation(74). In contrast, mature fibrils are insoluble(10). All the amyloid assemblies 
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here enumerated, regardless of their solubility, reportedly share a common predominant β-
sheet secondary structure(57). 
 
1.2.4  On Aβ42 peptide neurotoxicity  
 
At this point, the following questions remain to be addressed: If mature fibrillar Aβ42 
assembly are not the main culprit of AD, what is the key-feature that differentiates them from 
toxic soluble oligomers? What is the mechanism by which soluble Aβ42 oligomers disrupt  
hippocampal long-term potentiation and thereby cause deficits in learning behavior, as has 
been reported in in vivo studies conducted on rat models(75)? In other studies(76, 77), in vitro 
and in vivo treatment of cortical neurons with Aβ42 soluble oligomers led to the 
downregulation of NMDA receptors and affected the complex system of signaling pathways 
that are required for synaptic plasticity, thus supporting previous research. 
For decades, β-sheet architecture was regarded as the feature for toxicity in fibrils(10, 
78). Nowadays, the fibrillar amyloid complex is well accepted as the minimum-energy state 
of the self-assembly aggregation reaction, thus being the state “biologically conceived” to 
suppress intermediates toxicity in amyloidoses by capturing them in a more stable 
complex(9). Minimum-energy-state species are unlikely to take part in reactions whatsoever 
because they are in a thermodynamic sink. In contrast, soluble Aβ42 oligomers are high-
energy-state species, being the metastable first aggregated intermediates(79, 80). As a 
consequence, soluble Aβ42 oligomers cytotoxicity could originate from the interaction of 
these highly prone-to-react, and still soluble species with the synaptic membrane of 
neurons(9). This consideration implies the existence of a specific conformation for soluble 
Aβ42 oligomers that differs from the typical (β-sheet) arrangement of higher order 
aggregates(81). The extent of this difference had long been under debate, with studies 
proposing an antiparallel β-sheet motif for soluble oligomers only, in contrast to the widely 
accepted parallel β-sheet alignment encountered in fibrils(82, 83). Such a relatively small 
variation was nevertheless insufficient to compensate for the enormous free-energy 
difference between soluble Aβ42 oligomers and Aβ42 fibrillar assemblies reported in the 
literature(84). An elucidation came in 2010 from Ahmed et al, which published a work on 
the isolation of pentameric, disk-shaped Aβ42 oligomers that showed high toxicity when 
added to neuronal cell cultures(56). These unprecedented Aβ42 oligomer samples revealed 
homogeneous single size distribution of 24 ± 3 kDa. Structural studies indicated that these 
neurotoxic LMW Aβ42 oligomers were stabilized in a reportedly non-β-sheet secondary 
structure by the hydrophobic C-terminal residues (see Fig.1.2.6). The authors described a 
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structural conversion in the transition from pentameric Aβ42 oligomers to β-sheet rich pre-
fibrillar assemblies, which did not exhibit in vitro toxicity. 
 
 
Fig.1.2.6. Molecular models of Aβ42 oligomers and fibrils. (a) Schematic of the monomer within 
the oligomer complex of Aβ42. (b) Schematic of the Aβ42 pentamer. The orientation of the C terminus is 
toward the center of the pentamer. (c) Three-dimensional image of single-touch AFM measurements of 
Aβ42 oligomers. (d) Schematic of the monomer within Aβ42 fibrils. (e) Schematic showing the parallel 
and in-register packing and staggering of the individual β-strands within Aβ42 fibrils. Image and caption 
reprinted from Ahmed et al, 2010(56), with permission from Nature Publishing Group. 
 
 
Fig.1.2.7. Simplified schematics of Aβ fibril formation pathway. At a specific concentration and 
under pathogenic conditions, monomers can misfold and re-organize into soluble aggregates commonly 
known as oligomers. The oligomeric complex rearranges to the prefibrillar assemblies, characterized by the 
so-called β-sheets structure (in red), typical of amyloid aggregates. Two such cross-β units comprise the 
protofilament, here represented in a simplified 2D-single layer. The mature fibrils are made by 2-6 
protofilaments. Image and caption adapted from Santi et al, 2014(85), with permission from the Society of 
Photo Optical Instrumentation Engineers. 
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1.3 Optical biosensors: state-of-the-art amyloid 
detection methods 
 
Currently, research is focusing on developing anti-amyloid therapy for future AD 
treatments aimed at preventing the onset of the disease, rather than curing the symptoms of 
AD(54, 86, 87). A substantial progress has been made in the understanding of the molecular 
mechanisms underlying AD. The investigation of the structural transition exhibited by the 
Aβ42 peptide from its monomeric form, to the soluble oligomer, and, finally, to the β-sheet 
rich pre- and fibrillar state has been of central importance for the ultimate understanding of 
toxicity in AD(9, 56). Especially, the notion that a hallmark for toxic oligomers could exist 
dramatically helps conceiving specific early diagnostic methods, to be applied prior to the 
onset of AD symptoms(88). In addition, potential molecular treatments begin to be devised 
based on the precise structure of the Aβ42 oligomer(86). Notably, a great effort is expended 
on the ongoing development of specific antibodies against Aβ42 peptide epitopes(89), which 
have hitherto revealed to be mostly ineffective, albeit highly promising(90). To help boosting 
the advances in the fields devoted to devising specific anti-Aβ42-oligomers treatments and 
studying oligomerization at a molecular level, a method for the effective and selective 
detection of soluble toxic Aβ42 oligomeric species is therefore of crucial significance(91). 
Such a method should provide reliable tools to cover the pathogenic transition occurring 
during Aβ42 oligomerization. The intimate understanding of this process is directly linked to 
the possibility of developing therapies. Unfortunately, there is a fundamental lack of valuable 
techniques capable to cover the early stage of Aβ aggregation process. Classical methods are 
unresponsive during the lag phase of aggregation, being sensitive to β-sheet structure and, 
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therefore, to high order aggregates. Traditional experimental methods have concentrated on 
the use of colorimetric assays, in which dyes such as Congo red or Thioflavine T (ThT) 
exhibit spectral variations upon binding to amyloid fibrils. Other methods, such as TEM, 
AFM and FTIR, are fundamentally unable to reveal LMW oligomers(73). Very often, not a 
valid unique technique, but a combination of often poorly selective, expensive and time 
consuming techniques are exploited(92). Therefore, there is an urgent need of highly sensitive 
and specific strategies for early Aβ42 oligomers detection that can improve the 
characterization at the molecular level of these transient intermediates. 
New generation optical biosensors should meet up to the challenge of studying 
biological events as complex as amyloid aggregation. Especially, the non-destructive 
chemical analysis of biological processes is made possible through optical biosensors. They 
offer high sensibility, selectivity and robustness(93). A number of sophisticated optical 
biosensors have been recently applied to biomolecular interaction analysis, delivering kinetic 
data about biological binding events in real time without labelling. The advantage of the label-
free concept, in which biomolecules are unlabelled or unmodified and are detected in their 
natural forms, is the elimination of detrimental effects from labels that may interfere with 
fundamental interaction and the absence of a time-consuming pre-treatment. Optical 
biosensors are also ideal for portable applications that are currently of great interest(91, 94, 
95). 
An excursus on the most outstanding optical biosensing methods for the detection of 
amyloid aggregates is presented in the following. 
 
1.3.1  Surface plasmon resonance sensing  
 
Since its first description by Wood in 1902(96), the phenomenon of surface plasmon 
resonance (SPR) has found countless practical applications in biosensing(97). At specific 
illumination conditions, surface plasmons (SP) can be excited at the interface between two 
media, one being a noble metal such as gold or silver. Those conditions are called the 
resonance ones, and are strongly depending on the refractive index of the outer media, into 
which the evanescent tail of SP propagates. Once a perturbation of the refractive index of the 
probed media occurs, new resonance conditions are needed to excite SP. In classical SPR 
biosensing, the surface of the metallic layer is functionalized with receptors or ligands for the 
selective recognition of the biomolecule that is under investigation. As the surface 
immobilization of the specific analyte occurs, an increase of the refractive index is detected 
as a shift of the resonance conditions or as a variation of the intensity of SP(98). 
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The most common biosensors used in proteomics are based on SPR(99). Devising SPR-
based analytical systems that could be applied to the monitoring of Aβ aggregation has gained 
enormous attention in the last two decades(92, 100). They offer the possibility to investigate 
environmental and molecular factors affecting Aβ40(101) or Aβ42(102) monomer tendency 
to aggregate. In addition, they permit the real-time monitoring of the kinetics of amyloid fibril 
formation, which can be achieve either by immobilizing pre-formed Aβ40(103, 104) or 
Aβ42(105) fibrils onto the sensing surface and monitoring their elongation, or by covalently 
binding the Aβ42 monomer onto the surface for a complete aggregation study(102). SPR has 
thus become devoted to the discovery of the intimate mechanisms that lead to amyloid 
aggregation. Even more interestingly, SPR-sensing strategy can also serve as a diagnostic 
tool for preventive treatments of AD, by the test of antibodies against Aβ42 monomer(106) 
and oligomers(107, 108). 
Unfortunately, SPR-based sensing is also subject to undesiderable factors. Generally, 
the disadvantages of SPR technique are a deficient sensitivity to a specific signal (due to the 
relatively small refractive index changes as a result of the binding) and undesirable 
susceptibilities to non-specific signals, such as detrimental interactions between the analyte 
and the material composing the metal film of the sensor(91). 
 
1.3.2  Surface-enhanced spectroscopy:  Raman and infrared 
 
Raman and FTIR spectroscopy both provide information on the secondary and tertiary 
structure of proteins in solution, thus having been exploited for multiple biochemical 
application. Specifically, Raman spectroscopy makes use of several vibrational modes for the 
analysis of protein structure. Most characteristic bands are associated with the amide group 
that links the amino acids, referred to as amide I (1700−1600 cm−1) and II bands (1500−1400 
cm−1), generated by the scattering of light by the vibrating molecules. Similarly, FTIR 
spectroscopy provides information about the secondary structure content of proteins. Again, 
characteristic bands found in the infrared spectra of proteins and polypeptides include the 
Amide I and Amide II. These arise from the absorption associated with the amide bonds, 
which is influenced by the protein three-dimensional arrangement and H-bond formation 
between amino acids(8, 109). 
Nevertheless, both these techniques suffer from some tremendous limitations. For 
example, Raman spectroscopy has a very low sensitivity and is affected by intrinsic 
fluorescence or absorption of bio-analytes(110), and FTIR performances are hampered by the 
strong adsorption of water, thus requiring the cumbersome solubilization of protein samples 
in D2O(111). Recently, these limitations have been overcome by increasing the output signal 
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via either electromagnetic field enhancement or SP, with the use of metallic surfaces onto 
which target molecules are adsorbed or to which they are very close to. Therefore, recent 
years saw the development of surface-enhanced Raman spectroscopy (SERS)(112) and 
surface-enhanced infrared absorption spectroscopy (SEIRA)(113). 
SERS techniques have been extensively employed to the study of amyloid aggregation. 
In this context, several publications can be found in the literature, spanning from the 
description of a nanoﬂuidic biosensor to observe Aβ in different conformational states during 
the self-assembly process(114), to a comparative structural investigation of toxic and non-
toxic Aβ42 oligomers(115). In another SERS-based strategy, Beier et al(116) envisaged the 
use of metallic nanoshells to excite SP and improve Aβ detection sensitivity to the pM range. 
The latter is a complex approach that consisted in monitoring Congo Red signal bound to Aβ 
peptide. This approach appears as a rather questionable choice if one takes into account that 
Congo Red binding is reportedly selective to β-sheet architecture only(117), and not to 
specific conformations of Aβ42 toxic oligomeric assemblies. More recently, Bhowmik et 
al(118) described a sensing scheme in which they made use of gold nanoparticles to excite 
surface plasmon and, thus, amplify the Raman signal. The authors were able to monitor 
spontaneous binding of Aβ40 oligomers to the lipid-bilayer-coating of the nanoparticles, 
which mimicked cell membranes, and to simultaneously provide secondary-structure 
information on the peptide. 
In contrast to SERS, SEIRA techniques are yet to be exploited for the study of amyloid 
aggregates, but they have delivered highly promising results in real-time monitoring protein 
interactions in native aqueous environment. In 2013, Adato et al(119) reported on what they 
called “plasmonic internal reflection-SEIRA concept”: making use of plasmonic 
nanoantennas, they were able to amplify the absorption signal in the infrared region, and to 
correlate it to the secondary structure of a protein throughout its binding to a specific receptor. 
In their work, the classical biotin-streptavidin affinity binding was investigated in situ, in 
water and with a monolayer-thickness sample. The eventual application of this sensing 
technique to the study of amyloid aggregation kinetics and structural transition properties is 
of extreme interest, especially for experiments could be carried out in the proximity of lipidic 
membranes coating the nanoantennas, thus mimicking the neural extracellular environment. 
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2. OBJECTIVES AND STRATEGY 
This chapter is  a partial adaptation of  the conference proceeding: 
Santi, S., Barakat, E., Descrovi, E., Neier, R. and Herzig, H. P., “Real-time protein aggregation monitoring 
with a Bloch surface wave-based approach,” Biophotonics: Photonic Solutions for Better Health Care IV, 
Jürgen Popp; Valery V. Tuchin; Dennis L. Matthews; Francesco Saverio Pavone; Paul Garside, Editors, 
Proc. SPIE 9129, 912918 (2014). 
Copyright © 2014 Society of  Photo Optical Instrumentation Engineers  
 
 
 
 
 
 
2.1 Aim of the project 
 
Predicting the three-dimensional configuration of a protein, the so-called protein-folding 
problem, is one of the most challenging topics of structural biology especially since an 
increasing number of degenerative pathologies results from an incorrect protein folding (or 
misfolding). Very often, the protein misfolding is associated with the formation of large 
insoluble proteic aggregates(1-3). Disorders such as Alzheimer and Parkinson diseases, 
Huntington’s chorea, Creutzfeldt-Jacob disease, cystic fibrosis, Gaucher's disease, type II 
diabetes mellitus and the wide group of systemic amyloidosis are associated with aggregation 
of misfolded polypeptide chains, commonly referred to as amyloid fibrils. As introduced in 
Chapter 1, amyloid fibrils, particularly in their prefibrillar forms (oligomeric precursors), can 
be highly toxic to cells, suggesting their key role in disease pathogenesis. In the specific case 
of the Alzheimer’s disease (AD), the amyloidogenic peptide is known to be the Amyloid-β 
(Aβ) peptide, which is naturally formed by the cleavage of a neural transmembrane 
protein(4). Its aggregation pathway has been extensively studied(5-7). It is schematically 
represented in Fig.2.1.1 and it is believed to proceed as follows: the monomeric Aβ peptide, 
under pathogenic conditions, self-assembles to form the first small soluble aggregate, the 
oligomers. The oligomeric complexes rearrange to the prefibrillar assemblies, which are 
formed by the so-called β-sheets structures, typical of amyloid aggregates. Prefibrillar 
assemblies are hence the building block, via monomer addition, to the formation of 
protofilaments, which, as the strings of a rope, are the fibrillar subunit of the mature and 
insoluble amyloid fibril. A range of experiments, indicates that the fibrils have extensive β-
sheet character, and that these sheets run perpendicular to the fibril axis to generate what is 
described as a cross-β structure(8). Nevertheless, for many years the only structural 
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information about amyloid ﬁbrils came from imaging techniques (TEM, AFM) and from X-
ray ﬁber diffraction(9). Thus far, the real-time monitoring of the Aβ aggregation process is 
very difficult, if not impossible, with the standard amyloid detection techniques(10). This 
problem arises from the fact that those valuable techniques are sensitive to the extent of the 
mature fibril formation, and mainly silent during the first steps of the oligomerization process. 
This limitation becomes even more significant if one factors in that oligomers are thought to 
be the main toxic species, leading to the onset of the AD. In fact, it has been shown(11) that 
Aβ oligomers interact with the membrane of neurons, causing the disruption of ion 
homeostasis and oxidative stress. 
 
 
Fig.2.1.1. Schematic and simplified amyloid-beta peptide aggregation pathway. The dotted 
orange sigmoidal curve represents the signal obtained while monitoring the time-depending aggregation 
via the use of a standard amyloid detection technique (ThT binding essay, Congo Red staining, FTIR, etc.). 
Hence, those are not sensitive to the formation of the small, soluble and toxic oligomers, and the first part 
of the sigmoidal curve is commonly known as “lag-phase”(7, 9). Image reprinted and caption adapted from 
Herzig et al, 2014(12), with the permission from the Swiss Physical Society. 
 
In vitro studies on these soluble cytotoxic oligomeric Aβ aggregates should provide a 
description of the fibril formation mechanism at the very early stages of aggregation(13). 
Understanding why and how the peptide may adopt a non-native fold is essential for 
designing therapeutic approaches(14). In view of these arguments, we chose to study Aβ42 
peptide aggregation. This peptide is the longest of the family of Aβ peptides (42 amino acids) 
and the most fibrillogenic(15).  
This work aimed at developing an innovative label-free optical biosensing platform 
based on a Bloch Surface Waves (BSW) resonator, which is highly sensitive to variations of 
optical properties due to the conformational changes in proteins. The sensor was applied to 
the detection of the early dynamic events of fibrillogenesis of the Aβ42 peptide linked to the 
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Alzheimer’s disease in an effort to overcome the limitation imposed by classical amyloid 
detection techniques, unable to cover the first aggregation phase during which the formation 
of soluble toxic Aβ oligomers occurs. We exploited the potential of our innovative label-free 
optical sensing approach based on BSWs to monitor in real time the refractive index changes 
(Δn) of a solution containing an initially monomeric Aβ42 peptide. Throughout aggregation, 
the refractive index properties of the peptidic solution change and it is possible to correlate 
them to the different steps of Aβ42 peptide fibrillation. 
A number of sophisticated optical biosensors have been recently applied to biomolecular 
interaction analysis, providing kinetic data about biological binding events in real time 
without labelling. The advantage of the label-free concept, in which biomolecules are 
unlabelled or unmodified and are detected in their natural forms, is the elimination of 
detrimental effects from labels that may interfere with fundamental interaction and the 
absence of a time-consuming pre-treatment. They are also ideal for portable applications that 
are currently gaining great interest(16-18). Recent progresses on optical sensing for protein 
interactions permit the construction of biosensors that utilize the refractive index change as 
the sensing transduction signal. A number of bio-detection schemes were proposed, using 
different strategies for enhancing the performances of the SPR mechanism, which remains 
one of the most simple and widespread used configuration in sensors(19). SPR, 
interferometers, waveguides, fiber gratings, ring resonators, and photonic crystals are optical 
label-free biosensing platforms that represent the majority of research activities in optical 
label-free sensor development(20, 21). 
In the specific, BSW-based sensing has been validated as a sensitive and reliable 
approach for label-free and real-time biosensing(18, 22-24). BSWs are Surface 
Electromagnetic Waves (SEWs)(25, 26). SEWs are non-radiative waves confined at the 
interface between two media. The optical characteristics of the two media determine the kind 
of SEW that can be sustained. For example, Surface Plasmon Polaritons (SPP) can be coupled 
at metal/dielectric interfaces, while Surface Phonon Polaritons can propagate on polar crystals 
such as SiC mid-infrared wavelengths. One way to create such a kind of SEW is to use a 
dielectric multilayer. Since the surface confinement obtained on dielectric multilayers is 
intimately related to the layers periodicity, this SEW is called Bloch Surface Wave(27, 28). 
The advantages of BSW, compared to SPP, is the high energy that can be confined at the 
surface of the multilayer and the larger spectral tunability allowed by the low dispersion of 
refractive index (n) in the dielectric material (instead of metal for SPP). A very high intensity 
can be produced at the surface of the multilayer used for the BSW generation(29). This 
property, characteristic of BSW, allows the creation of very sensitive sensors and avoids some 
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of the disadvantages existing with SPR sensors such as the thick sensing region that can 
decrease the sensitivity. In the case of a BSW-based sensor, the active part is the last layer of 
the 1D photonic crystal which generates the surface wave. In particular, the surface wave can 
be guided in order to enhance the sensitivity of the sensor(30). The sensing scheme adopted 
in this work is described in details in the following section.  
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2.2 The BSW-based sensing principle and platform 
This section is  a partial adaptation of  the journal article:  
Santi, S., Musi, V., Descrovi, E., Paeder, V., Di Francesco, J., Hvozdara, L., van der Wal, P., Lashuel, H. 
A., Pastore, A., Neier, R. and Herzig, H. P. (2013), Real-time Amyloid Aggregation Monitoring with a 
Photonic Crystal-based Approach. ChemPhysChem, 14: 3476–3482.  
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
 
Periodic stacks of dielectric materials (known as Bragg gratings, one-dimensional (1D) 
photonic crystals, or, simply, multilayers) with different refractive index constants can sustain 
optical surface modes(28) with either transverse electric (TE) or transverse magnetic (TM) 
polarization. Such modes are called Bloch surface waves (BSWs) and have a significant 
amount of their overall power confined close to the truncation interface of the photonic 
crystal(25). Optical surface waves are solutions of Maxwell’s equations. The energy flow is 
confined on a region that is localized at or near the surface(31). They propagate along the 
interface and the ambient medium leading to a high field enhancement. The amplitude of 
these waves decay exponentially in the directions both parallel and perpendicular to the 
boundary with different decay constants. Operating in Kretschmann configuration, the 
incident light is coupled under total internal reflection (TIR). The coupling occurs when the 
projection of the incoming wave vector ?⃗? 𝑖𝑛 onto the multilayer interface matches the wave 
vector of the BSW ?⃗? 𝑝 (28, 32), according to Eq.(2.1): 
2𝜋
𝜆
𝑛𝑜 sin 𝜃𝑖𝑛 = 𝑘𝑝   (2.1) 
where no is the refractive index of the prism, and 𝑘𝑝  the propagation constant of the BSW, 
and λ and θ the resonance wavelength and angle, respectively. In our experiment we work at 
a fixed wavelength λ (632.8 nm), hence the coupling is achievable only at the specific incident 
angle θ, as depicted in Fig.2.2.1. 
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Fig.2.2.1. Sensing scheme in Kretschmann configuration. The coupling of light into the BSW is 
here represented with a geometric model, where the electromagnetic wave is represented by its wave 
vector ?⃗? 𝑖𝑛. The projection of the incoming wave matches the BSW propagation constant vector ?⃗? 𝑝  under 
the coupling condition (Eq.(2.1)). Thus, θ and λ become the resonance angle and wavelength, the coupling 
is achieved, and the BSW is excited in TIR(16). Hence, the outcoming wave leaves the surface with the 
same angle of the incident light, deprived of the BSW resonance energy. 
 
An intensity dip in the reflected beam is produced when the light is coupled into the 
BSW(33). As the multilayer consists of dielectric materials, the associated losses can be made 
very low leading to a narrower reflectance dip as compared to SPs. Another advantage in 
using BSWs is the possibility of operating within a broad range of wavelengths, by properly 
designing a suitable multilayered structure. This tunable localized field confinement is 
particularly attractive for sensing applications(22, 34, 35). 
The experimental apparatus developed in-house in collaboration with Dr. Descrovi and 
Dr. Ballarini from the Politecnico di Torino, Italy, consists of a prism-based goniometric 
setup, as depicted in Fig.2.2.2. 
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Fig.2.2.2. Schematic top-view of the optical setup. A He-Ne laser (1) is used to illuminate the 
photonic crystal contacted to a prism (4). The beam is conditioned by using an objective (2) and two 
subsequent lenses (3) in order to obtain the divergent incident beam whose optical rays are incident on the 
multilayer at a small range of different angles. The light is then reflected by the multilayer (5) towards the 
CMOS camera.  
 
A proper silicon-based multilayer is used as a photonic structure sustaining BSWs (see 
section 2.2.1). In the optical setup, a He-Ne laser illuminates the photonic crystal (λ = 632.8 
nm). The TE-polarized laser source is first focused and then expanded on the multilayer 
through the side facet of a prism (see Chapter 8 for details). The angle of incidence of the 
beam on the prism can be varied in a controlled way. The incident beam is slightly divergent, 
thus multiple optical rays are incident on the multilayer at different angles. Since the BSW is 
excited in a Kretschmann configuration, the glass substrate hosting the photonic crystal is 
optically contacted to the prism by means of an index-matching oil. The light is then reflected 
by the multilayer towards the detector, which is a CMOS camera. The truncation interface of 
the photonic multilayer is sealed to a fluidic cell, in which a thermocouple and a Peltier 
element in closed feedback loop can maintain a constant temperature. As the laser impinges 
on the multilayer at the specific BSW resonant angle, part of the laser power is transferred to 
the BSW mode, resulting in an evanescent field extended in the external (aqueous) medium 
for a distance of about 0.5μm. As a result, the coupling is observed as an intensity dip in the 
reflected angular distribution. The reflected spot containing the BSW resonance dip is leaving 
the prism with a given angular divergence, and is imaged on the linear camera. The position 
of the dip on the linear camera is indicative of the angular position of the BSW resonance dip 
and hence of the refractive index as sensed by the BSW. The response will therefore be 
reported in numbers of pixels The sensing approach is similar to the well-known SPR 
scheme(36).  
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In the present work, we exploit BSWs to locally probe the refractive index variations 
(Δn) of a solution wherein the Aβ42 peptide is initially injected in a monomeric form and is 
progressively aggregating to form fibrils (Fig.2.2.3). 
 
 
Fig.2.2.3. Lateral enlargement of the sensing chamber. The microfluidic cell is positioned 
vertically. The laser beam generates the BSW, which is probing the protein solution via an evanescent tail 
of its associated electromagnetic field distribution. As for SPR, the coupling is observed as an intensity dip 
in the reflected angular distribution (represented in dark). Any variation in the refractive index of the liquid 
is resulting in a shift of the reflection minimum (in pixel). 
 
The sensing fluidic chamber is positioned vertically. This specific optical arrangement 
has never been reported before by others. The vertical position allows for accomplishing our 
specific biosensing goal. The evanescent tail of the BSW probes the Aβ42 solution. During 
Aβ42 aggregation, the insoluble fibrils precipitate away from the surface sensed by the BSW, 
thus causing a variation in the refractive index of the solution. As refractive index 
perturbations occur within the fluidic cell, the position of the BSW dip shifts (see Fig.2.2.3). 
The angular position of the dip moves toward smaller output angles as the refractive index 
decreases. Thus, the detectable signal is the angular shift of the reflection minimum, that is 
the resonance dip, (in pixel) as the Δn occurs throughout the aggregation process.  
As previously mentioned, in our experiments, the photonic structure is a multilayer made 
of alternating layers of silicon oxi-nitride and silica. The detailed description of the photonic 
multilayer and its properties is reported in the following. Moreover, to calibrate the response 
of the BSW dip shift upon refractive index perturbations in the solution(24), control 
experiments were performed using solutions with different known refractive indices. 
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2.2.1 1D photonic crystal design and fabrication 
 
The design and fabrication of the multilayer was performed by several internal and 
external collaborators. For the sake of completeness, I here report a short description of the 
methods used and of the accomplished simulation results. 
The dielectric multilayer was designed by Dr. Descrovi from the Politecnico di Torino, 
Italy, to work in water (n = 1.33) and to couple the BSW with a TE-polarized laser working 
at λ = 632.8 nm. The structure is composed of 4 alternating periods constituted by high (H) 
and low (L) refractive index dielectric materials, according to the scheme: glass-(H-L)x4-H’-
water, depicted in Fig.2.2.4. Thicknesses and refractive indices of the materials are reported 
in Tab.2.2.1. The dielectric layers were deposited on a glass substrate via plasma-enhanced 
chemical vapor deposition (PECVD) by Mr. Di Francesco from the Optics & Photonics 
Technology Laboratory, EPFL. 
 
 
Fig.2.2.4. Multilayer design representation, according to the scheme: glass-(H-L)x4-H’-water, 
where H is silicon nitride, Si3N4, L is silicon oxide, SiO2, and H’ is the silicon nitride top layer, which is in 
contact with the aqueous analyte. 
 
Material Layer Thickness Refractive Index (n) 
Silicon Nitride (H) 130 nm 1.95 
Silicon Oxide (L) 175 nm 1.46 
Silicon Nitride (H’) 30 nm 1.95 
Tab.2.2.1. Thicknesses and refractive indices of the materials used in the deposition of the 1D 
photonic crystal multilayer. We thank J. Di Francesco and Dr. E. Barakat from the Optics & Photonics 
Technology Laboratory, EPFL, for the multilayers fabrication, and Dr. E. Descrovi from the Politecnico di 
Torino, Italy, for the multilayer design. 
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To predict the sensitivity of the BSW supported by the one-dimensional photonic crystal 
described above, Dr. Barakat from the Optics & Photonics Technology Laboratory (EPFL) 
performed the simulation of the BSW response upon a precise refractive index variation of 
the aqueous medium. For our simulations, the transfer matrix method was used. It is based 
on dividing the grating into N sections so that each section can be approximately treated as 
uniform. By applying the appropriate boundary conditions and solving the coupled-mode 
equations, the transfer matrix gives the relation between the fields at z and at z + L where L 
is the total length of the grating(28). Specifically, the BSW intensity dip is resulting from the 
satisfaction of the coupling conditions (see Eq.(2.1)), which in our case are λ = 632.8 nm and 
θ = 64.075. When perturbing the medium of a Δn = 1·10-3, the BSW dip is shifted towards a 
larger θ, equal to 64.125. This is shown in Fig.2.2.5. Hence, it is possible to theoretically 
determine the sensitivity: Sth = 50° / RIU. This value is consistent with others reported in the 
literature(37, 38). 
 
 
Fig.2.2.5. Simulated angular shift of the BSW intensity dip upon a perturbation of the aqueous 
medium refractive index Δn of 1·10-3. We thank Dr. E. Barakat from the Optics & Photonics Technology 
Laboratory, EPFL, for the simulation. 
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2.2.2 Experimental correlation between angular and pixel shift  
 
With the aim of correlating the angular shift of the BSW intensity dip with the 
corresponding pixel shift, as imaged onto the CMOS camera(38), we performed an 
experimental determination of the conversion factor Δθ / pixel shift. Prior to this, we had to 
take into account that, in our measurements, the illumination angle θ is the angle at which the 
laser impinges the surface of the multilayer through the BK7 glass prism contacted with the 
multilayer itself. A θ value of 64.075° is theoretically calculated according to the simulation 
described above, and is determined by the design of the multilayer. To determine the 
illumination angle onto the prism γ (see Fig.2.2.6) a simple trigonometric relation was used, 
which considers the refractive index of the material of the prism, as reported in Eq.(2.2): 
𝛾 = sin−1(𝑛𝑝 sin(45° − 𝜃))   (2.2) 
where np is the prism refractive index, which at the laser wavelength λ = 632.8 nm is equal to 
1.51509. If we solve Eq.(2.2) for θ, the resulting relation is expressed by Eq.(2.3): 
𝜃 = 45° − sin−1
sin𝛾
𝑛𝑝
    (2.3) 
 
 
Fig.2.2.6. Schematics of the illumination angle. θ is the illumination angle onto the multilayer 
surface, and γ is the illumination angle onto the prism surface. 
 
Therefore, to experimentally determine the conversion factor degrees/pixels we manually 
rotated only the CMOS camera at precise angles γn, while incubating d.i. water at constant 
conditions. We thus recorded the pixel shift of the BSW dip position as imaged onto the 
camera. Then, with Eq.(2.3) we determined θn for each γn. We performed this experiment 
with two multilayers from the same production batch to test the reproducibility of the result. 
The result is shown in Fig.2.2.7, where the two independent sets of data are presented. The 
fit shows a linear correlation between angular and pixel shift for both data sets. 
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Fig.2.2.7. Experimental correlation between angular and pixel shift. Two sets of data are reported, 
in black and in grey, respectively. The experiment was performed rotating the CMOS camera only, within 
an angular range of ± 0.05°. 
 
From the linear fits of data in Fig.2.2.7, an averaged slope of 0.00104° / pixels was 
determined, which is the conversion factor between angular and pixel shift, as imaged onto 
the CMOS camera. This factor allows determining the experimental sensitivity of the 
multilayer, as explained in the following.  
 
2.2.3 1D photonic crystal experimental characterization and 
BSW response calibration 
 
For our experimental refractive index range, a BSW response calibration was carried out 
according to two different procedures. The main goal was to prove the linear relationship 
between the observed shift and the refractive index of the solution, as predicted by known 
formulas(37), and to determine the experimental multilayer sensitivity. 
At first, the angular shift of the BSW resonance dip was obtained varying the 
temperature of a d.i. water sample directly in the sensing chamber, and hence its refractive 
index, and to follow the shift of the BSW dip position over the pixels of the detector. 
Refractive indices of d.i. water at different temperature and at λ = 632.8 nm were chosen as 
OBJECTIVES AND STRATEGY 
 
41 
 
reported elsewhere(39) (see Appendix 1 for details). The temperature of the d.i. water sample 
was varied from 40 to 60 °C. This temperature-range choice allows for a linear-regime 
relationship between the variation of the temperature and Δn of water at 632.8 nm. In the 
second method, glucose solutions at different concentration (% m/v) were used. This method 
is fully described by Giorgis et al(37), where the refractive indices of different glucose 
solutions are reported (see Appendix 1 for details). To calculate the sensitivity of the 
multilayer, the experimentally determined conversion factor of 0.00104° / pixels was used, 
as explained in the previous section. 
For the first method, the result is presented in Fig.2.2.8. The relationship is linear, as 
predicted by known formulas(37).  
 
 
Fig.2.2.8. Linear relationship between the module of Δn of d.i. water (upon change of 
temperature) and the shift of the BSW dip position along the pixels of the detector, a CMOS camera.  
Data were interpolated with a linear fit and the slope of the line represents the sensitivity of the multilayer 
in pixel / RIU. Inset: sensogram obtained upon the temperature variation of the d.i. water sample, 
corresponding to the indicated experimental points. 
 
From the slopes of the linear fit, it is possible to estimate a sensitivity of 23174 pixel / RIU. 
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The same calibration experiment was conducted using solutions at different % in m/v of 
glucose in water at 25 °C(38). The displacement of the BSW dip over the pixels of the camera 
was recorded, and the result is presented in Fig.2.2.9. As expected, also in this case the 
relationship between Δn and the pixel shift is linear.  
 
 
Fig.2.2.9. Linear relationship between the module of Δn of glucose solutions at different 
concentration (% m/v) in d.i. water and the shift of the BSW dip position along the pixels of the 
camera. Data were interpolated with a linear fit and the slope of the line represents the sensitivity of the 
multilayer in pixel / RIU. Inset: sensogram obtained upon the injection of 5 different glucose solutions 
corresponding to the indicated experimental points. 
 
The slope of the fit allows the estimation of a sensitivity of 25044 pixel / RIU.  
If we consider the experimentally determined conversion factor 0.00104° / pixel, the 
sensitivity can be written as: Sexp = 24.10° / RIU and Sexp = 26.05° / RIU for the temperature-
based calibration and for the glucose-based calibration, respectively. Those experimental 
sensitivity values are about the half of the theoretically calculated value, estimated through 
the simulations presented at the beginning of this section. The main reason for such a 
difference lies in the fabrication inhomogeneities of the layers in the stack. 
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A further calibration experiment was devised to correlate the response of the BSW-based 
sensor to the Aβ42 peptide concentration. We prepared samples of Aβ42 monomers at 
different and known concentrations, and we registered the pixel shift of the BSW dip, as 
imaged onto the CMOS camera. The test was carried out with the same concept as for the 
previously reported BSW response calibrations, but it was for us impossible to extract 
valuable data from it. The main reason for the failure of the attempted tests was related to 
problems of bubbles and foam formation while emptying the chamber, followed by Aβ42 
sample injection difficulties. The BSW resonance position was then difficult to estimate with 
small uncertainty and without a rough pixel shift approximation, and reasonable results were 
impossible to obtain. 
The experimentally observed sensor resolution was determined using glucose solutions 
at different concentrations (% m/v), similarly to the experimental system calibration reported 
in the previous. The result of this investigation is shown in Fig.2.2.10. 
 
 
Fig.2.2.10. Experimental sensor resolution determination. Sensogram obtained upon the injection of 
glucose solutions in different concentrations (% m/v) corresponding to the indicated experimental points 
(see Appendix 1 for details). Glucose solutions at concentration lower than 0.05% m/v were tested. The 
corresponding signals are not shown in the sensogram since it was adapted to better appreciate the BSW 
shift at higher concentrations, as imaged onto the camera pixels. 
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The smallest Δn variation detected by the system, compared to the signal obtained upon d.i. 
water injection, was Δnr = 7.6·10−5 RIU, and it corresponded to the injection of a glucose 
solution at a concentration of 0.05% m/v(37). This experimental system resolution is thus 
lower than others reported in the literature(38), but it is sufficient to our purpose. 
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3. REAL-TIME AMYLOID AGGREGATION 
MONITORING WITH A PHOTONIC 
CRYSTAL-BASED APPROACH 
This chapter is  a partial adaptation of  the journal article : 
Santi, S., Musi, V., Descrovi, E., Paeder, V., Di Francesco, J., Hvozdara, L., van der Wal, P., Lashuel, H. 
A., Pastore, A., Neier, R. and Herzig, H. P. (2013), Real-time Amyloid Aggregation Monitoring with a 
Photonic Crystal-based Approach. ChemPhysChem, 14: 3476–3482.  
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3.1 Introduction 
 
The misfolding and aggregation of specific proteins have been recognized as the cause 
of widespread degenerative pathologies such as AD and Parkinson’s diseases(1). In the 
specific case of AD, the neuronal and synaptic loss has been commonly identified with the 
presence of senile plaques of extracellular highly fibrillogenic Aβ peptides. These peptides, 
one of the longest being Aβ42, are produced as soluble monomers. As already explained in 
Chapter 1, the prevailing hypothesis is that cell toxicity, associated to neuronal death, is 
triggered by intermediate soluble oligomeric forms of Aβ peptide developing at a very early 
stage of aggregation, rather than by the final insoluble plaques composed of Aβ fibrils(2, 3). 
Aβ aggregation is thought to proceed through the NP model(4-6). This model consists of a 
first rate-limiting nuclei formation, described as “lag-phase”, corresponding to the formation 
of toxic oligomeric species at the early stages of Aβ aggregation, followed by an 
elongation/polymerization phase, which leads to the formation of fibrils. One of the major 
challenges for AD research is to detect the early events of aggregation since the classical 
detection methods, such as Congo red and ThT staining, TEM, X-ray diffraction and classical 
NMR are all too insensitive to detect the minute soluble species formed during the lag-
phase(7, 8). A prompt and sensitive detection would also be crucial to allow AD early 
diagnosis and design of powerful therapeutic treatments. 
In this chapter, we present the unique properties of an optical label-free refractometric 
sensing platform as a novel approach for investigating the initial lag-phase of Aβ42 
aggregation. Our sensing approach allows the real-time optical detection of local refraction 
index changes occurring as aggregation takes place. The method is based on the optical 
interrogation of a dielectric multilayer (1D photonic crystal) sustaining an electromagnetic 
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surface wave(9, 10). The sensing technique is reminiscent of SPR: Instead of having a SP 
propagating on a thin metallic film, an evanescent SEW called BSW is coupled on a purely 
dielectric multilayer structure(11) (see Chapter 2 for details). Depending on the materials 
used and the layout of the periodic dielectric multilayer, the BSW can be produced in a wide 
spectral range, from the visible to the near-infrared(12-14). This spectral tunability represents 
one of the main advantages of BSW-based optical transduction systems, as compared to SPR. 
In addition, BSWs present very narrow resonances that can increase the resolution and the 
limit of detection in label-free detection schemes. BSWs generated on dielectric multilayers 
are sensitive to external perturbations of the refractive index close to the surface of the 
photonic multilayer(15-17). 
In the following, we report on a proof of principle of the BSW-based detection technique 
for sensing protein aggregation by monitoring in real time the refractive index variation (Δn) 
of an aqueous solution containing the Aβ42 peptide during early aggregation and fibril 
formation. The multilayer surface is directly contacted with the probed aqueous medium and 
the sensing chamber is positioned vertically, as explained in Chapter 2. Hence, the 
measurements using BSWs monitor a local variation of the refractive index of the solution, 
which is directly related to the depletion of the concentration of the Aβ42 monomeric form 
during aggregation.  
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3.2 BSW-based Aβ42 aggregation sensing  
 
The monomeric Aβ42 peptide was incubated at 37 °C in the fluidic chamber in presence 
of an initial bare (non-functionalized) multilayer. (For details on sample preparation, see 
Chapter 8.) The measurement consisted in time-monitoring the angular position of a BSW 
resonance dip upon a laser illumination through the prism. A selection of aggregation curves 
obtained during incubation of the Aβ42 peptide is shown in Fig.3.2.1. The variation of the 
refractive index Δn of the initially monomeric Aβ42 solution is monitored as a function of 
time by tracking the BSW resonance position on a linear CMOS camera (see Chapter 2). For 
this reason, in the monitorings presented in Fig.3.2.1, but also in measurements presented in 
the following Chapters, Δn corresponds to the shift of the BSW resonance position in pixels. 
For the results presented in this thesis work, it is important to highlight that the zero value in 
pixel shift corresponds to the BSW resonance position at the beginning of the measurement, 
and not to the signal of the reference buffer solution (10 mM Tris HCl), unless stated 
otherwise. All the measurements of the Aβ42 aggregating peptide in Fig.3.2.1 show an initial 
increase followed by a decrease of Δn of the solution. The Δn decrease is in accordance with 
the Aβ42 monomer depletion due to aggregation. The BSW-assisted monitoring was 
compared with TEM imaging data to allow the detection of the Aβ42 species and their 
corresponding morphologies before and during aggregation(18). TEM imaging was 
performed on an Aβ42 sample probed at different stages of aggregation, thus revealing the 
morphological evolution of the peptide from a monomeric (Fig.3.2.2, micrograph (a)), to an 
oligomeric and pre-fibrillar stage (Fig.3.2.2, micrographs (b), (c) and (d)), and to a non-
soluble aggregate fibrillar conformation (Fig.3.2.2, micrographs (e) and (f)).  
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Fig.3.2.1. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide. 
Refractive index variation Δn, in pixel shift, of Aβ42 peptide solutions incubated at 37 °C. Six distinct 
Aβ42 samples (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 monomer concentrations: (a) 17.3 and 17 
µM; (b) 13.9 and 13 µM; (c) 7.7 µM,) were incubated in the BSW sensing cell. The overlap of the three 
distinct measurements is presented in a close-up view in graph (d), where colors are consistent with those 
used for the single measurements. In (b), the curve corresponding to the monitoring of the Aβ42 peptide at 
the initial concentration of 13 µM (in magenta) was perturbed by the probable formation of bubbles in the 
sensing cell. Nevertheless, the measurement reveals the characteristic evolution of Δn.  
 
The six curves in Fig.3.2.1 show the real-time Δn variation of the initially monomeric 
Aβ42 solutions at three sets of concentrations: 17.3 and 17 μM (Fig.3.2.1 (a)), 13 and 13.9 μM 
(Fig.3.2.1 (b)), and 7.7 μM (Fig.3.2.1 (c)). We observed that working in such a small range 
of low concentrations did not affect the overall evolution trend of the Δn as sensed by the 
BSW, as shown in the overlap of the measurements presented in Fig.3.2.1 (d). Remarkably, 
the maximum amplitude of the Δn measurement is attained at approximately 2 hours, 
regardless of the initial peptide concentration. Differently, the initial sample concentration 
appears influencing the extent of the refractive index increase in this time frame, being greater 
for higher, and lower for smaller Aβ42 peptide concentrations. Moreover, a positive 
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correlation is also observed between the subsequent refractive index decrease rate and the 
peptide concentration. 
 
 
Fig.3.2.2. TEM micrographs of Aβ42 peptide at different stages of aggregation. The initial Aβ42 
concentration was 17 μM (in 10 mM Tris HCl, pH 7.4). Micrographs were taken at: (a) t = 0, T = 4 °C; 
(b) t = 30 minutes, T = 37 °C; (c) t = 2 h, T = 37 °C; (d) t = 10 h, T = 37 °C; (e) t = 24 h, T = 37 °C; 
(f) t = 48 h, T = 37 °C. The morphological changes of the Aβ42 peptide during incubation are displayed.  
 
In our measurements, the real-time refractive index variation of the aggregating Aβ 
solution is the result of different contributions, which are difficult to study individually. A 
simple empirical model describing the variation of Δn as sensed by the BSW involves the 
contribution from two terms, shown in Eq.(3.1): 
Δn = Δns + Δnb   (3.1) 
wherein Δns is the refractive index variation due to surface adsorption/desorption processes, 
and Δnb is the refractive index variation occurring in the bulk solution, as observed within the 
evanescent tail of BSWs. (Notably, this model to interpret the BSW-based measurements is 
a simplified approach, and others might be considered.) Since our multilayer presents a bare 
silicon oxi-nitride surface, Δns is mainly due to the hydrophobic adsorption of the Aβ42 
peptide onto the surface. Instead, Δnb refers mainly to the variation of the Aβ42 monomer 
concentration in the bulk solution throughout aggregation: The decrease of the monomer 
concentration reveals the formation of non-soluble aggregates. The final result of the Aβ42 
aggregation process, the precipitate of the non-soluble fibers, statistically accumulates at the 
bottom of the vertically positioned sensing chamber, away from the BSW probe. 
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The overall time evolution of the refractive index value Δn as shown in Fig.3.2.1, can 
be divided into three distinct stages, which are labeled with roman numbers in Fig.3.2.3, 
where the Aβ42 aggregation monitoring in Fig.3.2.1 (a), in black, is displayed as a 
representative measurement. These stages are discussed in the text following Fig.3.2.3. 
 
 
Fig.3.2.3. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide. 
Refractive index variation Δn, in pixel shift, of an Aβ42 monomer peptide solution incubated at 37 °C at 
the initial concentration of 17,3 µM in 10 mM Tris HCl, pH 7.4. Roman numbers refer to the three distinct 
zones of the Δn monitoring, as described in the text. The lowercase letters refer to the TEM micrographs 
collected at different stages of aggregation, during the Δn monitoring, and reported in Fig.3.2.2.  
 
I. An initial period characterized by a steep increase of Δn during the first approximately 
2 hours of the experiment. This is consistent with the adsorption or physisorption of the 
Aβ42 peptide in an adhesion-competent conformation, onto the silicon oxi-nitride 
surface. This event produces a local increase of Δns. This surface-loading mechanism 
hampers the direct observation of the Δnb decrease due to peptide aggregation in this 
very early stage. Nevertheless, at this specific early stage, the changes of the 
concentrations in the bulk solution are expected to be negligible. 
a
b
c
d
e
I
II
III
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II. A maximum amplitude of the curve, attained at ~ 2 hours and characterized by the 
amount of the overall Δn change as measured from the start of the experiment. The 
reaching of the maximum refractive index value can be associated to an equilibrium 
condition due, e.g. to the saturation of the surface and a decreased availability of free 
adhesion-competent peptides because of a simultaneous polymerization occurring in the 
solution.  
III. A slow and steady decrease of Δn as observed after passing the maximum. The 
exponential decrease of the refractive index can be possibly ascribed to two processes: 
the detachment of the peptide from the surface, and/or the formation of fibrillar structures 
according to the aggregation mechanism, and thereby depleting the bulk solution. Both 
of them lead to a decrease of Δnb.  
In the following section we show that different conformational species of Aβ42 exhibit 
different affinities for the surface. 
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3.3 BSW-based protofibrillar and fibrillar Aβ42 
aggregation sensing 
 
We finally considered Aβ42 samples containing defined populations of Aβ species, 
including protofibrillar and fibrillar forms of Aβ42. (For sample preparation, see Chapter 8.) 
The purpose of these measurements was to try identifying the different aggregation states 
with the sensograms obtained along the amyloid pathway of Aβ42 samples. Protofibril 
samples are heterogeneous prefibrillar aggregates of different morphologies and sizes(18), 
reported to be generally unable to assemble into fibrils in the absence of the Aβ42 
monomer(19, 20), and showing low induced fluorescence response upon binding ThT. The 
mature aggregates, the fibrils, filamentous aggregates presenting considerable β-sheet 
structure, strongly bind ThT. ThT-binding fluorescence assay is used to routinely control the 
aggregation state of aggregating Aβ42 samples since it is reported to specifically bind 
amyloid aggregates(6). In this specific case, we performed a control test on Aβ42 peptide 
samples to assess the extent of fibril formation via ThT fluorescence enhancement under the 
same conditions as for the BSW-assisted monitoring. Hence, the emission fluorescence 
intensity of ThT at 482 nm was measured at different times, as shown in Fig.3.3.1. Two types 
of experiments were performed: a classical ThT binding assay, presented in Fig.3.3.1 (a), and 
a “seeding” assay, in which at the starting monomeric Aβ42 peptide was added 5% molar 
ratio of pre-formed Aβ42 fibrils, presented in Fig.3.3.1 (b). 
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Fig.3.3.1. ThT binding assay. (a) Enhancement in fluorescence at 482 nm given by the binding of 
ThT to the Aβ42 peptide during the aggregation at 37 °C. The initial concentration of the monomeric 
peptide was 8 μM in 8 mM Tris HCl, 50 mM gly-NaOH and 10 μM ThT, pH 7.8-8.2. (b) Time course of 
seeded Aβ42 aggregation at 37 °C monitored by change of ThT fluorescence at 482 nm, and time course 
of not seeded Aβ42. Experimental concentrations were 8 μM for the peptide, 8 mM for Tris HCl buffer, 
50 mM for gly-NaOH, and 10 µM for ThT. 
 
As highlighted by Fig.3.3.1 (a), there is a threshold in the aggregate concentration value at 
which the ThT fluorescence enhancement is exhibited. After a critical incubation time, the 
Aβ42 sample self-assembles into β-sheet secondary structures, allowing the insertion of ThT 
molecules into the channels made by the long axis of this domain(21). Thus, the ThT 
fluorescence intensity enhances upon binding. This occurs after about 15-20 hours of 
incubation at 37 °C. This aggregation mode is consistent with the nucleation-elongation 
model(5), where an initial lag phase is exhibited due to the early formation of small soluble 
oligomeric aggregates that are unable to incorporate the ThT molecules. After the nucleation, 
the aggregation proceeds abruptly. This corresponds to the elongation phase, during which 
Aβ fibrils are formed. After about 50 hours, the aggregate structure becomes too compact to 
embed the dye molecules, which are therefore excluded from the assembly. This is reflected 
in a decrease in the fluorescence intensity as demonstrated by many authors(6, 22) and shown 
by the measurement in Fig.3.3.1. It is possible to overcome the lag phase by adding 5% molar 
ratio of Aβ42 fibrils to the incubated Aβ42 monomer(4) (see Fig.3.3.1 (b)). In this scenario, 
the monomeric Aβ peptide is seeded by the presence of these already formed fibers, around 
which the aggregation proceeds. The ThT binding assays reveal the predicted time evolution 
of the fibril formation, as reported in the literature(18). Nevertheless, they emphasize the 
incapability of the ThT binding method to cover the early events of oligomerization. 
Finally, protofibrils (PF) and fibrils (F) were incubated at 37 °C in the BSW sensing cell 
with a bare multilayer, and the resulting profiles are shown in Fig.3.3.2, and compared to the 
profile of the initially monomeric peptide incubation (M), already presented in Fig.3.2.3.  
(a) (b)
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Fig.3.3.2. Real-time monitoring of the refractive index shift of incubating Aβ42 peptides. Real-
time refractive index variation Δn, in pixel shift, of Aβ42 peptides, incubated at 37 °C in 10 mM Tris HCl, 
pH 7.4, at different initial aggregation states and experimental conditions: M, 17.3 μM initially monomeric 
peptide, PF, 59 μM protofibril, and F, fibril form of the peptide (produced incubating a 15 µM monomeric 
Aβ42 sample at 37 °C for 48 h). The lower-case letters refer to the TEM micrographs collected at different 
stages of aggregation of protofibrils and fibrils during the Δn monitoring, and reported in Fig.3.3.3. 
 
Monomeric, protofibrillar and fibrillar forms of Aβ42 peptide present three distinct curves 
for the evolution of the refractive index over time. Regardless of the starting material used, 
the overall Δn decreases on the long run. The variation of the refractive index of the incubated 
protofibrils and fibrils is smoother with respect to the case of monomeric species, during 
incubation at 37 °C. Previous studies(18, 20) suggest that Aβ42 fibrils and, especially, 
purified protofibril species present a less pronounced tendency to further assembly, being 
already embedded in organized aggregation pattern. The TEM micrographs reveal a slow 
evolution of the Aβ42 protofibril during a 24-hour period of incubation, as shown in 
micrographs (a), (a1) and (b), (b1) of Fig.3.3.3. 
a, a1
b, b1
c
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Fig.3.3.3. TEM micrographs of Aβ42 peptides at different stages of aggregation. TEM 
micrographs of: protofibrils at the initial concentration of 59 µM at: (a&a1) t = 0 h, T = 4 °C; (b&b1) 
t = 24 h, T = 37 °C; fibrils at: (c) t = 0 h, T = 4 °C. 
 
Concerning the surface loading effect, we do not report an appreciable Δn increase when 
mature fibrils, identified by TEM imaging (Fig.3.3.3, micrograph (c)), are incubated in the 
BSW sensing cell. This evidence allows inferring that surface adsorption of mature fibrils can 
be safely neglected in this specific case. Since fibrils were obtained incubating a purified 
monomeric Aβ42 sample at 37 °C for 48 hours, the incubation of these mature aggregates 
can be even considered as pursuing the measurement of the Aβ42 monomer incubation, after 
48 hours, unaffected by any significant interaction with the multilayer. More interestingly, 
the BSW monitoring of the protofibrillar Aβ42 form shows no substantial surface adsorption. 
This observation is indicated by a minute increase of the Δn value during the first period of 
the incubation, as compared to the Δn of the M profile. The observed increase stays small 
especially if one takes into account that a four times smaller concentration of monomer was 
used in the experiment. Accordingly, the surface adsorption mechanism onto the 
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unfunctionalized multilayer is found being a process associated with and depending on the 
Aβ42 peptide in a specific aggregation form. Protofibrils seem to be less prone to be adsorbed 
onto the surface. The species that are strongly adsorbed onto the multilayer nitride surface 
have to be in a precise pre-fibrillar conformation, with a lower molecular weight than the 
average weight attributed to protofibrils. 
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3.4 Conclusion 
 
This chapter describes how a photonic crystal-based optical platform can be applied to 
monitor the Aβ42 peptide aggregation during the early events of the fibrillization process that 
lead to AD. By sensing the refractive index change of the peptide solution, this approach 
provides unprecedented information covering the transition period from a homogenous 
dispersion, the monomer solution, to a heterogeneous suspension containing fibrillar 
amyloids. The presented photonic crystal-based approach provides relevant information on 
the aggregation of Aβ42 peptides during the nucleation process, the silent lag phase, where 
other classical amyloid detection methods are limited by their sensitivity.  
As reported in the literature(23), the Aβ42 peptide undergoes major morphological 
changes during the aggregation process. The variation of the Aβ42 secondary structure has 
been extensively demonstrated(24, 25), especially in the transition from the monomeric form 
to the soluble oligomeric forms and these changes vary the water-exposed surface of the 
peptide(26). We suggest that the Aβ42 peptide desorption from the sensing surface should be 
caused by a variation in the secondary structure of the species initially adsorbed onto the 
multilayer surface. In the pathway from the oligomeric forms to the mature fibrils the 
structures become more compact and expose a different and less surface-affine pattern. The 
TEM micrographs in Fig.3.2.2 are in good agreement with this hypothesis, showing the 
formation of oligomeric protofibrils from lower to higher molecular weight, in 
correspondence with the establishment of the maximum amplitude of the Δn signal for the 
monomeric profile in Fig.3.2.3. The presented results support the hypothesis that the 
interaction with the unfunctionalized bare surface, and especially the postulated detachment 
of the peptide from it, may be determined by a specific early molecular structure variation. 
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An analogous event has been reported by Yagi et al(27), whose work suggests the formation 
of oligomeric Aβ seeds attached to a quartz surface.  
Despite the technical restrictions imposed by the prototype system, our approach reveals 
a high potential that might overcome some of the limitations in other techniques(28). The 
presented photonic crystal-based approach is a novel promising candidate for direct, label-
free and real-time monitoring of the Aβ transitions during oligomerization at early stages(29). 
In perspective, this innovative amyloid-sensing strategy can be exploited to screen for 
molecular factors that influence the oligomerization process. Furthermore, the photonic 
crystal-based sensing can serve as a direct screening tool for new potential inhibitor of Aβ42 
toxic oligomers and early nucleation events, as will be explained in Chapter 5. 
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4. CHEMICAL SURFACE MODIFICATION 
STRATEGY TO IMPROVE BSW-BASED-
SENSING PERFORMANCES 
 
 
 
 
 
 
 
 
 
4.1 On the choice of the surface functionalization 
approach 
 
In label-free biosensing, the main advantage is to perform investigations of analytes 
without the interference of a probe, the label, interacting with(1), covalently bond to(2, 3), or, 
in the case of isotopic labelling, being part of the molecule subject to the analysis(4). The 
label can be seen as a non-natural presence that could affect the behavior of the analyte(5). In 
the specific case of protein aggregation monitoring, the label could deeply vary the 
aggregation trend, for the variation of the hydrophobic/hydrophilic balance is essential for 
determining the predisposition to misfold(6). Moreover, label-based assays require additional 
sample treatments, which are time consuming and often expensive(7). However, introducing 
a label is frequently not only necessary to track the investigated protein: The presence of the 
label plays a fundamental role for specificity and signal amplification. Especially in complex 
matrices analysis, the label is essential to discriminate between signal and noise, thus 
providing a direct response even at very low concentrations(8, 9). 
In this work, we exploit the potential of a refractive index surface-sensing, which has 
the advantage of being label-free, but the drawback of monitoring a non-specific property of 
the Aβ peptide solution. Hence, the BSW-based sensing is non-selective. To overcome this 
limitation, a method to chemically modify the sensing surface with the aim of selectively 
probe the aggregation of the Aβ peptide only was developed and it is presented in the 
following sections. The original idea was to devise a functionalization method for the sensing 
surface that could serve for different applications, from the surface passivation, to the specific 
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attachments of ligands. Moreover, we aimed at monitoring the aggregation of the Aβ peptide, 
qualitatively studying the underlying mechanisms for its interaction with the sensing surface, 
as shown in Chapter 3. The quantitative analysis of the peptide sample was not our main goal, 
since it requires time-consuming procedures, such as the surface immobilization of 
monoclonal antibodies, and delivers results easily achievable with commercially available 
techniques, such as SPR sensing(10) or ELISA immunoassay(11, 12), among others. 
Many surface modification strategies have been proposed(13, 14). The general 
requirement is to guarantee a sufficient degree of freedom to the ligand allowing its 
unperturbed interaction with the analyte in its free solution conformation. Hence, a proper 
flexible linker must be designed for this purpose. On the other hand, the ligand should be 
bond near the surface for sensing purposes. Therefore, the linker length, and not only its 
flexibility, is of topmost importance. For the interaction with the analyte, correct ligand 
orientation is also imperative. The choice of a suitable functionalization strategy is thus 
imperative for the success of a binding experiment, especially in the scenario of surface 
sensing measurements. It becomes clear that physisorption as a means to devise surface 
modifications should be avoided. Under physisorption conditions, neither immobilization 
homogeneity, stability, nor ligand orientation and density can be easily controlled. The 
reproducibility of the surface modification is also an issue, since one would preferably 
perform multiple experiments under identical working conditions. Physisorption does not 
assure reproducibility of the surface treatment. On the contrary, chemical surface 
modification via covalent attachment strategies is an approach allowing to control many of 
these parameters(13). As explained in Chapter 2, our sensing surface is made of a stack of 
dielectric materials, the top layer being silicon nitride. Water and air oxidation of silicon 
nitride results in the formation of silicon hydroxyl groups at the surface of the multilayers(13). 
Therefore, silicon nitride surfaces can be, in a general approximation, treated as silica. 
Exploiting a glass-based surface functionalization chemistry appeared to be the most 
compelling approach to address the silicon oxi-nitride multilayer surface modification matter. 
To the best of our knowledge, to date there is no report on the chemical modification of 
silicon-nitride photonic-crystal surfaces in the literature. In the following sections, the 
strategy adopted in this project is presented in details. 
 
4.1.1 The glass-based surface functionalization chemistry : a 
multistep approach  
 
The chemical modification of the multilayer surface was devised in collaboration with 
Dr. Van der Wal from the Sensors, Actuators and Microsystems Laboratory (EPFL). Our idea 
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was to implement and develop a general strategy widely applicable to the introduction of 
small ligand molecules as well as to protein or antibodies. Especially, the goal of our work 
was dual and consisted in: a) generating a reproducible passivated surface that could sense 
the analyte without non-specific interactions; b) functionalizing the surface with a specific 
ligand for prefibrillar Aβ amyloids detection, thus increasing the selectivity of our sensing 
approach. Because of this dual purpose, we conceived a multistep chemical surface 
functionalization strategy that can be outlined with three main phases: i) treatment of the 
surface with an established chemical method to generate a suitable functional group, ii) 
attachment of a versatile bi-functional linker for spacing purposes, to which iii) the ligand 
could be covalently bond. Such a multistep approach is of great advantage in the context of 
batch surface modification. Each reaction step can be carried out with several multilayers at 
the same time. For the final ligand binding, the treated multilayers can be divided in two or 
more groups and made react with the specific desired molecule. 
Therefore, as we aimed at establishing a protocol enabling a wide variety of surface 
modifications, for the first reaction step i), we decided to employ the highly versatile glass-
based surface functionalization chemistry. It is based on the use of organosilanes. Silanization 
as surface modification method is characterized by high physical and chemical stability of 
the introduced layer, thus giving access to a wide variety of chemical reactions for further 
modifications. We selected an amino organosilane ((3-Aminopropyl)triethoxysilane, 
APTES) that has been extensively used by different research groups(15, 16). APTES 
introduces an amino group on the treated surface (see Fig.4.1.1). The free -NH2 group can be 
used as handle to attach probes or linkers using a well-developed and reliable chemistry. 
APTES has been reported to be a versatile tool for disparate applications(13, 16). Using 
APTES, good surface homogeneity has been achieved, and, depending on the reaction 
conditions, the formation of ordered self-assembled monolayers (SAMs) has been 
demonstrated(17). Moreover, the moderate length of the aliphatic chain connecting the amino 
group to the silicon atom in APTES brings the ligand close to the surface. This proximity is 
favorable in our sensing scheme, as the BSW is evanescent and field intensity, hence 
measurement sensitivity, exponentially decays with distance(18), as explained in Chapter 2. 
The mechanism by which APTES condensates onto hydrated silica surfaces is shown in 
Fig.4.1.1(16, 19). With APTES, the presence of water molecules at the surface is fundamental 
for the silanization process. The condensation reaction between two or more APTES 
molecules depicted in the top scheme in Fig.4.1.1 is possible both in solution and at the 
surface, but it is most likely to occur at the surface once the silanization reaction has 
commenced(16). 
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Fig.4.1.1. APTES surface condensation scheme. In the top scheme the hydrolysis of APTES in 
solution phase is presented to highlight the possible mechanism of initiation of the SAM formation. The 
following condensation reaction between two or more APTES molecules is also depicted in the top scheme. 
The presence of water molecules is fundamental for the surface silanization process, as shown in the bottom 
scheme. Scheme reprinted from J.A. Howarter and J.P. Youngblood, 2006(19) with permission from the 
American Chemical Society. 
 
For the following step ii), we envisaged using a bi-functional linker devised for 
antibodies attachment to AFM tips, adapted from a work published by Wildling et al in 
2011(20). The linker was synthetized in our group by Dr. Kolympadi, and it carries an N-
hydroxysuccinimide (NHS) ester function and an aldehyde protected group (see Fig.4.1.2). 
Regardless of the nature of the final ligand, all the reactions involved in our multistep 
surface chemistry strategy are presented in Fig.4.1.2 and discussed in details in the following 
paragraph. 
Finally, depending on the selected ligand, the final binding step iii) is described in details 
in section 4.2 for the surface passivation procedure (compound 4a in Fig.4.1.2), and in section 
4.3, for the selective prefibrillar Aβ recognition experiment (compound 4b in Fig.4.1.2), 
respectively. 
APTES 
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Fig.4.1.2. Surface functionalization chemistry scheme. The silicon nitride surface is represented 
by hydroxyl functions in the top layer. The sensing surface was treated via subsequent reaction steps: 
(a) aminosilanization with APTES; (b) attachment of the acetal-NHS linker via amide bond formation; (c) 
linker deprotection: conversion of the acetal to the aldehyde function; (d) ligand coupling via Schiff-base 
formation and reduction to stable C-N single bond (see sections 4.2 and 4.3); (e) end-capping of unreacted 
linker. Buffer A was 100 mM NaCl, 50 mM NaH2PO4, pH 7.5. Steps (b), (c), (d), (e) were adapted from 
the literature(20). See Chapter 8 for details. 
 
All the surface modification reaction steps in Fig.4.1.2 were performed by immersion, 
either vertically positioning the dielectric multilayers in the reaction bath, or placing them at 
the bottom of it, with the dielectric layers oriented upwards. After each reaction step, the 
multilayers were extensively rinsed with water or with the organic solvent used in the reaction 
bath, and then dried with a gentle N2 flux. This procedure was essential to avoid the staining 
of the substrates.  
As a preliminary step, the silicon nitride surface was treated with a piranha solution (3:1 
H2SO4:H2O2). Piranha is a potent oxidizing agent, which removes unwanted organic 
contaminants and generates silanols functions Si-OH able to react with APTES(21). For the 
aminosilanization with APTES (Fig.4.1.2 (a)), 5% of water was added to the toluene bath to 
(a) (b)
(c)
(d)
(e)
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induce APTES surface condensation(16), as previously explained. The following step 
consisted in binding the bi-functional linker 1 to the free amine groups of the APTES-
modified surface, as presented in Fig.4.1.2 (b). The acetal group of 2 was subsequently 
deprotected with mild acid, thus creating the aldehyde 3 (Fig.4.1.2 (c)). Finally, 3 was 
connected to the free amino group of the ligand via Schiff-base formation. The consecutive 
in situ reduction resulted in the stable compounds 4a and 4b (Fig.4.1.2 (d)). As a final 
step(20), we end-capped the unreacted activated linker 3 via the use of ethanol amine 
(Fig.4.1.2 (e)). For further details on the functionalization strategy, see Chapter 8. 
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4.2 Polyethylene glycol self-assembled monolayer 
coating 
This section is  a partial adaptation of  the journal article:  
Santi, S., Musi, V., Descrovi, E., Paeder, V., Di Francesco, J., Hvozdara, L., van der Wal, P., Lashuel, H. 
A., Pastore, A., Neier, R. and Herzig, H. P. (2013), Real-time Amyloid Aggregation Monitoring with a 
Photonic Crystal-based Approach. ChemPhysChem, 14: 3476–3482.  
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim   
 
For a better understanding of the type of process observed during the monitoring of the 
Aβ42 peptide, as presented in Chapter 3, we explored an approach based on “passivating” the 
multilayer surface by a chemical coating. The goal of these experiments was to indirectly 
investigate the Aβ42 surface interaction process throughout its aggregation. Polyethylene 
glycol (PEG) of a molecular weight of 750 Da, attached to a glassy surface, forms an ordered 
brush-like SAM(22). The SAM thickness is reported to be 50-70 Å. PEG coated surfaces 
successfully avoid non-specific protein interaction, independently of the nature of the 
surfaces(23), and were shown to be almost inert(24, 25). Synthetizing a PEGylated multilayer 
surface should therefore considerably reduce or even totally suppress the surface influence 
on the process of Aβ42 aggregation.  
As explained in the previous section 4.1, we devised a surface chemistry where a ligand 
can be bound to the surface if provided with an amino group. Therefore, methoxy 
polyethylene glycol amine 750, an α- and ω-substituted PEG derivate, was selected to be 
linked to the silicon nitride top layer of the sensing multilayer. Hence, the amino end-group 
of the modified PEG molecule 4a was reductively coupled to the linker 3 (see scheme in 
Fig.4.1.2), as presented in Fig.4.2.1. We thus obtained a PEGylated multilayer surface. 
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Fig.4.2.1. PEG coating scheme. Methoxy polyethylene glycol amine 750 was reductively coupled 
to the aldehyde function of the linker. In contrast to higher-molecular-weight PEGs forming bundle-like 
SAMs, PEG750 forms an ordered brush-like SAM on the multilayer surface(22). The selected PEG derivate 
was 50-70 Å long and formed by approximately 16 ethylene glycol units. 
 
4.2.1 Bovine Serum Albumin aggregation sensing: effic acy test 
of the passivation treatment with PEG  
 
Bovine Serum Albumin (BSA) is a model protein widely used for several protein 
chemistry and biochemistry applications due to its high availability, stability at room 
temperature and low purchase price(26). For example, BSA is employed in ELISA tests as 
blocking agent(27), in the Bradford protein assay as reference for protein quantification(28), 
and in cell cultures as nutrient(26). BSA has frequently been employed as a passivating agent 
for prosthetic implants, due to its high propensity to adhere to almost any hydrophilic surface 
because of its overall negative charge at neutral pH(29). Provided the easy access to this 
protein and its countless applications, many research groups are using BSA as a model to 
study aggregation in vitro. It has been shown that BSA undergoes aggregation at high 
temperatures forming an amyloid-like pattern. The native structure of BSA is an all-α helix. 
Upon aggregation, a strong increase of β-sheet content, a typical feature of amyloidogenicity, 
has been reported(30). A series of investigations lead to the identification of the conditions 
and mechanism for the BSA amyloid-like self-assembly. Interestingly, thermally induced 
<n>≈16
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ordered fibrillization occurs at pH values above the protein isoelectric point (4.8) and at a low 
concentration regime(31). In the view of these findings, we selected the BSA protein as a 
suitable candidate to perform a real-time BSW-based monitoring. The purpose of these 
experiments was dual: Provided the properties of this peptide to be adsorbed onto hydrophilic 
surfaces and to aggregate in controlled conditions, we employed it as a control test for the 
PEGylation coating effectiveness, and, in a second series of experiments, as a model for 
studying the kinetics of aggregation. 
To prove the capability of PEG to prevent non-specific protein interactions with the 
multilayer surface, we separately incubated two identical BSA sample solutions in the 
presence of a bare and of a PEGylated multilayer. The signal obtained from the real-time 
monitoring of the refractive index variation of these samples, as sensed by the BSW, is shown 
in Fig.4.2.2 and in Fig.4.2.3. Note that, for the set of BSW-assisted monitorings presented in 
this section only, the d.i. water pixel value prior to the BSA incubation was set to zero. 
 
 
Fig.4.2.2. Real-time monitoring of the refractive index shift of incubating BSA protein with a 
bare multilayer. The BSA sample (initial monomer concentration 0.56 mg/mL, in 0.1 M PBS, pH 8.9) 
was incubated at 57 °C in contact with a bare multilayer. Inset: enlargement of the sensogram obtained 
upon the injection of the BSA sample, following the calibration with PBS at 57 °C. The d.i. water pixel 
value prior to the BSA aggregation monitoring was arbitrarily set to zero. 
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As shown in Fig.4.2.2, the incubation of BSA with a bare multilayer was performed with 
an initial protein concentration of 0.56 mg/mL in PBS at 57 °C. PBS which was also used to 
calibrate the BSW response before the incubation of the protein, as presented in the inset. 
BSA concentration, buffer and incubation temperature were chosen according to the 
literature(31), where they have been reported to promote a steady amyloid-like aggregation 
process within few hours. After more than 20 hours of incubation, no significant change of 
the refractive index as sensed by the BSW could be correlated to BSA aggregation or 
secondary structure variation process. The scattering signal after 30 hours of incubation has 
to be best regarded as the effect of temperature fluctuations, rather than as the monitoring of 
BSA aggregation. As expected, the initial monitoring of the BSA sample revealed an abrupt 
positive pixel shift. As seen in Chapter 3, this signal is related to a strong adsorption of the 
protein onto the bare surface of the sensor. A significant local increase of the refractive index 
is therefore observed. Highlighted by the inset in Fig.4.2.2, the signal resulting from the first 
hour of monitoring was increasing with a steady but intermittent trend. The BSW, at this 
specific monitoring stage, was reasonably sensing both the BSA aggregation occurring in the 
bulk and the unspecific BSA protein adhesion onto the surface. We propose that the 
undulating trend of the refractive index, as sensed by the BSW, was the result of those two 
concomitant processes. 
Finally, PBS was employed to extensively wash the fluidic cell and then incubated 
without varying the temperature of the system, as presented in the inset of Fig.4.2.2. The 
signal resulting from the monitoring of PBS in this condition was not constant and did not 
reach the initial pixel value exhibited before the BSA incubation. A reasonable explanation 
can be that the multilayer surface was steadily coated by surface-adsorbed BSA proteins. The 
consequent shielding of the BSW sensitivity could be the reason for the absence of refractive 
index variations of the solution, as sensed by the BSW, for long incubation time. 
To verify the correlation between the positive pixel shift and the BSA surface adsorption 
process we performed the same experiment with a PEGylated multilayer, and the result of the 
monitoring is presented in Fig.4.2.3, where the real-time monitoring of the proteic sample 
refractive index variation, incubated at 57 °C, is shown. As explained before, the goal of this 
test was to provide a proof for the effectiveness of the PEG coating, which should avoid any 
non-specific protein-multilayer interactions throughout a real-time BSW-assisted 
measurement. 
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Fig.4.2.3. Real-time monitoring of the refractive index shift of incubating BSA protein with a 
PEGylated multilayer at 57 °C. The BSA sample (initial monomer concentration: 0.52 mg/mL, in 0.1 M 
PBS, pH 8.9) was incubated at 57 °C in contact with a PEGylated multilayer surface. Inset: enlargement of 
the sensogram obtained upon the injection of PBS, before and after the BSA sample incubation, at 57 °C. 
The d.i. water pixel value prior to the BSA aggregation monitoring was arbitrarily set to zero. 
 
As shown in Fig.4.2.3, with a PEGylated multilayer surface the initial positive pixel shift is 
almost negligible. This observation is compatible with the hypothesis that the BSA protein 
non-specific interaction with the multilayer surface is prevented by the PEG coating. The 
observed decrease of the pixel shift can be attributed to the monitoring of the BSA 
aggregation occurring in the bulk. Moreover, as presented in the inset of Fig.4.2.3, after 
washing the fluidic cell with PBS, the signal returns to approximately the same pixel value 
as exhibited before the incubation of BSA. This behavior is compatible with the proposal that 
almost no BSA coating was formed, which might have affected the BSW sensitivity. From 
the result presented in Fig.4.2.3, a steady refractive index decrease throughout incubation can 
be noticed. This signal variation can be tentatively correlated to the aggregation of the BSA 
protein. These observations and interpretations are similar to those reported for the 
monitoring of the Aβ42 peptide presented in Chapter 3. 
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Hence, we performed a second series of experiments with the purpose of investigating 
the capability of the BSW-based sensing approach to detect different BSA aggregation 
dynamics. The result of this study is presented in Fig.4.2.4 and Fig.4.2.5, and it stems from 
the choice of thermally inducing the BSA protein fibrillization at different temperatures, as 
suggested by the work published by Vetri et al(31). We selected to carry out the BSW-based 
monitoring at 57 °C, as already presented in Fig.4.2.3, and at 67 °C, as presented in Fig.4.2.4. 
The aggregation at the higher temperature has been reported to be the most rapid. At this 
condition, the authors described the BSA aggregation to occur without a lag-phase and to 
reach an abundant fibril extent within few hours, as confirmed by other studies(30, 32). 
Within this temperature range and at 632.8 nm, the refractive index of aqueous solutions 
varies linearly(33), as explained in Chapter 2. 
 
 
Fig.4.2.4. Real-time monitoring of the refractive index shift of incubating BSA protein with a 
PEGylated multilayer at 67 °C. The BSA sample (initial monomer concentration: 0.52 mg/mL, in 0.1 M 
PBS, pH 8.9) was incubated at 67 °C in contact with a PEGylated multilayer surface. Inset: enlargement of 
the sensogram obtained upon the injection of PBS before the BSA sample incubation, and after the system 
calibration with d.i. water, at 67 °C. The d.i. water pixel value prior to the BSA aggregation monitoring 
was arbitrarily set to zero. 
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As shown in Fig.4.2.4, the BSW-based monitoring was able to detect a decrease of the 
pixel shift in time, which can be attributed to the BSA protein aggregation at 67 °C. The 
protein interaction with the sensing surface was negligible based on the absence of an initial 
refractive index increase. As predicted, the presence of the PEG coating successfully 
prevented non-specific protein-surface interactions.  
To perform a comparison between the monitorings of the BSA protein aggregation 
dynamics at the two selected temperatures, we had to normalize the signal. To take into 
account the different Δn response at different temperatures(34), we considered the pixel shift 
between water and PBS (Δpixelwater/PBS) at each experimental temperature as a reference, and 
used this value to normalize the signal of the monitorings. At 57 °C, Δpixelwater/PBS = 2 (see 
Fig.4.2.3, inset), and, at 67 °C, Δpixelwater/PBS = 3 (see Fig.4.2.4, inset). The two normalized 
experimental curves were shifted to zero to enable their comparison, and are presented in 
Fig.4.2.5. 
 
 
Fig.4.2.5. Comparison of the real-time monitoring of the refractive index shift of incubating 
BSA protein with a PEGylated multilayer. Two BSA samples (identical initial monomer concentration: 
0.52 mg/mL, in 0.1 M PBS, pH 8.9) were incubated at 57 °C and 67 °C, separately, in contact with a 
PEGylated multilayer surface. The curves were normalized and the initial data points were set to zero for 
the comparison. 
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At the two selected working temperatures, the monitorings of the aggregating BSA protein, 
as sensed by the BSW, resulted in similar signals. For both measurements, the refractive index 
steadily decreases almost immediately after the beginning of BSA incubation. As expressed 
before, we attributed the decrease of the refractive index to the extent of the BSA fibril 
formation. The rate of this refractive index decrease at 57 °C is comparable with, or at least 
not distinguishable from that of the BSA incubation monitoring at 67 °C. The main difference 
between the results presented in Fig.4.2.5 is that, after approximately 1.5 hours, the 
monitoring showed a continuing decrease at 67 °C. At 57 °C, a plateau was instead reached. 
The signal plateau is likely to be ascribed to the end of the BSA fibrillization process. This 
hypothesis assumes that no concentration variations of the soluble prefibrillar BSA form is 
sensed by the BSW once the plateau is reached. Indeed, our measurement relies on the 
monitoring of the refractive index variation of the solution, which is related to the BSA 
monomer concentration depletion during aggregation. As explained in the previous chapter, 
the extent of the fibril formation is therefore indirectly assumed upon refractive index 
decrease. Therefore, we speculate that a higher extent of BSA fibril was formed at 67 °C, 
leading to a larger putative plateau. However, at 67 °C, the apparent fibrillation rate was the 
same as at 57 °C (or maybe even slower than at 57 °C). This result is in disagreement with 
what reported in the literature, where authors have reported a higher fibrillar extent, but also 
a faster fibrillization rate, exhibited by the BSA protein when incubated at 67 °C, compared 
to the same experiment performed at 57 °C(31, 35). Further attempts to duplicate the 
experiment lead to outcomes that were comparable to those reported in Fig.4.2.5. At present, 
we are unable to explain the last part of the signal we obtained employing the BSW-assisted 
approach to cover the BSA protein aggregation at 67 °C. To deduce conclusions on the 
intimate dynamics of BSA aggregation, supporting biochemical experiments are needed. As 
the investigation of the aggregation dynamics of the BSA protein was not the prime goal of 
our research, we therefore concentrated on the study of the Aβ42 peptide, for which 
complementary studies were performed in parallel to those based on the BSW sensing 
approach (for further studies on the Aβ42 peptide, see Appendix 2).  
 
4.2.2 Aβ42  aggregation sensing with a PEGylated multilayer 
surface 
  
Results on the variation of the amyloid aggregation dynamics as sensed by the BSW 
with a passivated PEGylated multilayer are presented in Fig.4.2.6. We incubated initially 
monomeric Aβ42 samples at 37 °C in the fluidic chamber of the sensor under the same 
conditions as with the bare multilayer. The monitoring of the refractive index change 
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throughout the Aβ42 aggregation process revealed a variation in the first part of the 
measurement compared to the monitoring of the Aβ42 peptide with an unfunctionalized 
multilayer. This preeminent variation was concerning the amount of peptide interacting with 
the surface. On the contrary, as explained in the following, the rate and timing of the 
fibrillization process resulted unaffected by the presence of the PEG coating. A comparison 
between results obtained monitoring the Aβ42 peptide with a bare and a PEGylated multilayer 
surface, respectively, is presented in Fig.4.2.7, as revealed by the BSW-based sensing. 
 
 
Fig.4.2.6. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide with a 
PEGylated multilayer surface. Three Aβ42 samples (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 
monomer concentrations: (a) 17.3 µM; (b) 17.3 µM; (c) 7.7 µM,) were incubated at 37 °C in contact with 
a PEGylated multilayer. The overlap of the three distinct measurements is presented in a close-up view in 
graph (d), where colors are the same as those used for the single measurements. 
 
The monitoring of Aβ42 aggregation with a PEGylated multilayer was performed with 
initial peptide concentration of 17.3 and 7.7 µM (see Fig.4.2.6). The results are reproducible 
and consistent, as highlighted by the overlap of the three curves presented in Fig.4.2.6 (d). A 
higher initial monomer concentration led to a larger initial refractive index increase, and to 
an acceleration of the refractive index decrease rate (consistent with the results presented in 
Chapter 3). These observations are in accordance with the results reported the literature(36-
(a) (b)
(c) (d)
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38), where a positive correlation between Aβ peptide initial concentration and amyloid 
aggregation rate has been demonstrated.  
 
 
Fig.4.2.7. Selection of real-time monitorings of the refractive index shift of incubating Aβ42 
peptide. Comparison of the monitoring presented in Fig.3.2.3, in grey, and in Fig.4.2.6 (a), in black, 
respectively. They correspond to the results obtained incubating two distinct Aβ42 samples (in 10 mM Tris 
HCl buffer, pH 7.4, identical initial monomer concentration 17.3 µM, T = 37 °C) with a bare and with a 
PEGylated multilayer surface, respectively. 
 
 To analyze the effect of the surface PEGylation on the monitoring of Aβ42 aggregation 
one may especially focus on the comparison shown in Fig.4.2.7, where selected real-time 
monitorings of the Aβ42 peptide aggregation without and with surface coating are presented. 
In the measurements with a PEGylated multilayer surface, the curve (in black) reveals an 
initial positive pixel shift that is four times smaller compared to the same experiment with a 
bare multilayer (in grey). As discussed in Chapter 3, the real-time refractive index variation 
of the aggregating Aβ solution, as sensed by the BSW, were interpreted as the result of 
different contributions, which can be described by Eq.(3.1): 
Δn = Δns + Δnb  (3.1) 
CHAPTER 4 
79 
 
wherein Δns is the refractive index variation due to surface adsorption/desorption processes, 
and Δnb is the refractive index variation occurring in the bulk solution, as observed within the 
evanescent tail of BSWs. On the PEGylated multilayer surface a smaller amount of adhesion-
competent peptide is adsorbed, causing a smaller Δns increase. After 10 hours of incubation, 
this curve reaches negative values for the BSW resonance shift. Therefore, the refractive 
index of the solution, as sensed by the BSW, has become lower than at the initial stage of the 
incubation. This does not happen when incubating the Aβ42 monomer with a bare surface. In 
this context, the BSW resonance shift onto the camera pixels remains positive because of the 
shielding due to the initial mass-loading mechanism. The peptide surface-loading effect is 
therefore hampering the BSW sensitivity. On the contrary, the presence of the PEG coating 
effectively decreased the loading effect, thus making the BSW mainly sensitive to bulk 
fibrillization. After an incubation time between 8 and 12 hours, the two curves presented in 
Fig.4.2.7 show decreasing slopes that present similar rates. Therefore, for long incubation 
time (over 8 and 12 hours), the temporal evolution of the refractive index change is in general 
related to the bulk of the solution only, Δnb, where the fibrillization of the Aβ42 peptide 
occurs, regardless of the surface functionalization. We infer that the fibrillization process 
should not be affected by the surface-adsorption mechanism. With a bare multilayer surface, 
the surface-loading process only results in a decrease of sensitivity, still allowing estimating 
the time rate of Δnb. For an incubation time between approximately 2 and 8 hours, the 
descending Δn profiles of the monitorings in Fig.4.2.7 present different rates. Especially, with 
a bare multilayer surface Δn decreases with a faster rate. Having established that the 
fibrillization with a PEGylated and bare multilayer occurs with similar rates, the contribution 
of Δnb to the general Δn decrease should be the same with and without surface PEGylation. 
Therefore, we suggest that this difference should be ascribed to the desorption of the peptide 
from the bare multilayer surface, causing a decrease of Δns. 
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4.3 Sensing selectivity enhancement: Tryptophanol 
surface functionalization 
 
Many dyes specifically recognizing amyloid structures, such as Congo Red and ThT, 
have been used in the last 60 years(1, 39-41). They all are extrinsically fluorescent, meaning 
that their association with an amyloid pattern results in a considerable enhancement of their 
fluorescence quantum yield. Notably, ThT has been extensively used to monitor the 
aggregation pathway of the Aβ peptide, for its intrinsic fluorescence is reported to increase 
upon binding to amyloid like structures(42, 43). A great effort to find even more selective 
molecules has been invested. This has led to the investigation of various fluorescent dyes that 
could overcome the low sensitivity of ThT towards the first oligomerization stages of amyloid 
aggregation(44, 45). Among others, a class of indoles has been identified to be selective for 
the recognition and the binding of prefibrillar Aβ aggregates(46). In this thesis project, we 
focused on L-Tryptophanol ((S)-2-amino-3-(3-indolyl)-1-propanol, TROL, see Fig.4.3.1) as 
a representative of this class. TROL selectivity has been reported to be nearly 20-fold greater 
than that of ThT(47). In an article appeared on ChemBioChem journal in 2010, Reinke et 
al(48) described TROL as capable of binding both Aβ40 and Aβ42 early aggregates, covering 
the first steps of amyloid aggregation and overcoming the heretofore silent “lag phase”, which 
corresponds to the early stage oligomerization process. Their experiment consisted in a ThT-
like spectroscopic assay, where intrinsic TROL inherent fluorescence was quenched upon 
binding prefibrillar Aβ aggregates, but not by mature Aβ fibrils. They suggested that TROL 
specificity towards prefibrillar aggregates is due to the interaction of the indolic moiety (see 
Fig.4.3.1) with one or more sites, especially charged residues, of the amyloid prefibrillar 
structure that are buried, or are altered, in the mature amyloid fibrils. 
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Fig.4.3.1. Structure of TROL. The compound is characterized by an indolic moiety (in red) that 
grants inherent fluorescence properties. 
 
We chose TROL as a ligand for the surface functionalization strategy presented in the 
previous sections. We selected this indole molecule to address selective prefibrillar Aβ42 
aggregates detection via the BSW-based sensing approach. As presented in Fig.4.3.2, the 
TROL molecule (corresponding to molecule 4b, see scheme in Fig.4.1.2) could be covalently 
bond to the linker 3 via its amino group using the functionalization strategy we devised. 
 
 
Fig.4.3.2. TROL functionalization scheme. The primary amine group of TROL (Fig.4.3.1) was 
reductively coupled to the aldehyde function of the linker. The indolic moiety of the compound should still 
be available for amyloid binding. 
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4.3.1 On an attempt to perform selective Aβ42 aggregation 
sensing with a functionalized multilayer surface 
 
We hoped to finally identify the aggregation state of the Aβ42 species interacting with 
the bare multilayer surface. From the observation of the results we heretofore obtained we 
inferred that prefibrillar or oligomeric Aβ42 peptides were the species interacting with the 
surface. In this scenario, the goal of the TROL-functionalization was to capture Aβ42 
oligomers near the multilayer surface, and therefore increase the signal during the first part 
of our monitoring. Enhancing the interaction of the Aβ42 oligomers with the TROL-
functionalized multilayer surface should increase the local refractive index, as sensed by the 
BSW. We expected a larger maximum amplitude of the signal in the time frame of the first 2 
hours of the real-time monitoring compared to the monitoring of the Aβ42 peptide with a bare 
multilayer surface. The interaction of the Aβ42 with TROL was reported to not affect the 
peptide aggregation dynamics(48). Therefore, for the second part of the measurement (after 
approximately 2 hours of incubation), where the BSW is mostly sensible to the bulk variation 
of refractive index Δnb, we expected a Δn variation similar to the experiment using a bare 
multilayer. Our predictions are summarized in Fig.4.3.3, where a hypothetic real-time Δn 
monitoring with a TROL-functionalized surface is compared to an experimental result of the 
Aβ42 aggregation with a bare multilayer, as sensed by the BSW. 
 
 
Fig.4.3.3. Prediction of a real-time monitoring of the refractive index shift of incubating Aβ42 
peptide with a TROL functionalized multilayer surface. Comparison of the experimental monitoring 
with a bare surface presented in Fig.3.2.3 (initial Aβ42 monomer concentration 17.3 µM, in 10 mM Tris 
HCl buffer, pH 7.4), in solid line, and of the predicted monitoring of the same Aβ42 aggregating sample 
but with a TROL functionalized surface, in dashed line. 
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However, the experimental results presented in Fig.4.3.4 are distinctively different from 
our predictions (see Fig.4.3.3). We incubated initially monomeric Aβ42 samples at 37°C in 
the fluidic chamber of the sensor under the same conditions as the other measurements, 
regardless of the surface functionalization. With a TROL-functionalized multilayer, the 
monitoring of the refractive index change throughout the Aβ42 aggregation process revealed 
a distinct behavior compared to the monitoring of the Aβ42 peptide with an unfunctionalized 
multilayer. 
 
 
Fig.4.3.4. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide with a 
TROL functionalized surface. Three Aβ42 samples (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 
monomer concentrations: (a) 17.3 µM; (b) 17.3 µM; (c) 7.7 µM,) were incubated at 37 °C in contact with 
a TROL functionalized multilayer. The overlap of the three distinct measurements is presented in graph (d), 
where colors are consistent with those used for the single measurements results. 
 
As shown in Fig.4.3.4, in the first phase of the real-time monitoring of the refractive 
index variation of aggregating Aβ42 peptide samples with a selectively TROL-functionalized 
multilayer we observed a local refractive index increase of the probed solution, as sensed by 
the BSW. This positive signal was reasonably correlated to the interaction of the peptide with 
the multilayer surface. As for other real-time measurements obtained with bare or PEGylated 
(a) (b)
(c) (d)
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multilayer surfaces, the extent of this surface interaction was concentration dependent. As 
shown by the overlap presented in Fig.4.3.4 (d), the initial monomer concentration of the 
Aβ42 peptide sample incubating in the sensing chamber was proportional to the amplitude of 
the increasing signal. For a better understanding of the results in Fig.4.3.4, a comparison 
between two measurements made under the same experimental conditions, but the first with 
a bare and the second with a TROL functionalized multilayer surface, is presented in 
Fig.4.3.5. 
 
 
Fig.4.3.5. Selection of real-time monitorings of the refractive index shift of incubating Aβ42 
peptide. Comparison of the monitoring presented in Fig.3.2.3, in black, and in Fig.4.3.4 (b), in grey, 
respectively. They correspond to the results obtained incubating two distinct Aβ42 samples (in 10 mM Tris 
HCl buffer, pH 7.4, identical initial monomer concentration 17.3 µM, T = 37 °C) with a bare and with a 
TROL functionalized multilayer surface, respectively. 
 
The comparison in Fig.4.3.5 shows that the surface-loading process of the Aβ42 peptide 
to the bare or to the TROL-modified surface occurs in the same time frame for both 
measurements. Nevertheless, in the case of a TROL functionalized multilayer, the amplitude 
of the induced signal is much smaller.  
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For long incubation time, no further changes of the signal can be revealed by the BSW-
based sensing. Interestingly, we did not observe a similar effect on the BSW sensitivity when 
measuring the Aβ42 peptide aggregation with a PEGylated multilayer. With a PEG coating, 
the BSW reveals changes in the refractive index of the solution even over long incubation 
times. As mentioned in the dedicated section (4.2), with a PEGylated surface the signal 
reaches negative values (Fig.4.2.7). The BSW thus becomes mostly sensitive to Δnb, which 
is correlated to the decrease of the Aβ42 monomer concentration due to fibrillization. The 
chemical process adopted for the production of PEGylated and TROL-functionalized sensing 
surfaces was the same (section 4.1). Hence, we assume that an adequate surface modification 
treatment should not hamper the BSW sensitivity in general. As a consequence, the 
differences in the measurements presented in Fig.4.3.5 should be correlated to the presence 
of the surface-bound TROL molecule, which interacts with the Aβ42 peptide. In this context, 
we therefore assume that the peptide-loading effect should be reasonably ascribed to the 
presence of the TROL molecule, and not to an aspecific physisorption process, as seen in the 
case of the monitoring of the Aβ42 peptide aggregating with a bare multilayer. The 
experiment presented in the next section aimed at testing this working hypothesis. 
 
4.3.2 ThT-like fluorescence assay with Tryptophanol  
 
To further investigate the role played by the TROL molecule in our measurements, we 
decided to duplicate the ThT-like spectroscopic assay that was reported in the literature by 
Reinke et al(48), who for the first time described this indolic compound as a prefibrillar 
amyloid ligand. Provided that our purpose was not to study the fluorescence properties of 
TROL in the context of amyloid detection assays, we anyway decided to verify its effective 
and selective binding with the prefibrillar Aβ42 peptide.  
In view of the results obtained with the BSW-based sensing approach, we especially 
aimed at investigating the time lapse of the local increase of the refractive index that we 
attributed to the peptide interaction with the TROL-modified surface (Fig.4.3.4 and 4.3.5).  
For the fluorescence quenching experiment with TROL, the Aβ42 peptide was 
separately incubated, and TROL fluorescence response was measured adding solutions of the 
indolic molecule to aliquots of the aggregating peptide. As reported in the literature(46, 48), 
the intrinsic fluorescence of the indolic compound is quenched upon binding to prefibrillar 
Aβ42 peptide, but not to fibrils. The result of the fluorescence assay is presented in Fig.4.3.6, 
where the fluorescence response of TROL throughout Aβ42 peptide aggregation at 37 °C is 
plotted against incubation time. We successfully duplicated the experimental results reported 
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in the literature (Fig.4.3.6), thus confirming the capability of TROL to bind the prefibrillar 
species of the peptide in our experimental conditions. 
 
 
Fig.4.3.6. TROL binding assay. Fluorescence quenching (λex = 280 nm, λem = 355 nm) given by the 
binding of TROL to the prefibrillar Aβ42 peptide during the Aβ42 aggregation at 37 °C. The initial 
concentration of the monomeric peptide was 28 μM in 10 mM Tris HCl. For each measurement, 100 µL of 
10 μM TROL (in 50 µM Gly-NaOH, pH 8.2, 0.01% DMSO) were added to 10 µL peptide solution. Grey 
bars represent the standard deviation of each measurement. 
 
Interestingly, TROL fluorescence quenching originating from the Aβ42 peptide binding 
occurs in a time frame (approximately from 0.5 to 2 hours) that is compatible with the 
formation of the prefibrillar aggregates(37), as shown in Fig.4.3.6. The Aβ42 peptide surface 
interaction process revealed by the BSW-based measurements (Fig.4.3.5) occurs in the same 
time frame. Hence, we can tentatively infer that the local increase of the refractive index 
revealed by BSW-based monitoring corresponds to the surface binding of the Aβ42 peptide 
in a prefibrillar conformation, both in the case of a bare and of a TROL-functionalized 
multilayer surface. This result is in accordance with the general model that we adopted to 
interpret the signal obtained with our sensing measurements. 
TROL fluorescence signal in Fig.4.3.6 remains quenched after many incubation hours. 
The same behavior was reported in the literature(48). This is remarkable considering that the 
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Aβ42 peptide has plausibly reached a mature fibrillar state (after 48-hour incubation). The 
literature(48) claims that TROL fluorescence signal is quenched exclusively upon the binding 
with prefibrillar Aβ forms. Hence, TROL fluorescence should become more intense as soon 
as substantial quantities of fibrils are formed. However, as suggested by the literature(48), it 
is impossible to rule out the presence of prefibrillar Aβ in complex fibrillar mixtures of 
samples of advanced state of aggregation(49). Therefore, at long incubation time, these 
prefibrillar assemblies should be the responsible for the high TROL fluorescence quenching, 
as seen in Fig.4.3.6. With the same logic, the constant signal that we obtained real-time 
monitoring the aggregation of the Aβ42 peptide with a TROL-functionalized multilayer 
(Fig.4.3.4) may be the consequence of the persistence of such prefibrillar Aβ42 aggregates 
on the TROL modified surface. We speculate that, even at long incubation time, those 
prefibrillar species are bound to the TROL molecule that is chemically attached at the surface, 
thus generating a local and constant overestimation of the refractive index of the solution, as 
sensed by the BSW. TROL either irreversibly sequesters the early formed prefibrillar 
assemblies thus inhibiting the elongation of fibrils, or captures them from the solution as soon 
as they are formed, in a rapid dynamic on-off binding equilibrium. The experiment presented 
in the next section aimed at investigating these two alternatives. 
 
4.3.3 BSW-based aggregation monitoring with free, unbound 
Tryptophanol 
 
The result presented in Fig.4.3.4 are of complex and challenging interpretation. 
Especially, it is difficult to rationalize the incapability of the measurement using the TROL-
functionalized multilayer to cover the further steps of the Aβ42 fibrillization, as minor or 
negligible refractive index variations are sensed by the BSW for long incubation time (see 
Fig.4.3.4). Assuming that prefibrillar Aβ42 species are bound to the surface via the interaction 
with TROL, one would expect to observe signals due to the elongation of fibrils onto the 
multilayer surface for long incubation time. As amyloid aggregation proceeds, a local 
increase of the refractive index, as sensed by the BSW, thus corresponding to an increase of 
the positive pixel shift, would be expected. 
Two hypothesis can be suggested to explain the observation that the measured refractive 
index change was only minor, or almost absent for long incubation time (after approximately 
2 hours, Fig.4.3.4): either TROL interferes with the amyloid aggregation by sequestering 
prefibrillar Aβ42 assemblies, or the TROL-driven surface-loading process creates a peptide 
overlayer, shielding the BSW and resulting in a lack of sensitivity. The first hypothesis is in 
disagreement with the literature(46, 48). To test the behavior of TROL, we performed a BSW-
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based refractive index monitoring incubating a solution containing both TROL and the Aβ42 
peptide using a bare multilayer. Here, the assumption is that surface-bound TROL and free 
TROL exhibit similar behavior towards the Aβ42 peptide. The result of this study is presented 
in Fig.4.3.7. The comparison with a real-time monitoring of the pure Aβ42 peptide 
aggregation, under the same experimental conditions, is shown in Fig. 4.3.8. 
 
 
Fig.4.3.7. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide with 
TROL. The Aβ42 sample (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 monomer concentration 
13.9 µM) was incubated at 37 °C with TROL in molar ratio of 1:10. The multilayer surface was 
unfunctionalized. 
 
The real-time monitoring of the Aβ42 aggregation in the presence of TROL with a bare 
multilayer revealed a refractive index variation of the solution that was qualitatively similar 
to those of other measurements performed in the absence of TROL (see Chapter 3). As sensed 
by the BSW, the refractive index evolution of the solution throughout the peptide aggregation 
is characterized by an initial sharp increase, followed by a slower exponential-like decrease 
(see Fig.4.3.7). 
To better evaluate the potential interference of TROL on Aβ42 aggregation, the 
monitoring of the Aβ42 peptide aggregation in the presence of TROL (Fig.4.3.7) was 
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compared to the signal obtained in the absence of TROL, under identical experimental 
conditions. The overlap of the two real-time measurements is shown in Fig.4.3.8. 
 
 
Fig.4.3.8. Comparison of real-time monitorings of the refractive index shift of incubating Aβ42 
peptide. Comparison of the monitoring presented in Fig.3.2.1, in grey, and in Fig.4.3.7, in black, 
respectively. They correspond to the results obtained incubating two distinct Aβ42 samples (in 10 mM Tris 
HCl buffer, pH 7.4, identical initial monomer concentration: 13.9 µM) without and in the presence of TROL 
in a molar ratio of 1:10, respectively. Both measurements were carried out with a bare unfunctionalized 
multilayer surface. 
 
The two curves presented in Fig.4.3.8 show that the overall refractive index variations 
throughout the measurements are similar. Therefore, our BSW-based sensing measurements 
detect approximately no influence of TROL on the Aβ42 aggregation process.  
As the BSW-based measurements seem independent on the presence or the absence of 
significant amounts of TROL in the solution, we inferred that TROL does not interfere with 
the Aβ42 aggregation process, as reported in the literature(46, 48). Reasonably, TROL should 
not irreversibly sequester prefibrillar assembly nor inhibit the fibrillation process. Hence, we 
tentatively assume that the presence of surface-bound TROL does not affect the Aβ42 
aggregation process neither. 
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Under these circumstances, we should resort to the second hypothesis: We therefore 
attributed the invariance of the signal after the initial sharp local refractive index increase 
(Fig.4.3.4) to a reduced sensitivity of the BSW occurring once the surface is covered by the 
TROL-Aβ42-aggregate complex. The specific peptide surface-loading effect, driven by the 
presence of TROL chemically attached to the sensing surface, has as a consequence a rapid 
and complete saturation of the surface. The multilayer surface is therefore shielded and the 
BSW becomes insensitive to further refractive index changes induced by the Aβ42 
fibrillization process occurring in the bulk.  
However, a decreased BSW sensitivity due to surface saturation does not fully justify 
the overall trend of the refractive index, as sensed by the BSW, in the measurements with a 
TROL-functionalized multilayer surface (Fig.4.3.4). Especially, we are not yet able to explain 
the observation that the amplitude of the local refractive index increase, corresponding to the 
peptide-surface interaction, is much smaller when compared to the same experiment with an 
unfunctionalized multilayer (see Fig.4.3.5).  
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4.4 Conclusions 
 
In this chapter, a chemical modification strategy to treat a silicon oxi-nitride photonic-
crystal surface was presented. As we aimed high, we developed a versatile step-by-step 
strategy that could be adopted for the binding of different ligands, from small molecular 
compounds to antibodies. This initial goal explains the implementation of a rather complex 
and demanding functionalization strategy, compared to the outcome results. 
The development of a surface coating strategy, aimed at preventing non-specific protein 
interaction onto the surface was accomplished and its effectiveness verified incubating the 
highly adsorption-prone BSA protein. With a PEGylated multilayer, almost no non-specific 
interaction was observed. However, the Aβ42 peptide surface-interaction still occurred, 
contrary to what observed while incubating BSA with a PEGylated multilayer. The results 
obtained by monitoring the Aβ42 aggregation in the presence of such a passivated surface 
demonstrated that the interaction with the silicon oxi-nitride multilayer surface is not 
fundamentally modifying the mechanism of the aggregation. With a bare multilayer surface, 
for long incubation time, the mass-loading mechanism has definitely reached stationary 
conditions. As a result, an overlayer of Aβ42 peptide steadily adsorbed on the surface is 
formed. The presence of such an overlayer produces a shielding effect leading to a general 
overestimation of the solution refractive index. With PEG, almost no overlayer is formed on 
the surface and the BSW resonance position should be directly related to the refractive index 
of the solution. Moreover, the effective despite partial Aβ42 peptide desorption from the 
sensing surface is supported by the PEG-coating passivation experiment.  
The monitoring of the Aβ42 peptide aggregation with a TROL functionalized multilayer 
surface did not cover the overall fibrillization process. The refractive index of the solution, 
CHAPTER 4 
 
92 
 
as sensed by the BSW, was approximately constant after the initial increase due to the peptide 
surface-loading process. We propose that a steady shielding effect caused by the interaction 
of the peptide with the indolic ligand reduced the BSW sensitivity. However, the hypotheses 
we postulated to interpret the results of the monitorings of the Aβ42 peptide aggregation with 
TROL-functionalized surfaces were not sufficiently confirmed by experimental results. 
Nevertheless, the latter support the hypothesis that the Aβ42 species interacting with the 
sensor surface are in a prefibrillar aggregation stage, as suggested by the measurements 
presented in Chapter 3.  
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5. THE BSW-BASED PLATFORM AS A TOOL 
TO INVESTIGATE MOLECULAR PROBES 
INTERFERING WITH Aβ AGGREGATION 
 
 
 
 
 
 
 
 
5.1 State of the art of the research on small-molecule 
inhibitors of toxic Aβ42 fibril formation  
 
AD is currently a major plague of the developed countries and the research on drugs able 
to stop or slow down the brutal progression of the disease has become more and more 
significant(1). Currently available therapy simply addresses the enhancement of cholinergic 
functions, but this clinical effect is not sufficient, since it is treating the symptoms but not the 
cause of the disease(2, 3). For this reason, many research laboratories aim at developing new 
potential inhibitors of the Aβ42 fibrillization, not only by testing candidate molecules(4), but 
also devising new methods for their discovery and in vitro validation(5). Moreover, the 
discovery and development of new compounds interacting with different aggregate species, 
thus acting as probe molecules, is fundamental for the ultimate understanding of the amyloid 
aggregation mechanism(6). 
Recently, a big effort has been made to qualify compounds, mainly natural products, as 
potent anti-amyloid-fibrillization agents. The majority of these molecules contain phenolic 
moieties, and, although they all have very different chemical structures, they share common 
features presumably required for activity: a second terminal aromatic moiety and a short 
linker unit connecting the aromatic moieties. The optimal linker has been reported to contain 
two rotating bonds and to have a length between 8 and 16 Å(7). Among others, 
apomorphine(8), resveratrol(9), curcumin(10), tolcapone(11), (-)-epigallocatechine gallate 
(EGCG)(12), bi- and mono-flavonoids(13), tannic acid(14), nordihydroguaiaretic acid(15), 
RS-0466(16) and RS-0406(17), are well-known examples of polyphenols that have been 
extensively investigated for their potential to prevent the formation of toxic Aβ42 species(10) 
(see Tab.5.1.1).  
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Tab.5.1.1. Selected examples of polyphenolic inhibitors of Aβ aggregation. (a) EGCG; 
(b) tolcapone; (c) apomorphine; (d) tannic acid; (e) resveratrol; (f) backbone of flavonol, substituents are 
indicated with numbers, and are mostly -OH or -OCH3, thus defining a precise flavonol; (g) curcumin, here 
presented in the keto form, which is the thermodynamically stable tautomer in water. The tautomeric enol 
form exists too, being thermodynamically preferred in the solid phase; (h) nordihydroguaiaretic acid; (i) 
RS-0466; (l) RS-0406. In a colored background, the two compounds that have entered clinical trials Phase 
II: EGCG and RS-0406(18). 
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Despite the great effort put on the study of these molecules, their presumed efficacy is 
yet to be fully demonstrated and little is known about their mode of action in the central 
nervous system. Notably, only few of them have entered clinical trials, with the exception of 
EGCG and RS-0406, which have entered clinical Phase II of trials(18). The compound RS-
0406 has raised great interest since it was reported to inhibit the Aβ42 fibrillogenesis in the 
ThT binding assay. In their work of 2002, Nakagami et al(17) claimed that the compound 
was also capable of disassembling preformed fibrils. For this reason, RS-0406 is known as a 
“β-sheet breaker”(18). Further studies have confirmed the efficacy of RS-0406 towards Aβ 
fibrillation inhibition, suggesting the hydrophobic central region of the Aβ42 peptide as the 
target for its action. RS-0406 in vivo test reported improvements in behavioral deﬁcits seen 
in the early stages of AD(19). The implications of the investigation of RS-0406 opened new 
scenarios for the understanding of the mechanism of fibrillogenesis. However, the ThT 
binding assay performed to test the capability of RS-0406 to inhibit Aβ42 ﬁbrillogenesis is 
not sufficient to elucidate the mode of action of the drug. The lack of sensitivity of the ThT 
binding assay during the crucial step of Aβ42 oligomerization(20) precludes a full description 
of the mechanism of fibrillogenesis inhibition performed by RS-0406. 
Therefore, we tested the application of the BSW-based sensing platform to the 
monitoring of the aggregation dynamics of the Aβ42 peptide in the presence of RS-0406. The 
goal is to validate the BSW-based sensing strategy as a powerful and direct screening tool for 
new potential inhibitors of toxic Aβ42 oligomer formation and of early nucleation events. In 
parallel, NMR studies were carried out in collaboration with Dr. Dalvit from the University 
of Neuchatel, with the goal of obtaining complementary and independent information on the 
inhibition mechanism of RS-0406. Dr. Dalvit previously reported on an innovative NMR-
based approach for the identification of compounds with binding affinities to proteins, called 
“WaterLOGSY”(21). Dr. Dalvit applied this method to the study of the interaction between 
RS-0406 and the Aβ42 peptide during aggregation. 
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5.2 Test of molecular probes that interfere with the Aβ 
peptide aggregation dynamics 
 
The BSW-based approach can be applied to provide new insights into the complex 
mechanism of aggregation in the presence of small molecular probes able to interfere with 
the dynamics of amyloid formation. For this aim, we selected the two molecules shown in 
Fig.5.2.1: R548332 as a suitable reference molecule, and RS-0406, a compound reported as 
an inhibitor of the oligomer formation, and as a molecule capable of breaking-up pre-formed 
fibrils(17), as mentioned in the previous section. 
 
 
(1)        (2) 
Fig.5.2.1. Structure of the molecules R548332 (1) and RS-0406 (2). The red asterisk on (1) 
indicates the position bearing the functionality CF3-C-OH, crucial for non-specific interaction with the 
peptide(4). 
 
R548332 was chosen based on a recent publication on screening of potential inhibitors 
of amyloid aggregation(4). In this work, an impressive series of compounds, mostly indole 
derivatives, were systematically tested by the authors for their capacity of inhibiting Aβ42 
oligomerization and Aβ40 fibrillogenesis, respectively, via ThT binding assay, AFM 
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experiments, and quantitative biotinyl-Aβ42 single-site streptavidin-based assay. In this 
context, we selected R548332 as a commercially available surrogate for a compound reported 
in this work, which was bearing an extra -CF3 substituent in the position marked with * in 
Fig.5.2.1. In the context of NMR-based ligand-peptide interaction experiments, the 
compound R548332 was found appropriate for its small size and the presence of a -CH3 and 
-CF3 groups, suitable for WaterLOGSY and 19F T2 filter experiments, respectively(22) (see 
section 5.2.2). 
Finally, concerning RS-0406 our interpretation for the reported interaction with the Aβ 
peptides is based on the analysis of the structure of the compound. The groups -N=CR-NH- 
could be seen as analogous and isosteric to amide bonds, thus intervening via H-bond 
replacements in the β-sheet architecture. Moreover, the phenol groups are a key feature for 
solubility, since they can be partially deprotonated in water. 
 
5.2.1 BSW-based aggregation monitoring  
 
Results on the variation of the amyloid aggregation dynamics in the presence of 
R548332 and RS-0406 were obtained separately and are presented in Fig.5.2.2, and Fig.5.2.3. 
We incubated initially monomeric Aβ42 samples at 37 °C in the fluidic chamber of the sensor 
with the selected molecules, in a molar concentration ratio of 1:10. For all the measurements 
presented in this Chapter, a bare unfunctionalized multilayer surface was used. In these 
conditions, the monitoring of the refractive index change throughout the Aβ42 aggregation 
process revealed a variation in the dynamics of the aggregation process. This variation was 
both concerning the timing and the rate of the fibrillization, compared to the monitoring of 
the aggregation of the pure Aβ42 peptide. Comparisons of the results obtained monitoring 
the Aβ42 peptide alone with those obtained in the presence of R548332 and RS-0406 are 
presented in Fig.5.2.4 and Fig.5.2.5, as revealed by the BSW-based sensing approach.  
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Fig.5.2.2. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide with 
R548332. Three Aβ42 samples (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 monomer concentrations: 
(a) 13 µM; (b) 13.9 µM; (c) 13 µM,) were incubated at 37 °C with R548332 in molar ratio of 1:10. The 
overlap of the three distinct measurements is presented in a close-up view in graph (d), where colors are 
consistent with those used for the single measurements. The central gap in (b) is due to an unexpected 
interruption of data recording, which, nevertheless, did not affect the experiment. 
 
As shown in Fig.5.2.2, the monitoring of Aβ42 aggregation in the presence of R548332 
was performed with initial peptide concentration of 13.9 and 13 µM. Results are reproducible, 
and the overall refractive index variations throughout the measurements are consistent, as 
highlighted by the overlap presented in Fig.5.2.2 (d). Furthermore, a higher initial monomer 
concentration led to a larger initial local refractive index increase, and, in general, accelerated 
the refractive index decrease rate, as observed in the results presented in Chapter 3. This 
effect is in accordance with what reported in the literature(23-25), where the positive 
correlation between Aβ peptide concentration and amyloid aggregation rate, in this work 
represented by refractive index variations (Chapter 3), has been demonstrated. 
 
(a)
(d)(c)
(b)
CHAPTER 5 
 
103 
 
 
Fig.5.2.3. Real-time monitoring of the refractive index shift of incubating Aβ42 peptide with 
RS-0406. Five Aβ42 samples (in 10 mM Tris HCl buffer, pH 7.4, initial Aβ42 monomer concentrations: 
(a) 17 µM; (b) 17 µM; (c) 13.9 µM; (d) 13 µM; (e) 13 µM) were incubated at 37 °C with RS-0406 in molar 
ratio of 1:10. The overlap of the five distinct measurements is presented in a close-up view in graph (f), 
where colors are consistent with those used for the single measurements. 
 
The real-time monitoring of the refractive index variation of the Aβ42 peptide 
aggregating in the presence of RS-0406, as presented in Fig.5.2.3, was carried out with initial 
peptide concentrations of 17, 13.9 and 13 µM. As for the results presented in Fig.5.2.2, the 
experiments are reproducible and consistent (Fig.5.2.3 (f)). However, the curve presented in 
(a)
(c)
(b)
(d)
(e) (f)
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Fig.5.2.3 (d) deviates from the general evolution characterizing the other refractive index 
measurements (Fig.5.2.3 (f)). The same applies to the last approximately 55 hours of the 
experimental signal reported in Fig.5.2.3 (e). Those two specific inconsistencies can be 
ascribed to background noise caused by the formation of bubbles (air or water vapor) in the 
sensing chamber, which create discontinuity in the refractive index, as sensed by the BSW. 
Despite this interference, the essential feature of the monitoring (an initial increase followed 
by a decrease of the refractive index, as sensed by the BSW) is not affected. Moreover, as 
reported for the measurements presented in Chapters 3 and 4, we observed a positive 
correlation between the initial Aβ42 peptide concentration and the rate of the aggregation, as 
sensed by the BSW and represented by the refractive index variation of the aggregating 
solution throughout the measurement. 
 
 
Fig.5.2.4. Selection of real-time monitorings of the refractive index shift of incubating Aβ42 
peptide. Close-up view of the first 10 hours of monitoring presented in Fig.3.2.1, in black, Fig.5.2.2 (b), in 
blue, and in Fig.5.2.3 (c), in red, respectively. They correspond to the results obtained incubating three 
distinct Aβ42 samples (in 10mM Tris HCl buffer, pH 7.4, identical initial Aβ42 monomer 
concentration 13.9 µM) without and in the presence of R548332 or RS-0406, respectively. 
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To analyze the effect of the molecular probes on Aβ42 aggregation, one may especially 
consider the comparison shown in Fig.5.2.4, where selected real-time monitorings of the 
Aβ42 peptide aggregation without and with RS-0406 and R548332 are presented. As 
formerly explained in Chapter 3, one might take into account that the model we propose to 
interpret the BSW-based measurements is a simplified approach(26). In our measurements, 
the real-time refractive index variation of the aggregating Aβ solution is the result of different 
contributions, which are of challenging interpretation. For a preliminary analysis, two aspects 
of the monitorings have to be considered: i) the point in time of the establishment of a 
maximum refractive index value, and ii) the rate of the subsequent refractive index decrease. 
In our interpretation (see Chapter 3), i) is related to an equilibrium condition of the refractive 
index variation that is due to the saturation of the surface and a decreased availability of free 
“adhesion-competent” Aβ42 peptides because of a simultaneous fibrillization occurring in 
the solution, and ii) is associated to the detachment of the Aβ42 peptide from the surface, 
and/or the formation of fibrillar structures away from the surface, thereby depleting the bulk 
solution by decreasing the monomer concentration(26). Thus, both i) and ii) are depending 
on the Aβ42 peptide aggregation rate. For a further analysis of the results, another feature of 
the measurements that has to be considered is the ascending rate of the refractive index 
variation before point i). This part of the curve can be regarded as related to the first steps of 
Aβ42 oligomerization, as fibrillization occurs in a subsequent time frame(24). Throughout 
the analysis of the results presented in this section, one should consider the distinctive 
difference between oligomerization, as the early aggregation events leading to pre-fibrillar 
and toxic soluble aggregates, and fibrillization, as the process of mature and insoluble fibril 
formation (see Chapter 1). We tentatively attempted to identify these discrete aggregation 
phases with a temporal portion of our measurements, according to the literature(24). 
Both the curves of the refractive index variation of the aggregating Aβ42 peptide in the 
presence of R548332 (in blue) and RS-0406 (in red) show some noticeable differences if 
compared with the reference, i.e. the curve corresponding to the monitoring of the pure Aβ42 
peptide (in black). As the conditions for the selected experiments were equal (same starting 
monomer concentration, same buffer and temperature), one can deduce that the reproducible 
and pronounced differences between the three presented measurements should be due to the 
interference of the molecular probes with the Aβ42 peptide aggregation.  
Specifically, R548332 (in blue) seemingly accelerates the Aβ aggregation. The 
maximum refractive index value is reached in a shorter time (t ~ 1 hour), and the subsequent 
decrease of the refractive index, as sensed by the BSW, is faster, reaching negative values in 
a relatively short period of time (t ~ 6.5 hour). The maximum amplitude of the curve is lower. 
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We tentatively attributed this observation to a smaller interaction of the peptide with the 
surface. This is consistent with a faster fibril formation, as mentioned above, which depletes 
the bulk solution of adhesion-competent Aβ42 peptides. However, R548332 apparently does 
not interfere with the Aβ42 oligomerization first steps, since the ascending rate of the 
refractive index change is indistinguishable in the presence or in the absence of the molecular 
probe.  
With the same approach, one can compare the curves of the monitoring of the refractive 
index of the solution where the Aβ42 peptide aggregates without (in black) and in the 
presence of the molecular probe RS-0406 (in red). One observes that the initial aggregation 
rate appears accelerated by the presence of RS-0406, since the maximum refractive index 
value is reached in a shorter time (t ~ 1 hour). Moreover, the rate of the local refractive index 
increase, as sensed by the BSW, is higher in the presence of the molecular probe (see Fig.5.2.3 
(c)). Interestingly, the maximum amplitude of the refractive index measurement appears for 
all intents and purposes equal for the measurement without and with RS-0406. Hence, almost 
the same amount of adhesion-competent Aβ42 peptide is formed in the absence of the 
molecular probe. We tentatively conclude that RS-0406 does accelerate the Aβ42 early 
oligomerization, but not the subsequent fibril formation process, producing the adhesion 
competent peptide with a distinctively faster rate, and thus contrasting the refractive index 
decrease due to the bulk fibrillization. This speculation is corroborated by the analysis of the 
second part of the refractive index monitoring, shown in Fig.5.2.5, between 10 and 20 hours 
of incubation of the Aβ42 peptide alone (in black), and with RS-0406 (in red).  
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Fig.5.2.5. Selection of real-time monitorings of the refractive index shift of incubating Aβ42 
peptide. Close-up view comparison of the monitoring of the Aβ42 peptide alone, presented in Fig.3.2.1, in 
black, and with RS-0406, presented in Fig.5.2.3 (c), in red, respectively. 
 
In this time frame, the refractive index descending rates of the aggregating Aβ42 peptide 
solutions without (in black) and with RS-0406 (in red) appear indistinguishable. In the 
presence of the molecular probe, negative refractive index values are reached at t ~ 17 hours, 
whereas the monitoring of the refractive index variation of the aggregating Aβ42 peptide 
alone is never showing negative amplitudes (see discussion in Chapter 4). Our rationale for 
the observation that the monitoring of pure aggregating Aβ42 never shows negative values is 
an overloading of the surface, causing a general overestimation of the refractive index of the 
bulk solution where the fibrillization occurs, as sensed by the BSW(26). This shielding effect 
becoming constant, the monitoring of the variation of the refractive index of the bulk results 
unaffected by the surface-loading process, thus allowing the estimation of the time rate of the 
refractive index variation due to the Aβ42 fibrillization only. Therefore, we can infer that the 
similar refractive index descending rate of the two measurements (Fig.5.2.5) equals to a 
similar fibrillization rate. Summarizing our conclusions, we speculate that RS-0406 interferes 
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with the first phase of the amyloid aggregation, accelerating the oligomerization, but not the 
further fibrillization process. All these interpretations are supported by the NMR-based 
experiments, for which a short description is reported in the following. 
 
5.2.2  NMR-based WaterLOGSY aggregation monitoring 
 
With the aim of verifying the results obtained applying the BSW-based platform to the 
monitor the Aβ42 peptide aggregation, the selected molecules, R548332 and RS-0406, were 
used to carry out parallel NMR studies, in collaboration with Dr. C. Dalvit from the 
University of Neuchâtel. In previous works(21, 27, 28), Dr. Dalvit reported on an innovative 
NMR-based approach called “WaterLOGSY” (Water-Ligand Observation with Gradient 
SpectroscopY) for the identification of compounds with binding affinity to proteins. The 
method relies on the exploitation of the large reservoir of bulk water magnetization. Hence, 
via transferring bulk water magnetization to the ligand in several relay pathways it is possible 
to detect small molecules that interact with a target biomolecule. The NMR WaterLOGSY 
experiments are recorded as a function of time for studying the kinetics of the Aβ42 peptide 
aggregation process. Water molecules are trapped into the peptide aggregates and are likely 
to be involved in the formation of intermolecular hydrogen bonds. Selective excitation of the 
bulk water signal followed by a mixing period in the WaterLOGSY experiment results in 
efficient magnetization transfer to the protons of the aggregates via the bound, yet 
exchangeable, water molecules and via chemical exchange with the numerous -OH and -NH 
groups of the aggregate species. Non-specific interactions between a selected reporter 
molecule and the aggregates result in partial transfer of the water magnetization stored by the 
peptide aggregates to the reporter molecule. This transfer of magnetization is then detected 
at the chemical shift of the free reporter molecule(27). The main advantage of this technique 
is the capability of ruling out artifacts and false positives and negatives in binding 
experiments(28). The method, like all the techniques based on ligand resonance observation, 
has the disadvantage of not offering information about the ligand binding site. Despite this 
drawback, the technique represents a powerful and highly reliable means for fast ligand 
identiﬁcation, providing binding information freed of false-positives. 
NMR studies were performed by Dr. Dalvit using the WaterLOGSY method. The 
spectra were recorded as a function of time for Aβ42 peptide samples at a concentration of 
15 µM in 10 mM Tris HCl, and at 37 °C. These experimental conditions are closely the same 
as for the BSW-based sensing. R548332 was used as a reporter molecule for its size and the 
presence of a CF3 group, which is suitable for complementary 19F transverse relaxation filter 
experiments, which “can be used to characterize equilibrium binding of low-affinity ligands 
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to proteins without the confounding contributions of chemical shift”(29). In addition, 1H 
selective T1 filter experiments were carried out, as another meaningful tool to detect and study 
protein binding mechanisms(30). Then, kinetics obtained by monitoring the Aβ42 
aggregation in the presence of R548332 were compared with results from the concomitant 
use of both R548332 and RS-0406 with the peptide. From this comparison, results suggest 
that the first phase of Aβ42 aggregation is seemingly accelerated by the presence of RS-0406. 
Dr. Dalvit speculates that the binding of RS-0406 molecule to the Aβ42 monomer, 
accelerating the self-assembly process of the peptide, would remove the intermediate 
oligomers via rapidly shifting the self-assembly reaction equilibrium towards the formation 
of higher order aggregates(31). This explanation would justify RS-0406 toxicity suppression 
towards Aβ42 aggregation reported in the literature, as discussed in the beginning of the 
chapter. These unpublished results are highly supportive of the model we used to describe the 
signal obtained‒in the same experimental conditions‒by applying the BSW-based sensing 
platform to the monitoring of Aβ42 aggregation. 
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5.3 Conclusions 
 
In this chapter, we presented the results obtained applying the BSW-based sensing 
platform to the investigation of molecular probes interfering with amyloid aggregation. Our 
sensing approach allows the reliable in vitro testing for potential inhibitors of the amyloid 
fibrillization in real-time, and without the use of detrimental labelling procedures. Studying 
the aggregation of the Aβ42 peptide in the presence of RS-0406, a molecule whose anti-
amyloid-aggregation properties had been reported in the literature(17), we could reveal the 
plausible mechanism for its presumed activity. Our tentative interpretation of the 
measurements indicates that RS-0406 should not inhibit the amyloid aggregation. On the 
contrary, RS-0406 seemingly accelerates Aβ42 peptide aggregation, thus depleting the 
solution of the soluble toxic oligomers in a shorter time frame. This outcome is strongly 
corroborated by parallel NMR-based experiments, carried out in collaboration with Dr. Dalvit 
from the University of Neuchâtel. Moreover, the NMR-based studies helped validating our 
sensing approach as a powerful and robust screening tool for molecular inhibitor of Aβ early 
oligomerization process. 
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6. COMBINING BSW-BASED SENSING AND 
LIGHT-SCATTERING MEASUREMENT: A 
SETUP IMPROVEMENT 
 
 
 
 
 
 
 
 
 
6.1 Light scattering for particle size characterization 
 
In the previous chapters, we have described the application of a BSW-based sensing 
platform to the real-time optical investigation of the aggregation dynamics of Aβ42 peptide. 
The main shortcoming of the proposed approach is that we were unable to fully segregate the 
bulk and surface contributions to the refractive index variations of the Aβ42 peptide samples, 
as measured by the BSW throughout aggregation. Therefore, we focused on obtaining 
complementary information on the mechanisms for the Aβ42 peptide interaction with the 
multilayer surface and on the precise conformation and size of the peptide during this surface-
loading phenomenon. In vitro studies of the prefibrillar Aβ42 peptide size evolution 
throughout pathogenic aggregation have been reported in the literature(1-3), and have 
revealed a size range of 10 to 15 nm in diameter for the early disc-shaped pentameric 
aggregates, while protofibrils reportedly reach a length of 200 nm with a diameter of 5 nm. 
Characterized by the typical filamentous morphology, mature fibrils have revealed a length 
of more than 1 µm with a diameter of 10 to 12 nm(4). We aimed at discriminating between 
these three distinct aggregated forms of the Aβ42 peptide throughout a BSW-based real-time 
monitoring experiment. The information obtained from this study would complement the 
measurements presented in Chapter 3, where experiments carried out with the peptide at 
isolated specific aggregation stages were presented. 
Light-scattering techniques have widely been used for many applications, spanning from 
cosmology to polymer science(5). They use the property of a light beam of being deflected 
upon encountering obstacles or irregularities in the propagation medium. When an incident 
photon encounters a molecule or a particle, it induces an oscillating dipole in the electron 
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cloud. As a consequence of the dipole variation, energy in the form of scattered light is 
radiated in all directions. For small particles, whose diameter is approximately less than 1/10 
of the light-source wavelength, the so-called “Rayleigh Theory” is applied: It states that the 
scattering is isotropic and that the intensity of the radiation is proportional to the particle 
size(6). 
In protein chemistry, light-scattering applications are routinely used to characterize the 
size of a protein in solution, and to monitor, for example, receptor binding and self-
assembling processes(7). Protein aggregation can be regarded as a special case of self-
assembling, and can be monitored in real-time using commercially available dynamic light-
scattering (DLS) tools. Those DLS-based instruments allow estimating the hydrodynamic 
radius and the translational diffusion coefficient of protein clusters(8). Contrary to static light-
scattering (SLS) techniques, where the signal is time averaged, DLS measures real-time 
intensity fluctuations I(t) of scattered light via a correlation function. DLS has thus become a 
cardinal technique in protein aggregation investigation(6). Being the result of Brownian 
motions, the variation of the intensity of the light scattered by proteins in solution is related 
to their aggregation state. Hence, DLS monitoring can be reliably used for studies of protein 
aggregation kinetics(9). 
Nevertheless, DLS technique suffers from the lack of selectivity and, in general, from a 
very low signal-to-noise ratio (SNR)(5, 10). For this reason, starting from the late 
eighties(11), DLS has been combined with evanescent wave generators used as light source. 
Recent years thus saw the development of the “total internal reflection microscopy” 
(TIRM)(12), a tool especially suitable for particle tracking and for investigating particle-
surface interactions in colloidal solutions. With TIRM, the light confinement achieved with 
the evanescent wave allows overcoming the low SNR in common DLS techniques. From the 
notion that light scattering can be induced by evanescent waves in a controlled way(13, 14), 
several other approaches have emerged, such as waveguide-enhanced DLS (WEDLS)(15) 
and resonance-enhanced DLS (REDLS)(16),where the evanescent wave is generated by a 
leaky waveguide or surface plasmons, respectively. They all share the common advantage of 
an increased SNR, thanks to the field enhancement of the evanescent wave, and the possibility 
to use different materials instead of only glass substrates, as in the case of TIRM(14). 
Moreover, a further benefit in employing these techniques in lieu of TIRM is the possibility 
to in situ tailor the penetration depth of the evanescent tail by changing the polarization of 
the light source, in the case of WEDLS(15), or the wavelength, in the case of REDLS(16). 
Employing correlation functions for scattering intensity analysis, one can derive information 
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about the dynamics of particle diffusion near the surface and, thus, about the size of the 
analyte(10).  
In this chapter, we present the first original conception of a BSW-enhanced DLS 
technique (BEDLS), in which the light source for scattering induction is the evanescent tail 
of the Bloch surface wave. A preliminary and simplified implementation of this technique is 
also presented. This work stems from the initial attempt of performing a simultaneous BSW-
based sensing and a DLS measurement, with the aim of monitoring the size evolution of the 
Aβ42 aggregates throughout fibrillization. In the following, the two different optical 
platforms that we developed for scattering analysis are described according to the 
chronological order of their conception. 
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6.2 Experimental optical setup modifications 
 
The original idea we conceived was to simultaneously investigate the size variation of 
the aggregating peptide in solution while performing a BSW-based measurements. We aimed 
at a non-invasive method that could be implemented in parallel and without fundamentally 
changing the optical sensing scheme. Combining DLS with our experimental approach was 
selected as the most appealing strategy. A DLS technique could be implemented in parallel 
using the existing setup upon making little variations. Commercially available DLS 
instruments are capable of determining the size of particles in a range of 0.3 to 10 µm, and 
require very small volume of analytes, in the order of some µL(8). Given the size of the Aβ42 
oligomers, protofibrils and fibrils(17), even a low-sensitivity in-house-built DLS platform 
should be capable of covering the size transition occurring along the fibrillization pathway. 
This particular setup modification is presented in section 6.2.1. 
Afterwards, we recognized the potential of inducing light scattering with the evanescent 
tail of the BSW, in an effort to increase the SNR and develop a more compact sensing tool. 
This idea and its development are discussed in section 6.2.2. 
 
6.2.1 Parallel DLS and BSW-based-monitoring setup 
 
The first experimental setup we developed to perform a combined DLS and BSW-based 
measurement is shown in Fig.6.2.1. It was built to achieve a simultaneous real-time 
monitoring of the light scattering intensity and of the refractive index, as sensed by the BSW. 
Two separate and independent illumination sources were used for the BSW excitement and 
the light scattering induction. The determination of the size evolution of the Aβ42 aggregates 
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during fibrillization would contribute additional information about the size of the aggregates. 
The results obtained from such a parallel measurement could help clarifying the correlation 
between the signal revealed by the BSW-based monitoring and the actual aggregation stage 
of the peptide. 
 
 
 Fig.6.2.1. Top-view simplified schematics of the experimental setup used for the simultaneous 
light scattering and BSW-based real-time monitoring. SMF: single-mode fiber; PBS: polarizing beam-
splitter; PMF: polarization maintaining fiber; MMF: multi-mode fiber. The dashed line symbolizes the light 
guided through the PMF to induce the light scattering phenomenon, and the light scattered by the analyte. 
For details on the setup, see Chapter 8. 
 
Compared to the initial BSW-based setup described in Chapter 2, several changes were 
made to allow the measurement of the light scattered by the Aβ42 aggregates in solution. 
Light coming from a He-Ne laser is coupled into a single-mode fiber (SMF). A polarizing 
beam-splitter (PBS) is used for the TE and TM polarization separation. After the PBS, 
polarization maintaining fibers (PMF) are employed to guide the light to the sensing chamber 
(see Chapter 8 for details). BSWs are excited with the TE-polarized part, and the Kretschman 
configured coupling system is the same as in the original setup described in Chapter 2, with 
the fluidic chamber positioned vertically(18). Additionally, as a source to induce the light 
scattering, the TM-polarized beam is impinging the multilayer surface above the critical angle 
for TIR and, thus, above the resonance angle, to avoid interfering with the BSW phenomenon. 
A circular Peltier element positioned behind the fluidic chamber is used for sample incubation 
and temperature stabilization. The element central hole allows the collection of the scattered 
light propagating from the sample, which is performed via a 2 mm-core multimode optical 
fiber (MMF) connected to a power meter (see Fig.6.2.2). 
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Fig.6.2.2. Pictures of the fluidic chamber adapted for the light scattering collection. (a) the MMF, 
in blue, is contacted to the back of the fluidic chamber, passing through the Peltier element (not visible), 
and collects the light scattered by the particles in solution via a back-window in the fluidic chamber, which 
can be seen in (b), as indicated by the yellow arrow. 
 
To test the performance of the modified setup, we measured the light-scattering response 
of an aggregating Aβ42 peptide solution at an initial monomer concentration of 5 µM. In 
parallel, we performed a BSW-based refractive index monitoring of the Aβ42 peptide 
solution during aggregation using a bare multilayer surface. The result of the BSW-based 
monitoring of the aggregating peptide was comparable to other measurements performed 
under the same conditions (Chapter 3). The light-scattering response of the measurement was 
compared to a reference signal obtained by incubating a sample of d.i. filtered water. Both 
samples were kept at 37 °C, which is the temperature at which the Aβ42 aggregation occurs. 
However, we did not observe substantial and rational light intensity fluctuation differences 
between the DLS monitoring of water and of the aggregating peptide. The signal was mostly 
characterized by unspecified noise. This was most probably due to the low SNR of the 
measurements: the MMF was also collecting part of the light used as illumination source for 
the DLS phenomenon. As a result, the signal from the scattering particles was too low 
compared to the background light intensity.  
 
6.2.2 BSW induced light scattering imaging 
 
Employing the BSW as the source for inducing the light scattering was the idea we 
conceived to overcome the low SNR exhibited by the measurement described above. BSWs 
are evanescent and do not propagate in the far field(19). In a similar sensing scheme as 
presented before (Fig.6.2.1), where a detector is placed opposite to the light source, with BSW 
(b)(a)
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as the source only the light scattered by the analyte should be recovered by the detector. 
Moreover, with BSW, the strong field enhancement and surface confinement of the 
evanescent wave should help boosting the signal(20, 21), similarly to what has been described 
in the literature for REDLS(16). We thus implemented a second experimental setup for 
scattering measurement, which is shown in Fig.6.2.3. The aim was to study the phenomenon 
of light scattering induced by BSW prior to modifying the experimental setup for the real-
time monitoring. The setup in Fig.6.2.3 is thus a preliminary and simplified implementation 
of a BEDLS platform. Being a prototype, it does not allow for a time-related signal intensity 
monitoring, as explained in the following. Therefore, we named this intermediary technique 
BILSI: BSW Induced Light Scattering Imaging.  
 
 
Fig.6.2.3. Schematics of the experimental setup for BILSI. PMF: polarization maintaining fiber; 
OM: optical microscope; HS: high sensitivity. A 20X microscope objective was used to collect the light. 
The dashed line symbolizes the light scattering phenomenon. We thank Dr. N. Descharmes from the Optics 
& Photonics Technology Laboratory, EPFL, for assisting with the setup construction. 
 
The setup consists of an upright optical microscope, used for scattered light collection, 
provided with a high sensitive camera for light detection and sample imaging. A dielectric 
multilayer is used in place of a standard glass microscope-slide. For sample illumination, the 
Kretschman configuration coupling scheme is the same as for the other setups. A He-Ne laser 
is used to excite the BSW via a right-angle glass prism. However, the multilayer is 
horizontally positioned and was designed to work in air (Fig.6.2.3). The multilayer was 
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designed as described in Chapter 8 by Dr. Barakat from the Optics & Photonics Technology 
Laboratory, EPFL. With the goal of performing a proof-of-principle experiment, liquid 
samples were deposited on the multilayer surface and let dry prior to perform the 
measurement. The choice of working with a “dry sample” was driven by the will to perform 
a quick test measurement, otherwise unfeasible in solution for the lack of a properly designed 
fluidic chamber that could be used with the optical microscope. To verify the scattering 
induction given by the BSW, the idea was to compare a reflected bright-field imaging under 
white light to a measurement in BILSI/BEDLS illumination scheme. The investigated sample 
was therefore the same in both experiments. We deposited a sample of 72 µM Aβ42 peptide 
in the fibrillar aggregation stage (for sample preparation, see Chapter 8) onto a photonic-
crystal multilayer. Upon illumination, the sample under the two different illuminations is 
presented with the picture in Fig.6.2.4, for the reflected bright-field imaging, and with the 
micrographs in Figs.6.2.5, 6.2.6, 6.2.7, 6.2.8 for the BSW illumination. From Fig.6.2.5 to 
Fig.6.2.8 the multilayer sample was sequentially shifted of 2 mm towards the laser 
illumination spot through the prism. For further details on image acquisition see Chapter 8. 
 
 
Fig.6.2.4. Reflected bright-field illumination imaging under white light. We thank Dr. E. Barakat 
from the Optics & Photonics Technology Laboratory, EPFL, for the image. 
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Fig.6.2.5. Micrograph obtained upon BSW illumination. The sample was 8 mm-far from the 
illumination spot. We thank Dr. E. Barakat from the Optics & Photonics Technology Laboratory, EPFL, 
for the micrographs. 
50µm
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Fig.6.2.6. Micrograph obtained upon BSW illumination. The sample was 6 mm-far from the 
illumination spot. We thank Dr. E. Barakat from the Optics & Photonics Technology Laboratory, EPFL, 
for the micrographs. 
50µm
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Fig.6.2.7. Micrograph obtained upon BSW illumination. The sample was 4 mm-far from the 
illumination spot. We thank Dr. E. Barakat from the Optics & Photonics Technology Laboratory, EPFL, 
for the micrographs. 
 
50µm
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Fig.6.2.8. Micrograph obtained upon BSW illumination. The sample was 4 mm-far from the 
illumination spot. We thank Dr. E. Barakat from the Optics & Photonics Technology Laboratory, EPFL, 
for the micrographs.  
 
The purely qualitative analysis of the results reveals a substantial difference in the image 
and micrographs under the two experimental conditions. In Fig.6.2.4, the light from the 
sample is mainly reflected, due to the illumination condition. The main difference between 
the illumination conditions from Fig.6.2.5 to Fig.6.2.8 was the sample proximity to the laser 
illumination spot through the prism. The BSW propagates on the multilayer surface and the 
intensity decreases with the propagation distance from the source(20). From a qualitative 
analysis, the intensity of the light, as imaged onto the HS camera, was increasing with 
proximity. In Figs.6.2.5, 6.2.6, 6.2.7, and 6.2.8 the light response was different from what 
exhibited in Fig.6.2.4. Under reflected bright-field illumination, particles under and near the 
surface were imaged onto the camera. Under BSW-illumination conditions, only the particles 
at the surface were selectively illuminated, due to the evanescent nature of the BSW. The 
microscope was thereby not collecting the light from the illumination source. As a 
consequence, a qualitatively higher contrast is exhibited by the micrographs in Figs.6.2.5, 
6.2.6, 6.2.7, and 6.2.8, compared to the image in Fig.6.2.4. We tentatively identified the light 
50µm
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from the samples illuminated under the BSW resonance condition with light scattered by the 
particles deposited onto the multilayer surface. Therefore, we could infer a light scattering 
induction via BSW illumination. However, due to the size of the analytes deposited onto the 
multilayer surface, we could not visually discriminate between the buffer salt residues and 
the Aβ42 fiber morphology. To this purpose, dedicated experiments should be designed. 
We are entirely aware that the micrographs in Figs.6.2.5, 6.2.6, 6.2.7, 6.2.8 do not fully 
validate our BSW-based technique as a means to enhance light scattering. However, these 
preliminary results are extremely encouraging. With BSW, a field confinement should 
increase the light scattered by the analyte, thus ameliorating the SNR. We are convinced that 
our technique is a highly promising concept for a facile combination of two different methods. 
A BEDLS sensing approach would offer the possibility to perform a refractive index 
monitoring simultaneously to the DLS measurement, which makes this technique extremely 
attractive for real-time monitorings of aggregation dynamics.   
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6.3 Conclusion 
 
This chapter reports on two innovative and original sensing approaches aimed at 
monitoring the DLS signal given by the aggregation of amyloid peptides. In the first, an 
attempt to perform a simultaneous DLS and BSW-based monitoring was carried out. This 
approach did not lead to the expected outcomes in the DLS signal, due to a very low SNR 
mostly related to the illumination scheme. The use of the MMF as the scattered light collector 
was also questionable. A MMF is highly sensitive to external perturbations (such as 
temperature) leading to optical path length fluctuations(22), and thus generating spurious 
signal variation contributing to additional noise. The choice of a MMF as the light collector 
has therefore to be avoided in future studies. Finally, introducing a converging lens positioned 
between the cell back-window and the fiber edge would have improved the light collection. 
The geometry and size of the fluidic cell imposed constraints that made this improvement 
impossible: The small back-window was too small to accommodate a lens. The design was 
limited by the Peltier element hole. 
In a second attempt, the methodology was based on the use of a one-dimension photonic 
crystal capable to generate a BSW, which itself was used as the source for light scattering 
induction. With a parallelism to REDLS (Resonance-Enhanced Dynamic Light 
Scattering)(16), where the source for the DLS monitoring are surface plasmons, we 
introduced the BEDLS (Bloch surface wave-Enhanced Dynamic Light Scattering) technique. 
Due to time restrictions, we did not accomplish the development of a setup (ideally described 
in Chapter 7), which could be demonstrated to be fully operational. We implemented a 
simplified and transitional setup, which allowed for a proof of principle of the feasibility of 
the proposed sensing scheme. We called this method BILSI (BSW Induced Light Scattering 
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Imaging), since the scattering enhancement was not experimentally validated, but it is 
theoretically demonstrated by similar methods(16, 21). 
The main advantage of technique described in this chapter should be an improvement of 
the SNR, due to the high light confinement achievable with the BSW(19). Although we did 
not explore its full potential, BILSI and BEDLS offer the opportunity to perform a refractive 
index monitoring simultaneously to the DLS measurement, which makes this technique a 
valid and attractive alternative to TIRM(12). Moreover, depending on the materials used in 
the fabrication, the multilayer can be designed to work at‒virtually‒any desired wavelength 
and at both polarizations(23-25). Hence, BEDLS appears more versatile even as compared to 
REDLS. In general, all the benefits achievable with the choice of BSW instead of SPR as a 
light source for the induction of light scattering are exploitable with BEDLS. 
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7. CONCLUSION AND PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
7.1 Conclusion 
 
This thesis project has tackled the experimental validation of a Bloch surface wave-
based sensing device conceived by the Optics & Photonics Technology laboratory (EPFL, 
Neuchâtel) for biosensing purposes. It is a novel sensing platform to perform refractive index 
measurements, reminiscent of SPR-based techniques. The potential of this original sensing 
approach based on BSWs was exploited by monitoring the toxic early progress of amyloid-
beta (Aβ) peptide aggregation. Understanding the process of the complex and still obscure 
amyloid aggregation is directly linked to the possibility of developing therapies for the fatal 
and incurable Alzheimer’s disease.  
The main outcome of this project has been the real-time monitoring of the dynamics of 
Aβ42 peptide oligomerization, aggregation and fibrils formation. The time frame that we 
were able to investigate is very often silent through the lens of classical amyloid detection 
techniques. At present, these conventional techniques, as well as other more sophisticated 
methods, such as X-ray crystallography and NMR, are often not suitable for studying the 
early dynamic events in the aggregation process of proteins. While our new biosensing 
approach provided a tool to monitor the early Aβ42 peptide aggregation dynamics, in parallel 
we were able to control the progressive formation of the amyloid structures by biochemical 
and biophysical methods (chromatographic techniques, optical spectroscopies, TEM) 
classically used for this purpose. 
Note that this sensing approach has not to be confused with a diagnosis tool. Our BSW-
based sensing method has to be understood more as a helpful tool for fundamental research 
on amyloid fibrillization. In addition, our optical sensing method could serve as a direct, easy-
to-perform screening apparatus for new potential inhibitors of Aβ42 toxic oligomers and early 
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nucleation events, in the context of lead finding and lead optimization for the development 
of new drugs. 
However, questions still remain unresolved, such as what is the nature of the species 
interacting with the sensing surface and what regulates this adsorption-desorption 
mechanism. From the hypothesis that this process could be correlated to a conformational 
transition of the Aβ peptide‒presumably of the middle-to-low molecular-weight soluble 
oligomers‒during early aggregation, we conceived experiments aimed at verifying our 
formulation. Hence, we devised a surface functionalization strategy, specific for silicon oxi-
nitride surfaces that decisively contributed to elucidate the process underlying the peptide 
surface-interaction. Moreover, the results obtained in this context were in good agreement 
with our proposal for the molecular processes involved in the early events of Aβ42 
aggregation. Additionally, we tested known molecular probes interfering with Aβ 
aggregation dynamics and kinetics to extrapolate details on the nature of the peptidic 
assembly that showed high affinity for the glass-like multilayer surface. The results we 
obtained are only in partial agreement with the literature. To acquire complementary 
information, a NMR-based investigation was carried out using WaterLOGSY experiments. 
The outcome of this powerful method was in accordance with the conclusion we infer from 
the BSW-based monitorings, still contradicting some results reported in the literature. Finally, 
to enhance the performances of the BSW-based sensing device, we implemented a measuring 
system for simultaneous light scattering experiments. 
We designed selective tests to indirectly rule out alternative versions of our hypothesis. 
This approach was driven by the limitations imposed both by the biological analyte, and by 
the prototypical nature of the optical setup. As in any field of scientific research, but 
especially under our working conditions, we were often in lack of valuable references to 
compare our results. For example, the inherent complexity of the Aβ42 aggregation process 
led to difficulties in handling the Aβ42 peptide sample. The monomeric Aβ42 peptide is 
notoriously metastable and rapidly converts into mature aggregates, which prevented us from 
directly calibrating the sensor with discrete toxic soluble Aβ42 oligomeric species, the target 
of our study. 
This thesis work stemmed for an interdisciplinary project carried out between two 
laboratories with a very different background, and profited from several valuable external 
collaborations. The Organic Chemistry group (UniNE) provided support for the surface 
functionalization chemistry, which I carried out by myself and developed under the 
supervision of Dr. van der Wal from the Sensors, Actuators and Microsystems Laboratory 
(EPFL, Neuchâtel). I could profit from the initiation to the handling of the peptidic samples 
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by the Laboratory of Molecular and Chemical Biology of Neurodegeneration (EPFL, 
Lausanne). From the valuable collaboration with Dr. Descrovi from the Politecnico di Torino 
(Italy), I was taught the know-how for operating the biosensing platform and achieve the 
reproducible results presented in this thesis. Dr. Descrovi considerably helped constructing 
the first optical setup presented in this thesis, which I then improved in terms of resolution 
and robustness. 
Finally, this thesis work is an effort to develop a reliable and powerful real-time sensing 
approach that could be applied to the investigation not only of the aggregation dynamics of 
the Aβ peptide, but also to a wider range of aggregating proteins. 
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7.2 Perspectives 
 
Many supplemental experiments were envisaged, but, due to a lack of time and other 
technical issues, were not actualized. In the following, a brief list of ideas and outlooks for 
this thesis project is presented. 
7.2.1 BEDLS sensing  
 
Among others, the most compelling follow-up to this project would be the realization of 
the BEDLS (Bloch surface wave-Enhanced Dynamic Light Scattering) setup, as described in 
Chapter 6. The aim would be to characterize the change in size of the Aβ42 peptide during 
aggregation via BSW-enhanced light scattering measurements, in parallel to the BSW-based 
monitoring. The prospective setup is represented in Fig.7.2.1. 
 
 
Fig.7.2.1. Top-view schematics of the BEDLS prospective setup. PMF: polarization maintaining 
fiber; OBJ: microscope objective; HS: high sensitivity. 
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A PMF guiding the TE polarized laser beam should be used to excite the BSW. The 
BSW response would be monitored via a CMOS camera tracking the BSW dip displacement 
in real time, as in the setups previously described in this thesis project. The BSW would act 
as the source for light scattering induction, which would be then collected by an objective 
and imaged onto a high sensitivity camera. A 1D or ROI (Region of Interest) integration of 
the image would follow. The system could be provided with an autocorrelator to extrapolate 
scattering intensity fluctuation in time. 
As a further amelioration, the actual fluidic cell could also be replaced by a microfluidic 
cell made of PDMS directly deposited onto the photonic crystal, whose features were 
described in a recent publication by Tonin et al(1). In this article, the authors reported on its 
fabrication and on the possibility to perform high-resolution optical microscopy through it. 
With this microfluidic cell, the sample volume could be scaled down to few µL. The cell 
thickness is reported as little as less than 0.2 mm. This condition is most likely to mimic the 
in vivo condition to perform a more accurate kinetic study of the aggregation process. In 
addition, this upgrade would allow the objective for the collection of scattered light (see 
Fig.7.2.1) to be oil-contacted onto the cell, thus improving light collection. The numerical 
aperture of the oil immersion objective could be as high as 1.49. 
 
7.2.2 Surface patterning for spatial selectivity 
 
A modification of the sensor surface to perform an internal-reference measurement was 
also regarded as a potential improvement of the device. 
The sensing surface could be angularly and spatially separated with the periodical 
deposition of thin-layer stripes of Plasma-Polymerized Styrene (PPST), alternating to a bare 
multilayer surface (see Fig.7.2.2).  
 
 
Fig.7.2.2. Scheme of the PPST surface patterning period. The bare surface is Si3N4. 
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This sensing approach is fully described by Ballarini et al(2), who have validated an 
experimental application of this strategy. In their publication, the authors demonstrate that 
this striped patterning of the multilayer allows for an internal referencing of the 
measurements: PPST films exhibit a significant hydrophobicity, a chemical inertness towards 
biomolecule functional groups, and acts as an anti-fouling layer, avoiding non-specific 
protein adsorption onto the surface. Thus, alternating PPST stripes to a bare multilayer 
surface a real-time comparison of the contribution to the signal given by the bulk effect and 
the surface-loading mechanism, respectively, is made possible. This strategy would improve 
the reproducibility of the measurements. As a further study of the aggregation of amyloid 
peptides, PPST striping would help identifying the signal revealed by our measurements with 
the specific conformational stage of the peptide. 
PPST supports the BSW phenomenon. However, the coupling conditions should be 
different from those used for the Si3N4 material of the top–bare–layer of the photonic crystal. 
Working at a fixed wavelength, the two different materials should be illuminated at two 
different angles. Thus, the BSW on different regions would selectively be excited according 
to an “on-resonance/off-resonance” illumination condition, depending on the angle of 
incidence. An adapted camera could be used to detect both the reference and the 
functionalized optical signal in reflection. A suited Labview program should be developed 
and adapted for this application. 
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8. EXPERIMENTAL MATERIALS AND 
METHODS 
 
 
 
 
 
 
 
 
 
8.1 Biochemical studies 
 
The Aβ42 peptide for the initial experiments was provided by the group of Hilal Lashuel, 
Laboratory of Molecular and Chemical Biology of Neurodegeneration, EPFL (Lausanne, 
Switzerland) and synthesized and purified as TFA salts by Elliott, WM Keck Facility, Yale 
University (New Haven, USA) as described in the literature(1). Aβ42 peptide was also 
purchased from Bachem AG, Bubendorf, Switzerland, and from PepMic Co, Ltd. (Suzhou, 
China). We did report no difference between the peptides provided by the three sources under 
the conditions of our experiments. Buffers and solvents for peptide preparation were 
purchased from SIGMA Aldrich and Fluka AG (Buchs, Switzerland). We used ultrapure 
water (Elix 3 water purification system, Merck Millipore, Darmstadt, Germany), unless stated 
otherwise. 
 
8.1.1 Aβ42 monomer, protofibril and fibril preparation  
 
The procedure for Aβ42 monomer, protofibril and fibril production was carried out 
according to the protocol developed by Jan et al(2). 
The preparation of Aβ42 monomers was performed by dissolving the peptide in 6 M 
Gnd-HCl and purifying it via size exclusion chromatography (SEC). The eluate 
corresponding to the Aβ42 monomer peak at the maximal absorption intensity was collected, 
separated in fractions of 200 μL, and immediately stored at 4 °C. 
For this purpose, the column Superdex 75 10/300 GL (GE Healthcare, Uppsala, Sweden) 
was used. It has a separation range for globular proteins of 3000 - 70000 Da, an exclusion 
limit of 105 Da, and a bed volume of approximately 25 mL. SECs were performed using an 
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Äkta Purifier 10 system (pumping system P-900) provided with a fraction collector Frac-920 
(GE Healthcare, Uppsala, Sweden). Eluent filters ExpressPLUS had a cut-off diameter of 
0.22 μm purchased from Millipore Corp. (Billerica, Massachusetts, USA). Buffers and 
solvents for SEC were purchased from SIGMA Aldrich and Fluka AG (Buchs, Switzerland). 
All SECs were performed at a flow rate of 0.5 mL/min at 25°C with 10mM Tris HCl elution 
buffer (pH 7.4). A column calibration with standard proteins was performed prior to its use. 
The calibration mix (SIGMA Aldrich, Buchs, Switzerland) was composed of 8 mg/mL BSA 
(MW monomer ~67 KDa; dimer ~130 KDa), 2.5 mg/mL Ovalbumine (MW ~ 43 KDa), 
2.5 mg/mL Carbonic Anhydrase (MW ~ 29 KDa), 5 mg/mL RNAse (MW ~ 13.7 KDa), and 
0.5 mg/mL Vitamin B12 (MW 1355 Da) in 10 mM Tris HCl buffer at pH 7.4. Prior to 
injection, the sample mix was centrifuged at 14000 rpm for 5 minutes. To assess the void 
volume of the column, 1 mg/mL Dextran Blue (MW ~ 2∙106Da) in 10 mM Tris HCl buffer 
at pH 7.4 was used. 
Aβ42 protofibril was obtained by dissolving the peptide in 100% DMSO and diluting 
the solution in ultrapure H2O, then purifying the obtained solution via SEC, using the 
chromatographic column described above(2). The final concentration of Aβ42 monomer and 
protofibril samples in 10 mM Tris HCl was assessed by UV absorption at 280 nm, and 
calculated using a molar extinction coefficient of 1490 M-1cm-1(3).  
Aβ42 fibrils were prepared by incubating the monomer sample, obtained as described 
above, at 37 °C for 48 h without agitation.  
 
8.1.2 Aβ42 sample characterization 
 
UV spectroscopy was used to calculate the purified Aβ42 samples concentration as 
explained above. Moreover, it was used to monitor the scattering profile of the absorbance 
spectra of monomer samples (Abs250/Abs280 ≤ 0.5, Abs333 ~ 0, after baseline correction), to 
rule out incipient aggregation when the sample was used within 24 h from the preparation. 
Unreliable Aβ42 samples were discarded. 
TEM imaging was performed depositing 2 mL of peptide samples on Formvar/carbon-
coated TEM grids negative stained by means of 2% uranyl acetate (2). The preparation of the 
TEM grids was carried out soon after sample preparation and then after different time lapses 
(from time 0 to 48 h for the monomer, at time 0 and 24 h for the protofibril, and at time 0 for 
the fibril) during peptide incubation at 37 °C. Both the grids and the stain were purchased 
from Electron Microscopy Sciences (Hatfield, USA). Micrographs were acquired on a Philips 
CM200 Transmission Electron Microscope. 
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8.1.3 Classical Aβ42 aggregation studies  
 
To monitor the Aβ42 amyloid aggregation, several techniques were used to predict the 
Aβ42 behavior throughout fibrillization, in parallel to the BSW-based sensing. 
All reagents and buffers for ThT-binding fluorescence assays were purchased from 
SIGMA Aldrich and Fluka AG (Buchs, Switzerland). For the assay, buffers and reagents were 
freshly prepared according to a protocol developed by Jan et al(2). A 100 μM ThT stock 
solution was prepared dissolving 0.32 mg of ThT in 10mL of ultrapure water. The reagent 
solution was filtered prior to use and stored at 4 °C protected from light for maximum one 
month. The reagent was filtered using a Minisart MNL syringe filter with a cut-off membrane 
of 0.22 μm (Sartorius Stedim, Aubagne Cedex, France). A 500 mM Gly-NaOH stock solution 
was prepared dissolving 376 mg of Gly in 10 mL of ultrapure water until a clear solution was 
achieved. The pH was brought to 8.5 by adding 3.75 M NaOH. The solution was filtered prior 
to use and stored at 4 °C. For fluorescence assays a fresh solution of Aβ42 monomer purified 
via SEC was used. It was incubated at 37 °C without stirring and 80 µL aliquots were added 
of 10 µL ThT stock solution and of 10 µL Gly-NaOH stock solution. Spectra detection 
parameters were selected according to a protocol developed by Nilsson(4). Emission 
fluorescence spectra were acquired in a wavelength range of 600-450 nm and recorded 
immediately after sample preparation on a LS50B fluorimeter (Perkin Elmer, Waltham, 
Massachusetts, USA). We used a fluorescence cell made of quartz SUPRASIL with a light 
path of 10 mm, and reduced volume of 100 µL purchased from Hellma (Müllheim, Germany). 
λex was 440 nm. To prevent auto-excitation phenomena, λex was not the ThT absorption 
maximum, which is 412 nm. The scan speed was 500 nm/min; the excitation slit was 5.0 nm 
and the emission slit 10.0 nm; the width was 7.5 nm. Spectra recording was performed with 
a 2-scan accumulation method. The fluorimeter allowed auto background subtraction. The 
blank was prepared replacing the peptide with 80 µL of 10 mM Tris HCl, pH 7.4. 
All reagents and buffers for the TROL fluorescence quenching assay purchased from 
SIGMA Aldrich and Fluka AG (Buchs, Switzerland). For the assay, buffers and reagents were 
freshly prepared according to the literature(5). A reagent stock solution was prepared 
solubilizing 0.19 mg TROL in 100 µL DMSO and adding 1000 mL of 50 mM Gly-NaOH, 
pH 8.2. 50 mM Gly-NaOH, pH 8.2, was prepared by dissolving 3.76 g of Gly in 1000 mL 
ultrapure water and adjusting the pH by adding 3.75 M NaOH. TROL buffered solution final 
concentration was 10 µM and it was assessed by UV-vis spectroscopy. It was calculated with 
a molar extinction coefficient of 5690 M-1cm-1. The fluorescence assays were performed on 
a Luminescence Spectrometer LS 55 (Perkin Elmer, Waltham, Massachusetts, USA), using 
a 96-well black, opaque, flat-bottomed microplate. The Aβ42 peptide was separately 
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incubated at 37 °C without agitation and 10 µL aliquots of the sample were added to 100 µL 
of 10 µM TROL buffered solution. Measurements were triplicated. Fluorescence intensity 
was recorded at λem = 355 nm (λex = 280 nm). The excitation slit was 5.0 nm and the emission 
slit 10.0 nm; the width was 7.5 nm. 
For the FTIR assays, HFIP and D2O were purchased from SIGMA Aldrich (Buchs, 
Switzerland). To prepare the sample for the ATR-FTIR analysis, 0.15 mg of purchased Aβ42 
peptide powder were solubilized in 100 μL of HFIP, as described in the literature(6). Aβ42 
peptide samples were then lyophilized using a freeze-dryer Cryodos (TELSTAR Industrial, 
Terrassa, Spain), working at a temperature of -56 °C and at a pressure of 0.2 mBar, provided 
with a vacuum pump (Edwards, Munich, Germany). After freeze-drying overnight, the 
sample was solubilized in 100 μL of D2O, leading to a peptide concentration of 332 μM. FTIR 
spectra were registered soon after D2O solubilization, and after sample incubation at 37 °C 
without agitation. The monomeric Aβ42 sample for the comparison between β-structure and 
non-β-structure was obtained solubilizing 0.3 mg of lyophilized Aβ42 in 100 μL of  30% v/v 
HFIP in D2O, as described in the literature(7). The final peptide concentration was 665 µM. 
The IR spectrum was registered after 10 minutes from the solubilization. Samples volume 
was 20 μL. The experiments were performed on a FTIR spectrometer Vertex 70 provided 
with an ATR cell holder BioATR II Confocheck (BRUKER Corp., Ettlingen, Germany). 
Spectra were recorded with the software OPUS version 6 (BRUKER), selecting experimental 
parameters according to the literature(7, 8). The background spectrum was registered for 
every new measurement and an automatic subtraction was performed by the software. All the 
spectra were registered in 32-scan accumulation. The frequency range was 4000-1000 cm-1, 
and scan velocity was 20 kHz. All spectra were vapor-free (no sharp absorption was observed 
between 1700 and 1800 cm-1). The beam diameter aperture was 6 mm. Interferograms were 
multiplied with the Blackman-Harris 3-Term apodisation function. Spectra were recorded at 
a spectral resolution of 4 cm-1. All measurements were performed at 25 °C. For the second-
derivative analysis, spectra in the amide I region were smoothened with a Stavitzky-Golay’s 
13-point smoothing function. 
UV spectroscopy was used to monitor the Aβ42 aggregation by recording absorbance 
spectra between 240 and 350 nm(2). Monomeric Aβ42 peptide samples were incubated at 
37 °C without agitation. Samples were centrifuged at 14000 rpm for 5 minutes. For the real-
time UV-absorbance monitoring, the absorbance at 250 nm was measured every 30 seconds. 
Aβ42 samples were incubated at 37 °C in the spectrometer cell, using the accessorial 
temperature controller Peltier system ETC-717 (Jasco Corp., Tokio, Japan). 
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8.1.4 Test of the molecular probes 
 
For the BSW-based measurement with RS-0406 in solution with the Aβ42 peptide, a 
16.7 mM RS-0406 stock solution (in 33% DMSO, 66% 10 mM Tris HCl, pH 7.4) was freshly 
prepared. As an example, to prepare a 150 µL final sample to incubate in the sensing chamber, 
1.2 µL of the stock solution were added to 148.8 µL of 13 µM monomeric Aβ42 peptide in 
10 mM Tris HCl, pH 7.4. The final sample concentration was 130 µM RS-0406 in 10 mM 
Tris HCl, pH 7.4, 0.28% DMSO. Volumes were adjusted for the peptide samples at higher 
concentration. The molar ratio between the molecule and the peptide was 10:1. 
For the BSW-based measurement with R548332 in solution with the Aβ42 peptide, a 
16.7 mM R548332 stock solution (in 33% DMSO, 66% 10 mM Tris HCl, pH 7.4) was freshly 
prepared. As an example, to prepare a 200 µL final sample to incubate in the sensing chamber, 
1.7 µL of the stock solution were added to 198.3 µL of 13.9 µM monomeric Aβ42 peptide in 
10 mM Tris HCl, pH 7.4. The final sample concentration was 139 µM R548332 in 10 mM 
Tris HCl, pH 7.4, 0.28% DMSO. Volumes were adjusted for the peptide sample at higher 
concentration. The molar ratio between the molecule and the peptide was 10:1. 
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8.2 Optical setups 
 
Three different optical setups were implemented in this thesis project. Details on their 
components, functioning and on data acquisition are presented in this Chapter, as follows: the 
optical setup for the BSW-based refractive index measurement is detailed in section 8.2.1, 
the setup for the parallel DLS and BSW-based measurement is described in section 8.2.2, the 
BILSI setup is discussed in section 8.2.3. 
 
8.2.1 BSW-based optical platform 
 
The light source was a stabilized He-Ne laser (λ = 632.8 nm), TE polarized via the use 
of a polarizer filter. An objective (20x), an optical diaphragm and two subsequent lenses 
(focal lengths 32 mm, reciprocal distance 165 mm) were used to condition the laser beam. 
The microscope objective was used to obtain a large divergent beam to have a sufficient 
illumination of the device. The lenses were mostly employed for the fine tuning of the angular 
range of illumination and to improve the intensity of the beam onto the device. The 
illumination of the photonic crystal was performed through a right-angle BK7 glass prism 
(refractive index 1.5149) to couple the light into the multilayer. The photonic-crystal layers 
were deposited on a BK7 glass substrate with an Oxford Plasmalab 80+ PECVD machine 
(Oxford, UK).  
The fluidic cell was designed by a previous collaborator of the Optics & Photonics 
Technology laboratory (EPFL), and it is presented in Fig.8.2.1.  
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Fig.8.2.1. Picture of the fluidic chamber for BSW-based monitoring. (a) injection tube; (b) 
extraction tube; (c) incubation chamber; (d) O-ring; (e) multilayer; (f) prism; (g) plastic elements used to 
hold the chamber and the prism together. 
 
The sample injection is made possible by two small channels inside the aluminum element, 
to which two Teflon tubes are glued. One tube is used for injection (Fig.8.2.1, a), the other 
for sample extraction (Fig.8.2.1, b). The two channels are converging into a central open 
cavity (Fig.8.2.1, c). The cavity is sealed against the multilayer via a plastic O-ring 
(Fig.8.2.1, d). The multilayer (Fig.8.2.1, e) is oil-contacted onto the prism (Fig.8.2.1, f). 
These three components are tightened together by two plastic components (Fig.8.2.1, g), 
which can be properly screwed onto the aluminum element to accommodate the prism. The 
fluidic cell volume is 200 µL. The incubation of the samples was performed at 37 °C 
(uncertainty ± 0.1 °C) via the use of a Peltier thermoelectric thermostat system connected to 
a temperature controller Lightwave ILX (Bozeman, USA). The Peltier element is positioned 
on the back of the aluminum chamber, opposite to the prism. The data acquisition of the BSW 
dip resonance position was started 1 min after the injection of the sample solution in the cell, 
to allow temperature stabilization. The laser beam reflected from the multilayer is directed to 
the detector, a 1.3 MP Monochrome 8-bit CMOS Camera (Mightex, Toronto, Canada), which 
allows monitoring the angular shift of the resonance conditions through the camera pixels. 
The response was therefore reported in numbers of pixels. The software for data collection 
was developed in collaboration with Dr. Descrovi from the Politecnico di Torino, Italy. The 
program makes use of a Lorentzian-function fit to interpolate the BSW dip and to track its 
displacement along the pixels of the camera. 
For the results presented in this work, it is important to stress that the zero value in pixel 
shift corresponds to the BSW resonance position at the beginning of the measurement, and 
not to the signal of the reference buffer solution (10 mM Tris HCl), unless stated otherwise. 
a
b
c
d
e
f
g
g
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To guarantee identical initial experimental conditions, a new multilayer was used for each 
measurement. 
 
8.2.2 Parallel DLS and BSW-based-monitoring setup 
 
For the DLS measurement, the original setup was modified using optical fibers to guide 
the light to the sensing chamber. The optical elements and fibers were purchased from 
Thorlabs Gmbh, Dachau, Germany. In the optical setup, a laser beam (λ = 632.6 nm) is guided 
into a SMF via a fiber port (f = 15.4 mm, output waist diameter 0.33 mm). The SMF has a 
cut-off wavelength of 500-600 nm, a mode field diameter of 3.6-5.3 µm at 633 nm, a cladding 
diameter of 125 ± 15 µm, and a numerical aperture of 0.10-0.14. The light is then conditioned 
with a polarizing fiber-bench beamsplitter module. Two PMF collects TE or TM polarized 
light, respectively. They both have a cut-off wavelength of 570 ± 50 nm, and a numerical 
aperture of 0.12. The light is then guided to the fluidic cell via two fiber port collimators. For 
BSW excitement, the beam was slightly divergent. For light scattering induction, the beam 
was collimated. For light scattering collection, a 2 mm-core MMF is employed. It was 
polished with a diamond film (mesh 100 nm). It was optically controlled, and it revealed 
defects size of less than 100 nm. 
 
8.2.3 BILSI setup 
 
The BILSI setup was constructed by adapting a Leika DMR upright optical microscope 
for reflected bright-field imaging (Leika Microsystems, Heerbrugg, Switzerland). The lens 
tube size of the microscope is 200 mm. The camera used for the imaging is a Hamamatsu 
ORCA 100 (Hamamatsu, Japan). It is high sensitive in vis-NIR region and has a high 
resolution of 1.37 million pixels. The camera pixel size is 6.45 µm. Images and micrographs 
were recorded with no binning, using a 20X microscope objective. The integration time for 
image in Fig.6.2.4 was 200 ms, while for the micrographs in Fig.6.2.5, Fig.6.2.6, Fig.6.2.7, 
and Fig.6.2.8 the integration time was 1 s.  
The multilayer used for BSW coupling in air was designed by Dr. Barakat from the 
Optics & Photonics Technology laboratory (EPFL), according to the scheme:  
glass-(H-L)x6-H’-air, where H is silicon nitride and L is silica. Layers thicknesses are: 
H = 150 nm, L = 230 nm, and H’ = 50 nm. For the BSW excitation, the light was guided via 
a PMF fiber (cut-off wavelength 570 ± 50 nm, numerical aperture 0.12). To couple light 
inside the multilayer, a right-angle BK7 glass prism was used. The illumination scheme was 
the same as described in the previous section. 
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8.3 Surface chemistry 
 
For the multilayer surface chemical treatments, all the reagents and solvents were 
purchased from SIGMA Aldrich and Fluka AG (Buchs, Switzerland), and Honeywell 
(Seelze, Germany). d.i. water was obtained with an AquaFine system (CHRIST, Valencia, 
USA) provided with an UV disinfection system. Each functionalization procedure was carried 
out for 20 multilayers. The multistep strategy was optimized and partially adapted from the 
literature(9), as described in the following. For piranha cleaning, multilayers were soaked in 
a piranha bath (98% H2SO4 and 30% H2O2 in a volume ratio of 3 to 1) at room temperature 
for 30 minutes. After this step, multilayers were carefully and extensively washed in d.i. water 
baths and dried with a gentle N2 flux. For the amino-silanization, we prepared a stirred bath 
of 95% toluene at 80 °C, and we added 10% v/v APTES and 0.5% v/v d.i. water. Multilayers 
were introduced in the bath after 30 minutes from its preparation. This step was important 
when glassware that could react with APTES was used. After 30 minutes, we assumed that 
the silanization of the glassware was terminated. The amino-silanization step was carried out 
by vertically placing the multilayers in a Teflon holder, then in the toluene bath for 2 hours. 
After this step, multilayers were washed twice in a 99% isopropanol bath, then gently dried 
with a N2 flux. When necessary, after this step multilayers were stored in a desiccator. For 
the linker binding, a room-temperature CHCl3 (HPLC purity grade) bath was prepared by 
adding 0.5% v/v TEA and 1 mg/mL acetal-NHS. Multilayers were placed at the bottom of 
the bath, with the dielectric layers oriented upwards for 2 hours. The bath was covered with 
a watch glass. After this time, the multilayers were washed three times in chloroform baths, 
and gently dried with N2 flux. The acetal-NHS linker was deprotected in a 1% m/v citric acid 
bath at room temperature. The multilayers were incubated for 15 minutes by placing them at 
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the bottom of the bath. Afterward, they were carefully washed three times in d.i. water baths 
for 5 minutes. For the final step, the ligand attachment, two separate buffer A baths added of 
4% of v/v 1 M NaCNBH3 were prepared. Buffer A was 100 mM NaCl, 50 mM NaH2PO4, 
adjusted to pH 7.5 with NaOH. For the preparation of 1 M NaCNBH3, 0.31 g of the substance 
were added to 5 mL d.i. water. The multilayers were divided into two sets of 10 multilayers 
each. For PEGylation, one set was positioned at the bottom of the buffered bath solution 
added of 0.25 mg/mL methoxy polyethylene glycol amine 750. Similarly, for TROL 
functionalization, the other set was positioned in the buffered bath added of 0.1 mg/mL          
L-Tryptophanol. The incubation was performed at room temperature for 1 h. After this time, 
4% v/v of 1M ethanolamine was added to each bath. After 15 minutes, we assessed the pH 
neutrality. Then, we removed the multilayers from the reaction bath and washed them three 
times, for 5 minutes, in PBS baths (150 mM NaCl, 5 mM NaH2PO4, adjusted to pH 7.4 by 
NaOH addition). Multilayers were then extensively washed in d.i. water baths, gently dried 
with N2 flux, and stored in a desiccator until use. 
The homogeneity of the PEG coating was confirmed using dark-field optical microscopy 
with a Nikon SMZ1500 stereomicroscope provided with a Nikon Dn100 camera. 
 
8.3.1 BSW-based sensing to assess surface functionalization 
effectiveness 
 
For the BSW-based monitoring with a PEGylated multilayer surface, BSA protein 
(SIGMA Aldrich, Buchs, Switzerland) was dissolved in 0.1 M PBS, pH 8.9, without 
pretreatments. The protein solution was filtered with a Minisart MNL syringe filter with a 
cut-off membrane of 0.22 μm (Sartorius Stedim, Aubagne Cedex, France). The protein 
concentration was assessed performing UV-Vis spectroscopy, using a molar extinction factor 
ε280 of 43.824 m-1cm-1 and accounting a MW of 66463 Da (ProtParam). 100 mL of 0.1 M 
PBS was prepared dissolving 1.42 g of Na2HPO4 in ultrapure water. The pH was adjusted to 
8.9 with 25% v/v HCl. The solution was filtered under vacuum with a cut-off membrane of 
0.22 µm. For the BSW-based measurement reported in section 4.2.1, the pixel-shift zero value 
was corresponding to the BSW dip position while incubating water at the temperature 
selected for the BSA incubation.  
For the BSW-based measurement with TROL in solution with the Aβ42 peptide, a fresh 
TROL stock solution was prepared before each experiment. 1.8 mg TROL were solubilized 
in 200 µL DMSO. 5 µL of the TROL stock solution were added to 10 µL of 10 mM Tris HCl, 
pH 7.4, leading to a final TROL concentration of 16.7 mM in 33% DMSO and 66% 10 mM 
Tris HCl, pH 7.4. To prepare a 200 µL final sample to incubate in the sensing chamber, 1.7 µL 
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of 16.7 mM TROL were added to 198.3 µL of 13.9 µM monomeric Aβ42 peptide, in 10 mM 
Tris HCl, pH 7.4. The final sample concentration was 139 µM TROL, 13.9 µM Aβ42 peptide, 
in 10 mM Tris HCl, pH 7.4, 0.28% DMSO. TROL stock solution concentration was assessed 
by UV-vis spectroscopy and it was calculated using a molar extinction coefficient of   
5690 M-1cm-1. 
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P, Pohl EE, Hinterdorfer P, & Gruber HJ (2011) Linking of Sensor Molecules with Amino Groups to 
Amino-Functionalized AFM Tips. Bioconjugate Chemistry 22(6):1239-1248. 
 
 
 
APPENDIX 1 
 
147 
 
APPENDIX 1: EXPERIMENTAL BSW 
RESPONSE CALIBRATION AND SENSOR 
RESOLUTION DETERMINATION 
 
 
 
 
 
 
 
 
For the calibration of the multilayer sensitivity, two methods were used. In the first, the 
angular shift of the BSW resonance dip was obtained varying the temperature of d.i. water 
(resistivity 13 MΩ/cm). Water refractive indices at different temperatures and at 
λ = 632.8 nm were extrapolated from discrete values reported in the literature(1), as reported 
in Fig.A1.1 (a). 
 
 
Fig.A1.1. Water refractive index nwater at different temperatures: (a) from 0 to 100 °C; (b) from 
40 to 60 °C, where the regime is linear(1). 
 
We decided to work in the linear regime of the refractive index variation, which occurs 
between 40 and 60 °C, as shown in Fig.A1.1 (b). From the linear fit we obtained Eq.(A.1): 
∆𝑛𝑤𝑎𝑡𝑒𝑟 = 1.33647 − 1.68 ∙ 10
−4 𝑇   (A1.1) 
which allowed calculating the refractive index of water at fixed temperatures between 40 and 
60 °C. 
(b)(a)
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In the second method, glucose solutions at different concentration C (% m/v) at 25 °C 
were used (see Tab.A1.1). For the conversion of the refractive index change of glucose 
solutions in d.i. water at λ = 632.8 nm we used the formula: 
Δn = β · C    (A1.2) 
where β = 1.527·10−3 RIU / %(2, 3). This method is fully described by Giorgis et al(4), where 
the refractive indices of different glucose solutions are reported as in Tab.A1.1: 
 
Glucose m/v Δn (at 25 °C and λ = 632.8 nm) 
0 % (d.i. water) 0 
5·10-4 % 7.6·10-7 
1·10-3 % 1.5·10-6 
5·10-3 % 7.6·10-6 
1·10-2 % 1.5·10-5 
5·10-2 % 7.6·10-5 
0.1 % 1.5·10-4 
0.5 % 7.6·10-4 
1.25 % 1.9·10-3 
2.5 % 3.8·10-3 
5 % 7.6·10-3 
Tab.A1.1. Concentration and Δn of different glucose solutions. Glucose concentration is reported 
in % m/v and the reference for Δn is d.i. water at 25 °C and λ = 632.8 nm(4). 
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APPENDIX 2: COMPLEMENTARY STUDIES 
ON THE Aβ42 PEPTIDE AGGREGATION  
 
 
 
 
 
 
 
 
 
In this appendix studies on the in vitro characterization of the Aβ42 aggregates 
conformation and kinetics of the process of ﬁbril formation are presented.  
The sample purification and identification were carried out using classical biochemistry 
techniques, such as SEC (size exclusion chromatography) and UV spectroscopy. After the 
preparation of the monomeric samples their conformational characterization was performed 
by traditional optical spectroscopies (UV-vis, Fluorescence, and FTIR). 
The kinetics of aggregation were monitored under conditions (pH, temperature, and 
ionic strength) responsible for fibrillation and the evolution of monomers into oligomers and 
mature fibril was controlled by ThT binding assay, FTIR, and UV spectroscopy. 
 
Aβ42 monomer purification and characterization 
 
Many protocols for preparation, purification and characterization of Aβ42 samples have 
been proposed(1, 2). In this project we used the one developed by Jan et al(3), in which the 
authors have described the Aβ42 sample preparation via a SEC-based method. SEC is a very 
commonly used technique to purify proteins exploiting their difference in molecular weight 
and hydrodynamic volume. The column we used is a Superdex 75 10/300 GL, where the 
stationary phase is a composite of cross-linked agarose and dextran porose structure with an 
optimum separation range for globular proteins of 3000 - 70000 Da and an exclusion limit of 
105 Da. 
Firstly, to ensure the functionality and separation properties of the size exclusion 
chromatographic column we calibrated the column with a mix of known proteins with a well-
defined MW. The mix was composed as follows: BSA 8 mg/mL; Ovalbumine 2.5 mg/mL; 
Carbonic Anhydrase 2.5 mg/mL; RNAse 5 mg/mL; Vitamin B12 0.5g/mL. The elution buffer 
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was 10 mM TRIS HCl, 150 mM NaCl (pH 7.4). It was similar to the one used for the Aβ42 
peptide sample preparation. The presence of a high salt concentration was necessary to avoid 
aspecific interaction between the column and the calibration proteins. The calibration test of 
the column was successfully performed. To complete the calibration, we estimated the void 
volume of the column using Dextran Blue at a concentration of 1 mg/mL. We separately 
performed this assay to prevent the Dextran Blue peak to overlap the BSA peak. The resulting 
chromatograms are shown in Fig.A2.1. 
 
 
Fig.A2.1. SEC chromatograms for the column calibration. Elution buffer 10 mM Tris HCl, 
150 mM NaCl, pH 7.4; flow rate 0.5 mL/min; absorbance recorded at 280 nm. In dashed line the 
chromatogram of the elution of Dextran Blue. In solid line: (A) BSA dimer; (B) BSA monomer; (C) 
Ovalbumine; (D) Carbonic Anhydrase; (E) Ribonuclease; (F) Vitamin B12. 
 
As shown in Fig.A2.1.1, each peak is narrow and well defined it was possible to assign 
unequivocally one peak to one protein in order to estimate the retention volume of each of 
them. From the chromatographs in Fig.A2.1 we extrapolated the data listed in Tab.A2.1. 
 
Tab.A2.1. List of the standard proteins used to perform the column calibration. Each standard 
protein is here reported with its molecular weight, retention volume Ve and diffusion constant Kd.  
Protein Ve (mL) MW (Da) Kd LogMW 
Dextran Blue 8.35 2000000 0 6.30103 
BSA dimer 8.98 134000 0.06116 5.12710 
BSA monomer 10.07 67000 0.16699 4.82607 
Ovalbumine 10.91 43000 0.24854 4.63347 
Carbonic Anhydrase 12.21 29000 0.37476 4.46240 
RNAse 13.92 13700 0.54078 4.13672 
Vit. B12 18.65 1355 1 3.13194 
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The coefficient values reported in the table above have been calculated with equation 
(A2.1): 
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   (A2.1) 
where Vo corresponds to Dextran Blue elution volume Ve (mL) and Vi is Vitamin B12 elution 
volume Ve (mL). It was therefore possible to calibrate the column as shown in Fig.A2.2. The 
results obtained from this test allowed us to confidently assume the proper functioning of the 
column, since the relation between logMW and Kd of the selected proteins was linear. 
 
 
Fig.A2.2. Calibration curve of the Superdex column. A linear relation between the calculated Kd 
and LogMW is shown. 
 
To prepare the Aβ monomeric samples, we performed SEC separations using as elution 
buffer 10 mM Tris HCl, without salt added. The chromatograph highlighting the elution 
volume of the protein is shown in Fig.A2.3. 
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Fig.A2.3. SEC purification of monomeric Aβ42 peptide. In grey and black line runs of Aβ with 
elution buffer 10 mM Tris HCl at different concentration (Vr Aβ42 oligomer 8.15 mL; Vr Aβ42 monomer 
12.53 mL). Flow rate 0.5 mL/min; absorbance recorded at 214 nm. The concentrations reported refer to the 
final concentration of the monomeric fractions collected. 
 
Lyophilized Aβ42 monomer was solubilized in 6 M Gnd-HCl and insoluble pre-existing 
aggregates were removed by centrifugation (14000 rpm, 5 min) before injection. The 
resulting chromatograms showed that the sample solutions contained predominantly 
monomeric Aβ42(3), as depicted in Fig.A2.3. The peptide eluted as a single peak in the 
included volume of SEC column (0.45–0.55 CV, elution volume 11-13 mL, Fig.A2.3, peaks 
A and B). Commonly, ~ 0.25 mg of lyophilized Aβ42 dissolved in 250 μL of Gnd-HCl 
yielded ~ 1.5 mL of purified monomer at concentrations of ~ 15–25 μM. Repetitions of SEC 
purifications showed that Aβ predominantly eluted as a monomer with high reproducibility. 
A low-intensity peak eluting at approximately 8 mL run volume was also reported (Fig.A2.3). 
The presence of a small amount of LMW oligomers, which exist in rapid equilibrium with 
the monomer both in Gnd-HCl solution and during the elution, has been suggested by the 
literature(3). We identified LMW oligomers with the low-intensity peak. However, it was not 
possible to predict the correct molecular weight of Aβ42 peptides via the linear relation 
extrapolated from the column calibration test (Fig.A2.2). Aβ42 monomers and oligomers are 
unfolded or only partially folded. The particular interaction of these highly hydrophobic small 
proteins with the column bed is not comparable with that of the globular protein used for the 
calibration(3). 
We used SEC fractions to perform quality-control assays of the monomeric Aβ42 
samples after 24 h storage at 4 °C (Fig.A2.4). The chromatogram showed two peaks eluting 
with the expected retention volumes(3). The most intense peak corresponded to the 
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monomeric form of Aβ42 peptide. However, it was impossible to totally inhibit the formation 
of even a small amount of oligomers (~ 5%) even at 4 °C. 
 
 
Fig.A2.4. Reinjection of purified monomers into the SEC column. Elution buffer 10 mM Tris HCl; 
flow rate 0.5 mL/min; absorbance recorded at 214 nm. A oligomer; B monomer; C flow-through. 
 
The SEC-based method ensured the starting material for the aggregation studies 
experiments to be predominantly monomeric Aβ42 peptide, free from protofibrillar or 
fibrillar aggregates. To further rule out the presence of fibrillar or protofibrillar aggregates in 
the SEC purified monomeric samples, aliquots were centrifuged and evaluated by UV 
spectroscopy (Fig.A2.5.). 
 
 
Fig.A2.5. UV-absorption spectrum of monomeric Aβ42. The concentration of the peptide was 
51.7 μM in 10mM Tris HCl buffer. The spectrum was recorded at 280 nm. 
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The shape of the spectrum in Fig.A2.5 is characteristic of soluble proteins or peptides(4). 
The maximum absorption intensity at 274 nm corresponds to the only Tyrosine (Y) present 
in the peptide chain. Between 260 and 267 nm two peaks are present due to the absorption 
contribution of the four Phenylalanines (F) of the Aβ42 peptide. No signal between 320 and 
350 nm was reported. This signal is very often correlated to aggregated forms present in the 
sample(5). UV spectroscopy was also used to carefully estimate the concentration of the SEC-
purified Aβ42 fractions, by using a molar extinction coefficient of 1490 M-1 cm-1 (determined 
with ProtParam). 
 
Aβ42 aggregation studies 
 
To monitor the Aβ42 peptide aggregation kinetics, several different analysis were 
routinely carried out. It was crucial to perform these controls before the BSW-based 
aggregation monitorings. The Aβ42 samples were incubated under specific conditions (pH, 
temperature, and ionic strength) responsible for protoﬁbril formation, then conformational 
analyses of samples were carried out by UV-visible spectroscopy and fluorescence 
spectroscopy via the ThT-binding assay. To determine the content of β-sheet secondary 
structure during the incubation, FTIR spectroscopy measurements were performed. As a final 
step, the samples were applied to the BSW device and incubated under the same conditions. 
 
ThT-binding fluorescence assay 
 
The most common technique to identify the presence of amyloid fibrils and to monitor 
their formation in time is the ThT fluorescence assay. Although ThT fluorescence is not the 
“definitive” criterion for kinetic studies on amyloid fibrils formation, it is well accepted as a 
probe of their presence in samples under aggregation conditions. ThT shows a very low 
fluorescence in the absence of the amyloid aggregates (Fig.A2.6). The assay measures the 
enhancement in fluorescence intensity of ThT upon binding to amyloid fibrils. The enhanced 
fluorescence can be observed at 482 nm; the excitation wavelength is 440 nm, a value close 
to the maximum in absorbance(6), which is 412 nm. The spectroscopic assay was carried out 
according to the literature(3). Despite this assay is commonly used to monitor fibril formation 
over time, it is not strictly quantitative. 
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Fig.A2.6. ThT fluorescence emission spectrum. The sample (10 μM in 10 mM Tris HCl, 50mM 
Gly-NaOH, pH 7.8-8.2) was excited at 440 nm. 
 
In the presence of a freshly purified Aβ42 monomer sample, an almost absent ThT 
fluorescence increase (see Fig.A2.7, first data point) is the hallmark of the absence of amyloid 
fibrillar aggregates. After incubation at 37 °C for several hours, a fluorescence enhancement 
was observed (see Fig.A2.7). 
 
 
 Fig.A2.7. ThT-binding assays. The ThT fluorescence enhancement given by the binding to the 
peptide during its aggregation at 37 °C is shown. The initial Aβ42 monomer concentration in sample A was 
9 µM, and in sample B was 8 µM. Buffer 10 mM Tris-HCl, 50 mM Gly-NaOH, pH 7.8-8.2. ThT was at 
10 μM in both experiments. 
 
As highlighted by Fig.A2.7, the ThT fluorescence enhancement was exhibited after 
several hours of incubation. This is consistent with what reported in the literature(6, 7). After 
a critical time of incubation, the peptide assembles into β-sheet secondary structure allowing 
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the ThT molecules to insert into the channels made by the long axis of this domain. Thus, the 
ThT fluorescence intensity is enhanced. 
To mathematically analyze the fluorescence data from the ThT-binding assays in 
Fig.A2.7 according to the nucleation-polymerization kinetic model for protein aggregation, 
fluorescence data were fitted with Eq.(A2.2):  
  (A2.2). 
It defines a two-steps aggregation mechanism of slow, continuous nucleation followed by 
typically fast autocatalytic growth. k1 and k2 are, respectively, the rate constant for nucleation 
and the rate constant for growth; [A]0 is the initial monomer peptide concentration and [B]t is 
the concentration of the aggregate at the time t. For this specific fitting, [A]0 corresponds to 
the fluorescence intensity at the end of the reaction, assuming that all the monomer has turned 
into aggregate; [B]t is the fluorescence intensity recorded during the incubation(8-10). 
According to the fitting in Fig.5.2.3, the calculated nucleation rate constant corresponded to 
6.18 10-4 h-1µM-1 and 2.04 10-4 h-1µM-1, for sample A and B, respectively. The calculated 
polymerization rate constants were 8.77-4 h-1 and 1.06-3 h-1, for sample A and B, respectively. 
These values are consistent with those reported in the literature(11) and describe a slow 
nucleation, followed by a faster fibril elongation. 
The model proposed is described by the two-steps reaction(9): 
        Nucleation (oligomers formation) 
 
                                     Growth (fibrillation) 
 
 
where n is representing the number of the molecules of monomer A that are assembling to 
form the oligomer B, and k1 is the rate constant of this nucleation reaction. Then, this nucleus 
recruits other monomers through the fibrillation reaction, whose constant rate is k2. The 
concentration of the monomer determines the velocity of the growing phase, pushing the 
equilibrium to the formation of the aggregate. This model is consistent with the results we 
obtained. 
 
FTIR Spectroscopy: a Probe of Secondary Structure Variation 
 
To assess the secondary structure of the Aβ42 peptide throughout aggregation, as 
reported in the literature(3, 6, 12), we performed FTIR spectroscopy experiments. We 
concentrated our study on the amide I band absorption that arises from the C=O stretching 
      
  
  
   
  
  
    
           
nA → Bn 
    A + Bn → Bn+1 
k1 
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vibrations of the peptide bond between 1700 and 1600 cm-1. This vibration mode is 
influenced by the protein backbone conformation. In Fig.A2.8 an IR profile of an initially 
monomeric Aβ42 peptide is presented. The lyophilized Aβ42 sample was dissolved in D2O 
and was subjected to deuteration at 4 °C for 1 hour. We unequivocally identified the amide 
A (~3300 cm-1), the amide I (1700-1600 cm-1), and the amide II (1500-1400 cm-1) bands. The 
deep trough in the middle region between 2700 and 2200 cm-1 is due to the O-D stretching of 
D2O and the dip at 1200 cm-1 is due to the O-D bending(13). 
 
 
Fig.A2.8. FTIR-ATR spectrum of Aβ42 peptide. The concentration of the protein was 332 µM in 
D2O.  
 
The sample was then incubated for two days at 37 °C in D2O and monitored through 
FTIR spectroscopy. The overlapping of the IR profiles of the peptide during the aggregation 
process is reported in Fig.A2.9 (solid lines). Unfortunately, dissolving the Aβ42 peptide in 
pure D2O caused an initial formation of oligomers. To assess the structural conformation of 
the monomer, we prepared the Aβ42 sample by dissolving the lyophilized powder in 30% v/v 
HFIP and 70% v/v D2O, which have been reported to be disgregant condition(14). HFIP has 
been shown to prevent the aggregation of the Aβ42 peptide(14, 15). The FTIR spectrum of 
the obtained Aβ42 monomeric sample is presented in Fig.A2.9 (dashed line). 
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Fig.A2.9. Close-up view of the amide I band region in the FTIR spectrum of the Aβ42 peptide. 
Solid lines: IR spectra of the Aβ42 peptide before and during incubation at 37 °C (initial monomer 
concentration 332 µM in D2O). Dashed line: IR spectrum of a monomeric sample (665 µM) in 30% v/v 
HFIP, 70% v/v D2O. 
 
From a first analysis of the spectra in solid lines in Fig.A2.9 it is possible to observe the 
presence of bands at 1625 cm-1 corresponding to a β-sheet structure, but it is not possible to 
draw more precise results because of a band broadening(12). Several methods for the 
deconvolution of these broad bands are used; we selected the second-derivative method 
because of its simplicity in extrapolation and interpretation(14), as presented in Fig.A2.10. 
 
 
Fig.A2.10. Second-derivative analysis of the ATR-FTIR spectra. The analysis of the Aβ42 peptide 
spectra in Fig.A2.9 was performed with a 13-smoothing point function.  
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In the second derivative of the IR spectra of the peptide in the amide I region a trough is 
shown at 1625 cm-1. This is characteristic of parallel β-sheet. Other three minima are 
detectable: one at 1654 cm-1 that has been assigned to random coil, one at 1673 cm-1 assigned 
to the presence of turns, and one at 1686 cm-1, that has been related to the presence of 
antiparallel β-sheet and aggregated strands(13, 16). These peaks are especially detectable in 
FTIR spectrum of the peptide sample that was kept at 4 °C (t = 0, Fig. A2.10). For this sample, 
a minimum at 1645 cm-1 is also detectable. We could not confidently assign this spectroscopic 
feature to a content in α-helix structure, but authors have suggested this correlation(13).  
Over incubation time, the intensity of the peak at 1654 cm-1 decreases. This is consistent 
with aggregates formation concomitant to the disappearance of a random-coil structure, 
which is typical of non-aggregated peptides. The band at 1625 cm-1 decreases over time and 
this effect may reflect the sample precipitation following aggregation. The persistence of the 
1625 cm-1 band over incubation time is indicative that a parallel β-sheet conformation is 
formed even in the early stage of aggregation. The band related to the antiparallel β-sheet 
(1686 cm-1), whose decrease has been correlated to the formation of more compact 
aggregates, such as proto fibrils and fibrils(17), is more intense at the beginning of the 
incubation and this is in agreement with a transition from an oligomeric to a fibrillar state. 
After an incubation time of 48 h, the most intense band was the one related to a β-sheet 
structure. Therefore, the Aβ42 peptide, under these experimental conditions, is mostly 
aggregated into fibrils. This is consistent with results reported in literature(17, 18).  
 
UV Absorption Spectroscopy 
  
To assess the results obtained for the Aβ42 aggregation as monitored with the BSW-
based sensing approach, we performed parallel incubations of the peptide at 37 °C and we 
monitored the UV absorption response of the samples. The Aβ42 sample was incubated under 
identical conditions compared to the refractive index measurement.  
Firstly, the Aβ42 peptide was incubated at 37 °C and centrifuged 14000 rpm for 5 
minutes prior to recording the sample absorbance in the UV range between 350 and 240 nm. 
The results of this investigation are presented in Fig.A2.11. 
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Fig.A2.11. UV spectra of the Aβ42 peptide during incubation. Samples were incubated at 37 °C, 
in 10 mM Tris HCl, pH 7.4. Left: sample at initial monomer concentration of 14.7 μM. Right: sample at 
initial monomer concentration of 22 μM. Spectra were not normalized. 
 
From the shape of the spectral profiles, we notice an absorption occurring between 320 
and 350 nm. Since this signal is not correlated to any chromophore in the peptide, it has been 
associated to Rayleigh scattering(5). This contribution to the signal was especially relevant 
during the first days of incubation (Fig.A2.11, curves in red). We propose that this 
phenomenon should be due to the formation of small soluble aggregates, such as Aβ42 
oligomers. Those aggregates do not precipitate after centrifugation. After several incubation 
days, the spectra maxima (280 nm) decrease. This event can be safely correlated to the 
formation of fibrils, which are excluded from the solution via centrifugation. The absorption 
profiles of the samples after 96 hours of incubation was exhibiting a minor scattering 
contribution between 320 and 350 nm, related to a decreased amount of soluble aggregates. 
These results are in accordance with the literature(3). 
A real-time absorbance monitoring of the Aβ42 peptide throughout aggregation at 
250 nm is presented in Fig.A2.12. 
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Fig.A2.12. Real-time absorbance change of aggregating Aβ42 peptide. Black: absorbance profile 
of the Aβ42 peptide at 250 nm during incubation at 37 °C without stirring (in 10 mM Tris HCl, pH 7.4). 
Initial monomer concentration: 9μM. Red: fitting curve obtained applying Eq. A2.1. 
 
The measurement was performed at the fixed wavelength of 250 nm, where the scattering 
contribution is directly correlated to the formation of aggregates(19). The peptide solution 
was incubated at 37 °C for 33 hours, without stirring. The profile in Fig.A2.12 presents an 
initial absence of signal variation (“lag-phase”), followed by a sharp increase of absorbance. 
A plateau in the signal is finally reached. The aggregation curve present similarities to the 
nucleation-polymerization model. From Eq.A2.2, we calculated k1 and k2 values, which 
corresponded to 5.49 10-6 h-1 and 1.91 10-3 h-1µM-1, respectively. These value are consistent 
with those reported in the literature(11). 
To monitor subtle structural changes in the tertiary protein conformation during the 
incubation(20), we investigated the changes in the phenylalanine peak ratio via a second-
derivative analysis of the spectra in Fig.A2.11. The variations are directly correlated to 
changes in the microenvironment around the aromatic amino acid. This study is presented in 
Fig.A2.13. 
The second-derivative analysis of the absorbance spectral profile aimed at studying the 
environment of the peptide phenylalanines residues during aggregation. This investigation is 
carried out observing the intensity variation of the troughs between 250 and 274 nm. It has 
been demonstrated that the positions of phenylalanine minima do not change upon 
microenvironment variations. This method is frequently used to detect protein aggregation or 
denaturation, since the intensity variation of minima is due to changes of the solvent 
exposition of aromatic amino acids(21). 
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Fig.A2.13. Second-derivative analysis of the UV spectra of the Aβ42 peptide during incubation. 
Original spectra are reported in Fig.A2.11. 
 
From the observation of the results presented in Fig.A2.13, one notices that the fine 
structure of the spectra disappears during the incubation (from 0 to 168 hours, on the left, and 
to 96 hours, on the righ). At long incubation times valleys disappear. This phenomen has been 
correlated to the “hiding” of the aromatic AA in the core of the structure, evidence of an 
aggregated conformational state of the peptide(21). 
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